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High body-mass-index (BMI), hyperglycaemia, and hypercholesterolemia are the leading risk 
factors for mortality and morbidity worldwide. As obesity has become an epidemic in all age 
groups globally, more and more women enter pregnancy with obesity. Pregnant women with 
high BMI often present with excessive gestational weight gain, hyperglycaemia, and 
dyslipidaemia during pregnancy, therefore expose the foetus to unfavourable intrauterine 
environment. Although maternal obesity and gestational hyperglycaemia have been associated 
with a series of adverse pregnancy outcomes in previous literature, lifestyle interventions during 
pregnancy do not confer significant benefit for composite maternal and neonatal health 
outcomes. Meanwhile, gestational dyslipidaemia has been recognised as an ignored metabolic 
risk factor for adverse pregnancy outcomes. Therefore, the aim of this project is 1) to explore 
the association between gestational dyslipidaemia and neonatal adverse metabolic conditions; 
2) to establish the most influential maternal metabolic risk factors for maternal and neonatal 
adverse metabolic conditions; 3) to investigate the metabolic profile in babies with different 
birthweight percentiles.  
 
In this project, a comprehensive systematic review followed by a prospective cohort study and 
an exploratory study were conducted to address the above objectives. In summary, maternal 
lipid levels are secondary to maternal metabolic dysfunction with no clear causal links to 
adverse neonatal metabolic conditions, although it has strong associations with adverse 
birthweight outcomes. High maternal pre-pregnancy BMI is the most influential upstream 
metabolic risk factor for both maternal and neonatal metabolic health outcomes, therefore 
weight management should be addressed from the preconception period. The differential 
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metabolic and inflammatory profile in small-for-gestational-age and large-for-gestational-age 
babies might be crucial for developing subsequent obesity, diabetes, and cardiovascular 
diseases. Tailored intervention strategies in babies with different birthweight percentiles are 
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1.1 Definition and health burden 
Overweight and Obesity 
Definition and diagnosis criteria 
‘Overweight’ and ‘obesity’ are terms used to refer to conditions of abnormal or excessive body 
fat accumulation possibly leading to short or long-term adverse health outcomes (1). Body Mass 
Index (BMI) is the most commonly used estimate of evaluating of body fat mass in individuals, 
and is calculated through dividing a person’s weight in kilograms by the square of their height 
in meters (2). The World Health Organisation (WHO) defines adults with a BMI greater than 
or equal to 25 kg/m2 as overweight, and those who have a BMI greater than or equal to 30 as 
obese (1). Obesity is further classified into three categories based on BMI values: Class Ⅰ, 30.0 
- 34.9 kg/m2; Class Ⅱ, 35.0 - 39.9 kg/m2; Class Ⅲ, ≥40 kg/m2 (3). 
The general WHO definition of BMI classifications was derived by morbidity and mortality 
data of white European populations, therefore hard to be generalised to other populations. The 
BMI classifications of overweight and obesity vary among different ethnic groups. WHO Asia-
Pacific defined that adults who with a BMI value below 18.5 kg/m2 are underweight, who with 
a BMI value between 18.5 and 22.9 kg/m2 are normal weight, and who with a BMI value 
between 23 and 25 kg/m2 are overweight, and who with a BMI value over or equal to 25 kg/m2 
are obese (4). The Indian Consensus Group proposed that the BMI criteria for the Indian 
population is 23 - 24.9 kg/m2 for overweight and ≥ 25 kg/m2 for obesity (5). Clinical guidelines 
from the Department of Disease Control Ministry of Health in China classified BMIs of 24 - 
27.9 kg/m2 and ≥ 28kg/m2 as overweight and obesity, respectively (6).  
It has been argued that BMI is not a perfect measurement for body fat mass, because it does not 
assess fat mass and its distribution directly (7). However, evidence has shown that BMI is 
strongly associated with body fat mass measured by Multi-Compartment Models (gold-
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standard methods), and has excellent performance when predicting disease risks (8, 9). BMI is 
also the easiest way for clinicians, scientists, and individuals to judge the level of body fat and 
their risk of associated health conditions. Other available measurements of fat mass include 
waist circumference, skinfold thickness, Bioelectrical Impedance Analysis, and Dual-Energy 
X-ray Absorptiometry (10). 
 
Prevalence of risk factors 
Overweight and obesity have become major public health concerns globally. It is widely 
considered to be a leading risk factor for total mortality and morbidity (11). The WHO estimates 
that about 26% (more than 1,250 million) and 13% (650 million) of adults (≥18 years) 
worldwide in 2016 were overweight or obese, respectively (1). The prevalence of overweight 
in male and female are almost equal (12). The age-standardised prevalence of overweight and 
obesity have increased substantially over the recent decades in both developed (e.g. United 
State: 41% in 1975 vs. 67.9% in 2016) and developing countries (e.g. China: 9.9% in 1975 vs. 
32.3% in 2016) (13).  
It has been estimated that approximately 24.5 million and 14.6 million pregnant women were 
overweight or obese worldwide in 2014, respectively (14). India and China had the largest 
number of pregnant women who were either overweight or obese (4.30 million in India and 
4.29 million in China), which altogether accounted for 22.1% of the global overweight burden 
in 2014 (14). Meanwhile, around 18% of children and adolescents aged 5-19 years were either 
overweight or obese in 2016 (15). The largest increase in trend occurred in China, where the 
crude estimate of overweight and obesity prevalence among children and adolescents doubled 




Definition and diagnosis criteria 
Dyslipidaemia refers to the altered amount of lipids or lipoproteins in the blood. It is normally 
characterized by increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), 
very-low-density lipoprotein cholesterol (VLDL-C), and triglycerides, as well as decreased 
high-density lipoprotein cholesterol (HDL-C) (16). Dyslipidaemia therefore also known as 
hyperlipidaemia, hypercholesterolemia, hyperlipidaemia, or hypertriglyceridemia. There is no 
established cut-off point between normal and abnormal lipid thresholds (17). BMJ best practice 
indicates that patients whose serum TC, LDL-C, apolipoprotein B, or lipoprotein (a) 
concentrations were over the 90th percentile, or HDL-C or apolipoprotein A-I concentrations 
were less than the 10th percentile, for the general population could be diagnosed as 
dyslipidaemia (18). The interpretation of lipid profiles in adults can be found in Table 1. In 
addition, the NHS indicated that TC levels should be 5 mmol/L or less and LDL-C levels should 




Table 1 Interpretation of lipid profiles in adults (20, 21) 
Lipids profile mg/dL mmol/L Interpretation 
TC <200 <5.2 Desirable 
 200-239 5.2-6.2 Borderline 
 >240 >6.2 High 
    
HDL-C <40 <1.0 Undesirable; risk increased 
 41-59 1.0-1.5 Okay, but not optimal 
 >60 >1.55 Good; risk lowered 
    
LDL-C <100 <2.6 Most desirable 
 100-129 2.6-3.3 Good 
 130-159 3.4-4.1 Borderline high 
 160-189 4.1-4.9 High and undesirable 
 >190 >4.9 Very high 
    
TG <150 <1.69 Normal 
 150-199 1.70-2.25 Borderline high 
 200-499 2.26-5.63 High 
 ≥500 ≥5.64 Very high 
Abbreviation: TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 




Prevalence of risk factors 
In 2008, the WHO estimated that the global prevalence of raised TC (≥ 5.0 mmol/L) was 39% 
in adults. The estimate of raised TC prevalence was highest in the WHO Region of Europe 
(54%) and was lowest in the WHO African Region (22.6%) (22). As a major risk factor for 
cardiovascular diseases,  dyslipidaemia is estimated to cause 7.9% of total mortality (4.4 million 
deaths) and 2.8% of total disability adjusted life years (40.4 million) (23). It has become a major 
health burden in both the developed and developing countries due to its contribution to rising 
morbidity, mortality, and medical costs (24). 
In 2015-2016, data from the Centres for Disease Control and Prevention showed approximately 
95 million United States (US) adults (aged over 20 years) have TC levels greater than 200 
mg/dL, and 71 million US adults have high LDL-C levels (≥100 mg/dL) (25, 26). In 2015-2017, 
the age-standardized prevalence of dyslipidaemia in rural areas of Henan Province (China) was 
32.21% (Male: 42.85% & Female: 26.16%). Only around 22.45% of patients with 
dyslipidaemia received treatment, with half of their lipid levels being well controlled (27). 
Except diet and physical interventions, available pharmacologic therapy for dyslipidaemia 
management containing statins (target on LDL-C), fibrates (only for severe 
hypertriglyceridemia), omega-3 fish oil (for severe hypertriglyceridemia), niacin (an adjunct 
for reducing triglycerides), bile acid sequestrants (for reducing LDL-C and modestly increasing 
HDL-C, but may increase triglycerides), cholesterol absorption inhibitors (for reducing LDL-
C), and proprotein convertase subtilisin/kexin type 9 inhibitors (in combination with statin for 
lowering LDL-C in individuals with familial hypercholesterolemia) (21). 
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Gestational weight gain 
Definition and diagnosis criteria 
Once women became pregnant, their weight changed in line with their pregnancy progression. 
Total gestational weight gain (GWG) can be defined as the altered weight in pregnant women 
between conception and the last prenatal visit before labour. In 2009, the Institute of Medicine 
(IOM) recommended that the optimal GWG of singleton pregnancy should range between 12.5-
18 kg, 11.5-16 kg, 7-11.5 kg, and 5-9 kg for women underweight, normal weight, overweight, 
and obese prior to pregnancy, respectively (28). Women whose GWG were over the upper limit 
of  the optimal range should be considered to have excessive GWG, and those whose GWG 
were below the lower limit of the optimal range should be considered to have inadequate GWG 
(28). 
In practice, women normally realize they are pregnant at or after four weeks of gestation. 
Therefore, pre-pregnancy weight information used for GWG calculation is often self-reported. 
Although women may potentially underestimate their weight, evidence suggests that most 
women still remain in the same BMI categories using self-reported pre-pregnancy weight (29).  
Since obesity has become an epidemic in both developed and developing countries, more and 
more women are now severely obese when they become pregnant. The IOM recommendations 
did not differentiate the optimal GWG ranges among women with different obesity classes , 
due to a lack of both short- and long-term evidence of GWG on severe obese women (30).  
The generalizability of the IOM GWG recommendations to Chinese women is a controversial 
issue, because the IOM recommendation was developed based on Caucasian and black 
populations.  Tan et al. applied IOM criteria in 4,567 pregnant women living in Chengdu and 
concluded that the IOM recommendation is fit for Chinese women with underweight and 
normal weight, but its criteria for overweight and obese women warrant further modification 
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(31). Similarly, Huang et al. suggested that the IOM recommendation is generally fit for 
Chinese women, but the BMI cut-off point remains to be legislated by Chinese guideline (32). 
 
Prevalence of risk factors 
A report from the US Centres for Disease Control and Prevention found that the overall 
prevalence of inadequate GWG was 20.4% and the prevalence of excessive GWG was 47.5% 
in 2012-2013 (33). Meanwhile, about one third of women gained excessive weight during 
pregnancy in Sydney (34). Compared to women with normal weight, women who were 
underweight before pregnancy had a 50% lower risk of excessive GWG, whereas women who 
were overweight or obese had an increased risk of excessive GWG (177% for overweight 
women and 166% for obese women) (35). Meanwhile, women who were underweight or 
obesity Ⅱ or Ⅲ before pregnancy, had an increased risk of inadequate GWG (underweight: 40%; 
obesity Ⅱ: 25%; obesity Ⅲ: 86%) (35). 
 
Gestational Diabetes Mellitus  
Definition and diagnosis criteria 
Gestational diabetes mellitus (GDM) refers to glucose tolerance that develops or is first 
recognised during pregnancy, and usually disappears after delivery (36, 37). The screening and 
diagnostic approaches and thresholds vary across countries.  
Women meeting one of the following criteria were recognized to have an increased risk of 
GDM: 1) obesity; 2) previously delivered a baby over 4.5kg; 3) had GDM before; 4) has a 
parent or sibling with diabetes; 5) family origins are Asian, Chinese, African-Caribbean, or 
Middle Eastern (38). The National Institute of Health and Clinical Excellence (NICE) in the 
United Kingdom (UK) recommends screening those women with one or more risk factors for 
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GDM (38). Other than NICE, guidelines and recommendations argue that using historical 
factors to identify high GDM risk population will miss about half of women with GDM, thus 
the impetus for GDM screening and diagnostic tests to be conducted in all pregnant women 
(39-44).  
There are two major strategies used for GDM screening and diagnosis: 1) One-step approach: 
75-g oral glucose tolerance test (OGTT); 2) Two-step approach: 50-glucose challenge test 
(GCT) followed by 100-g OGTT (in positively screened women) (45). The diagnosis thresholds 
for these two strategies can be found in Table 2. The majority of organizations recognize the 
one-step approach designed by the International Association of Diabetes and Pregnancy Study 
Groups (IADPSG) in 2010 (38, 40, 42-44), the American College of Obstetricians and 
Gynaecologists (ACOG) use the two-step approach (39), while the American Diabetes 




Table 2 Screening and diagnosis thresholds of GDM (39, 41) 




75-g OGTT 50-g GCT 
100-g OGTT 
Carpenter-Coustan NDDG 
Fasting 5.1 - 5.3 5.8 
1 hour 10.0 7.2 to 7.8 10.0 10.6 
2 hour 8.5 - 8.6 9.2 
3 hour - - 7.8 8.0 
One-step strategy: 75-g OGTT should be performed at 24-28 weeks of gestation in overnight fasting status. The diagnosis 
of GDM is made when any of the cut-off points of glucose values at three time points are met or exceeded. 
Two-step strategy: 50-g GLT should be performed at 24-28 weeks of gestation in non-fasting status. If the one-hour plasma 
glucose measurement is reached or is over 7.2 mmol/L, 7.5 mmol/L, or 7.8 mmol/L, proceed to 100-g OGTT. There are 
two diagnostic thresholds for three-hour OGTT listed in this table. Without clear comparative evidence, one set of 
diagnostic criteria cannot be recommended over the other. The diagnosis of GDM is made when at least two of the cut-off 
points of glucose values at four time points are met or exceeded. 




Prevalence of risk factors 
The estimate of GDM prevalence vary widely both within and between countries. A report 
based on WHO data shows that the median prevalence of GDM ranges from 5.8 % to 12.9% 
around the world between 2005 and 2015 (46). The estimate of GDM prevalence in Singapore 
was the highest (25.1%, based on the IADPSG criteria), while it in Ireland was the lowest (1.8%, 
using NICE criteria) (46). In 2015, approximately 4.4% of 956,861 pregnancies in the UK were 
diagnosed as GDM (47). A recent systematic review reported that the prevalence of GDM in 
China varies from 5.12% (Xinjiang) to 22.8% (Tianjin) (48). In the United States (US), around 
7.6 % pregnant women were diagnosed as GDM, 19.7% of them developed to type 2 diabetes 
postpartum (49). Another meta-analysis summarised that about half of pregnant women with 
previous GDM are at risk of GDM recurrence (50). 
 
Gestational Hypertension 
Definition and diagnosis criteria 
Gestational hypertension is defined as hypertension presenting after 20 weeks of gestation 
without significant proteinuria (over 300 mg protein in a validated 24-hour urine collection 
result, or creatinine ratio ≥ 30 mg/mmol) or previous hypertension (51, 52). The diagnosis 
threshold of gestational hypertension is a diastolic blood pressure (DBP) greater than or equal 
to 90 mmHg or a systolic blood pressure (SBP) greater than or equal to 140 mmHg (51, 52). 
Both NICE and European Society of Cardiology (ESC) further classified gestational 
hypertension as three categories: 1) Mild hypertension: DBP 90-99 mmHg or SBP 140-149 
mmHg; 2) Moderate: DBP 100-109 mmHg or SBP 150-159 mmHg; 3)Severe DBP ≥ 110 
mmHg or SBP ≥ 160 mmHg (52, 53). 
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Prevalence of risk factors 
The prevalence of gestational hypertension varies in different populations. In the US, 30.6 
women in every 1,000 deliveries experienced gestational hypertension in 2004 (54). Data from 
NHS Maternity Statistics summarised that about 6% of England women were reported as 
having hypertension during pregnancy in the period 1998-99 to 2000-01 (55). In 2011, reports 
of the prevalence of gestational hypertension in China range from 1.23% to 7.44% (56). The 
estimated prevalence of gestational hypertension was 7.5% in Brazil (1991-95) and was 5.9% 
in Nigeria (2016) (57, 58). Evidence also suggests that women with twin pregnancies may be 
more likely to experience gestational hypertension than women with singleton pregnancies (59). 
 
Low and high birthweight 
Definition and diagnosis criteria 
The term of ‘birthweight’ refers to the body weight of newborns at birth. Babies with a 
birthweight less than 2,500 grams are described as ‘low-birth-weight (LBW)’ (60), and those 
with a birthweight more than 4,000 grams are defined as having ‘macrosomia’ (61). As 
birthweight changes along with the gestation week of delivery and neonatal sex, the 
International foetal and newborn growth consortium developed the INTERGROWTH-21st 
Newborn Size at Birth Chart to help identify the relative position of individual newborns among 
the whole population (62). Babies with a birthweight below the 10th percentile for their 
gestational age are considered as ‘small-for-gestational-age (SGA)’, while those with a 
birthweight greater than 90th percentile for their gestational age are considered as ‘large-for-
gestational-age (LGA)’(63).  
The cut-off points for defining SGA and LGA were suggested by the WHO expert committee 
in 1996 and has been criticised for being arbitrarily chosen.  Using data from 17,979,120 
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singleton live births, Xu et al. suggested the optimal cut-off points for defining SGA and LGA 
for the risk of neonatal death and low 5-min Apgar score might be the 15th and 97th percentiles 
of birthweight, respectively (64).  
As a crucial indicator of prenatal developmental conditions for newborns, birthweight has been 
associated with both short- and long-term health outcomes, including stillbirth, infant mortality, 
obesity, type 2 diabetes, and cardiovascular diseases (65-67). Birthweight is one of the most 
intuitive and accessible indicators that can be precisely recorded in clinics, therefore it has been 
widely used by both clinicians and researchers. It is worth noting that birthweight is an 
imperfect proxy for neonatal development and body fat mass, so that it needs to be considered 
with caution (68). 
 
Prevalence of risk factors 
The WHO estimated that there are more than 20 million LBW newborns accounts for about 15% 
- 20% of all births worldwide in 2012 (69). In fact, around half of perinatal and one-third of 
neonatal overall mortalities can be attributed to LBW (70). The vast majority of LBW births 
(95.6%) occurred in low- and middle- income countries, especially in South Asia (data exclude 
China), where 28% of infants were born with LBW (71, 72).  
Data from WHO’s Global Survey on Maternal and Perinatal Health shows that the prevalence 
of macrosomia varies from 0.5% (India) to 14.9% (Algeria) among 24 developing countries in 
Africa, Latin American, and Asia (73). In the US, about 7% of infants were affected by 
macrosomia and 1% of infants had birthweight over 4,500g in 2015 (74). Similarly, in 2012, 
approximately 11.78% newborns in the UK have a birthweight greater than or equal to 4,000 
grams (75). A 2011 national cross-sectional survey in China summarised that the overall 
estimate of macrosomia prevalence was 7.3%, ranging from 4.1% to 13.4% by province (76).  
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1.2 Current guidelines and recommendations 
Weight management before and during pregnancy 
Weight management before pregnancy 
Advice on pre-pregnancy weight management is limited and ambiguous. One NICE public 
health guideline on weight management recommends that health professionals should 
encourage, educate, and help women with obesity to lose weight (ideally to reduce their BMI 
within 24.9 – 18.5 kg/m2) before becoming pregnant. Meanwhile, it also suggests that the NHS 
commissioner/managers and public health directors should ensure that health professionals 
appreciate the importance of weight management before pregnancy (77).  
Similarly, another guideline from the Royal College of Obstetricians and Gynaecologists 
(RCOG) in the UK suggests that primary care services should advise all women of childbearing 
age during their contraceptive consultations on their weight and lifestyle to ensure the best 
chance of optimising their weight before pregnancy, especially those with BMI of 30 kg/m2 or 
more. Women who have received bariatric surgery should wait for at least 12-18 months before 
conceiving (78). 
In addition, the IOM suggests that women should be informed of the importance of conceiving 
with a BMI within the normal range by federal, state, and local agencies (28). None of these 
guidelines focus on weight management in adults provide any specific suggestion for women 
of childbearing age to prevent adverse pregnancy outcomes (79-82). 
 
Weight management during pregnancy 
Recommendations on weight management during pregnancy are controversial. The IOM 
suggests that the weight gain of women during pregnancy should be routinely monitored by the 
Department of Health and Human Services (28). Both IOM and ACOG advise that health 
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professionals should provide guidance on weight gain, diet, and physical activity throughout 
the pregnancy to ensure that gestational weight gain is within the appropriate range 
recommended by IOM (28, 83).  
On the contrary, the NICE does not recommend regular weighing of women during pregnancy 
to ensure ‘appropriate’ gestational weight gain, as there is still lack of consensus on optimal 
weight gain during pregnancy (77, 78). It also suggests that all pregnant women should be 
offered practical and tailored advice on diet (both dieting and ‘eating for two’ are not 
recommended) and moderate-intensity physical activity (77). Women with a BMI of 30 kg/m2 
or more should be weighed again in the third trimester, and should be provided both with 
necessary information about the potential risk of obesity during pregnancy and with dietetic 
suggestions by professionals (78). Additionally, it is necessary to provide nutritional 
surveillance and specialised nutritional advice to women who have had previous bariatric 
surgery (78). 
 
Gestational diabetes mellitus  
Preconception planning and care 
The ADA suggests that health professionals should discuss the importance of family planning, 
effective contraception, and glycaemic control with women and their partners at the time of 
preconception counselling (84). Although all pregnant women should be screened for GDM at 
the end of the second trimester, an early pregnancy screening for undiagnosed diabetics in high-




Table 3 Strategy for Screening Undiagnosed Diabetes or Early GDM (39) 
Women who are overweight or obese with at least one of the following risk factors need to 
be tested: 
 Physical inactivity 
 First-degree relative with diabetes 
 High risk race or ethnicity (e.g. African American, Latino, Native American, Asian 
American, Pacific Islander) 
 Have previously delivered a macrosomia  
 Previous GDM, impaired glucose tolerance/fasting glucose, or HbA1c ≥ 5.7% 
 History of hypertension  
 HDL-C < 0.90 mmol/L, triglycerides > 2.82 mmol/L 
 With polycystic ovarian syndrome (PCOS) 
 Insulin resistance relevant clinical conditions (e.g. acanthosis nigricans) 




Glycaemic control during pregnancy 
The NICE suggests that health professionals should explain the implications of GDM and the 
importance of glycaemic control during pregnancy to women who were diagnosed as having 
GDM (38). Women with GDM need to be taught how to self-monitor their fasting and 
postprandial blood glucose levels (38, 84).  
Individualised and practical counselling of nutrition and exercise needs to be offered to women 
with GDM by a registered dietitian or other relevant health professionals (38, 39, 84). With 
lifestyle modification alone, the majority of women with GDM could meet the glycaemic 
targets successfully (Table 4) (84).    
If women with GDM fails to maintain adequate glycaemic control with lifestyle therapy alone, 
pharmacologic treatment needs to then be recommended (38, 39, 84). Both ADA and ACOG 
suggest that insulin is the preferred choice for GDM, since it cannot cross the placenta (39, 84), 
while the preferred method suggested by NICE is metformin (38). Other than insulin and 
metformin, glibenclamide could be considered as alternative treatment for women with GDM 
as well (38, 39, 84). The ACOG further points out that health care providers should discuss the 




Table 4 Glycaemic targets of women with GDM (38, 84) 
Glycaemic targets at 
different time points 
ADA NICE 
  Fasting 5.3 mmol/L 5.3 mmol/L 
  1-hour postprandial 7.8 mmol/L 7.8 mmol/L 
  2-hour postprandial 6.7 mmol/L 6.4 mmol/L 
The glycaemic level of women with GDM need to achieve the glycaemic target at fasting status 
and either the glycaemic targets at 1-hour postprandial or 2-hour postprandial.  
Abbreviation: GDM, gestational diabetes mellitus; ADA, American Diabetes Association; 





The NICE advises health professionals to discuss the timing and mode of delivery with women 
with GDM at the third trimester (38). In particular, for women with GDM who have an 
ultrasound-diagnosed macrosomic foetus, both NICE and ACOG indicate that the risks and 
benefits of each delivery mode need to be clearly explained by health professionals (38, 39).  
The NICE suggests that women with GDM should be advised to delivery no later than 40+6 
weeks, especially those with maternal or foetal complications (38). For women with GDM who 
have not yet given birth by that time, health professionals should offer an elective birth, 
including induction of labour and caesarean section (38). During labour, the capillary plasma 
glucose of women with GDM should be measured hourly and needs to be maintained between 
4 and 7 mmol/L (38).  
Meanwhile, the ACOG recommends that the timing of giving birth for women with GDM using 
non-pharmacologic therapy should be in the range of 39 to 40 + 6 weeks of gestation (39). For 
women with GDM who are taking pharmacologic therapy, the optimal timing of delivery is 39 
weeks of gestation (39).  
 
Postpartum care 
Both ADA and ACOG suggest screening women who are diagnosed as GDM 4-12 weeks 
postpartum to identify women with diabetes, impaired glucose tolerance, or impaired fasting 
glucose levels (39, 84), while the screening time suggested by NICE is 6 - 13 weeks postpartum 
(38). The ADA recommends using the 75-g OGTT with nonpregnancy criteria for postpartum 
screening (84). Conversely, the NICE prefers the fasting plasma glucose test, and suggests that 
the 75-g OGTT test should not be offered routinely (38). If a women has not performed a fasting 
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plasma glucose test by 13 weeks postpartum, a HbA1c test could be an alternative option if the 
fasting plasma glucose test is not possible after 13 weeks postpartum (38). 
For women who are diagnosed as GDM with a moderate risk of developing type 2 diabetes 
(fasting plasma glucose level < 6.0 mmol/L or HbA1c < 5.7%), the NICE recommends offering 
lifestyle advice and an annual HbA1c test. For women who are diagnosed as GDM with a high 
risk of developing type 2 diabetes (fasting plasma glucose level: 6.0 - 6.9 mmol/L or HbA1c: 
5.7 – 6.4%), advice, guidance, and interventions need to be offered to prevent the onset of type 
2 diabetes. Women with fasting plasma glucose ≥ 7.0 mmol/L or HbA1c level ≥ 6.4% at 
postnatal test could be directly diagnosed as type 2 diabetes (38).  
Both ADA and ACOG suggest that women who are diagnosed as GDM with a negative result 
of their postnatal test should be screened for type 2 diabetes every 1-3 years (39, 84). In future 
pregnancies, the NICE recommends that women with previous GDM should be offered an early 
pregnancy OGTT test or asked to self-monitor glucose levels (38).  
 
Gestational hypertension 
Management of hypertension in pregnancy 
For pregnant women with both diabetes and chronic hypertension, the ADA recommends that 
the blood pressure should be remained in the range of DBP 80 - 105 to SBP 120 - 160 mmHg 
(84). However, the ESC suggests that there is not enough evidence in support of setting up a 
blood pressure target in pregnancy (53). 
The NICE suggests that additional assessment and follow-up needs to be carried out in women 
who are diagnosed as gestational hypertension with the following risk factors: nulliparity, age 
≥ 40 years, pregnancy interval > 10 years, family or previous history of pre-eclampsia, multiple 
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pregnancy, BMI ≥ 35 kg/m2, previous gestational hypertension, or pre-existing vascular/kidney 
diseases (52). The management process of gestational hypertension is shown in Table 5. 
The ESC suggests pregnant women with a blood pressure of 170/110 mmHg or more are 
considered as emergency cases in need of hospitalization (53). The ACOG also indicates that 
antihypertensive treatment should be administered for those with acute-onset persistent severe 
hypertension within 30 - 60 minutes (51). Contrary with the NICE guidelines, the ESC suggests 
that all three medicines (labetalol, oral methyldopa, and nifedipine) could be used as first-line 
antihypertensive treatment (53). Use of i.v.hydralazine, i.v. urapidil, and sodium nitroprusside 
(last resort) could be carefully considered in women with severe hypertension, while 
angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, and direct renin 
inhibitors should be strictly contraindicated (53). In addition, magnesium sulphate, suggested 
by the ACOG, could be used to prevent seizure in women with gestational hypertension (51). 
The effect of non-pharmacological treatment on gestational hypertension is limited. The ESC 
advises that women who are diagnosed as gestational hypertension with obesity might need to 
be recommended regular exercise carefully to prevent excessive gestational weight gain (≥ 6.8 
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The ACOG recommends expectant management up to 37 + 0/7 weeks of gestation for women 
with gestational hypertension without severe features (51). After that, delivery is the best option 
rather than expectant management (51, 53). The NICE argues that the timing of birth should be 
discussed between the senior obstetrician and women, for those women with a blood pressure 
of 160/110 mmHg or less after 37 weeks (52). Delivery is recommended after maternal 
stabilization or with labour/pre-labour rupture of membranes, if a women with gestational 
hypertension has severe features at or after 34 0/7 weeks (51). In addition, women with 
gestational hypertension taking steroids should give birth as soon as possible (51, 52). 
 
Postpartum care 
Blood pressure should be monitored continuously in women who had gestational hypertension 
after giving birth (52). If blood pressure remains high (≥ 130/80 mmHg), women need to take 
antihypertensive medicines (except methyldopa) after delivery (52, 53). Medical review and 
specialist assessment needs to be offered to women who had gestational hypertension at the 
postnatal review (6-8 weeks after delivery) (52). Women who had gestational hypertension 
should receive a care plan and be transferred to community care (52).  
 
Low and high birthweight 
Low birth weight (LBW)  
The WHO suggests that very low birth weight (VLBW) and LBW infants should preferably be 
fed human milk exclusively until 6 months of age. Standard infant formula should be given 
from the time of discharge to six months postpartum to infants who could not be fed human 
milk. VLBW infants who fail to gain weight with adequate standard infant formula should be 
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fed preterm infant formula. VLBW infants fed with human milk should be given Vitamin D, 
Calcium, phosphorus, and iron daily for an appropriate time within 6 months of age (85).  
 
Small-for-gestational age (SGA) 
To prevent SGA birth, the RCOG suggests that the primary prevention efforts should be made 
to promote smoking cessation. In particular, antiplatelet agents need to be offered to women 
with a high risk of preeclampsia before or at 16 weeks of gestation, since this may be effective 
in reducing the risk of SGA. Umbilical Artery Doppler (UAD) is the primary surveillance tool 
to reduce the risk of perinatal morbidity and mortality, while Ductus Venous Doppler (DVD) 
has the predictive value at delivery for acidaemia and adverse outcomes in preterm SGA with 
abnormal UAD. For a SGA foetus with normal UAD and DVD, the timing and mode of delivery 
should be consulted with a senior obstetrician, and the time should be no later than 37 weeks 
of gestation (86). 
The Queensland Clinical Guideline recommends promoting and supporting breastfeeding for 
full-term SGA infants. Feeding should be in response to neonatal needs. If infants fail to suck 
breast milk, a feeding volume of 60 mL/kg should be offered in the first day of birth, and should 
then be increased by 30 mL/kg every day subsequently (87).  
 
Large-for-gestational age (LGA) or Macrosomia 
The NICE recommends the induction of labour should not be considered in women with 
LGA/macrosomic foetus if there is no other indication (88). No other recommendation for LGA 
or macrosomic infants was found. 
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1.3 Existing epidemiological evidence 
Maternal obesity 
Maternal pre-pregnancy obesity has been associated with adverse health conditions in both 
mothers and their offspring.  
 
Maternal obesity and maternal health 
The impact of maternal high pre-pregnancy BMI starts during early pregnancy. A large case-
control study shown that the risk of early miscarriage (odds ratio [OR] = 1.20, 95% confidence 
interval [CI] 1.01 to 1.46) and recurrent early miscarriages (OR = 3.5, 95% CI 1.03 to 12.01) 
in women with obesity were significantly higher than the risk in lean women (89). Compared 
with women with a normal pre-pregnancy BMI, the risk of stillbirth increased by 47% (95% CI 
8% to 94%) and 107% (95% CI 59% to 174%) among women with overweight or obesity, 
respectively (90). 
Women who were overweight/obese prior to pregnancy have an increased risk of developing 
GDM, gestational hypertension, and pre-eclampsia, compared with women with a normal BMI  
(91). The odds ratios of GDM increased by the degree of obesity, which are 1.97 (95% CI 1.77 
to 2.19) for overweight women (BMI 25 - 29.9 kg/m2), 3.01 (95% CI 2.34 to 3.87) for 
moderately obese women (BMI 30 - 34.9 kg/m2), and 5.55 (95%CI 4.27 to 7.21) for morbidly 
obese women (BMI ≥ 35kg/m2), respectively (92). Other than metabolic complications, women 
with pre-pregnancy obesity are more likely to experience depressive symptoms in pregnancy 
(OR = 1.43, 95% CI 1.27 to 1.61) and postpartum (OR = 1.30, 95%CI 1.20-1.42) (93).  
During the period of labour, infants of women with either pre-pregnancy overweight or obesity 
have increased risks of shoulder dystocia, caesarean section, and perinatal death, compared with 
lean women (91, 94). Maternal pre-pregnancy overweight is associated with both pre-term birth 
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(RR = 1.06, 95% CI 1.01 to 1.11) (95) and post-term birth (OR = 1.24, 95% CI 1.15 to 1.34) 
(96).  
In the postpartum period, compared with women with normal weight, obese women are less 
likely to initiate breastfeeding and more likely to have a delayed lactogenesis onset and 
inadequate milk supply (97). 
 
Maternal obesity and offspring health 
It is well known that maternal pre-pregnancy overweight/obesity has substantial impacts on the 
development of offspring.  
Evidence indicated that neonates born to women with overweight/obesity have an increased 
risk of neural tube defects (overweight: OR = 1.20, 95% CI 1.04 to 1.38; obese: OR = 1.87, 95% 
CI 1.62 to 2.15), compared with neonates born to lean women (98, 99). Meanwhile, the 
offspring of obese mothers were more likely to be affected by congenital anomalies, including 
spina bifida, hydrocephaly, anorectal astresia, limb reduction anomalies, cardiovascular 
anomalies, cleft palate, cleft lip and palate, and septal anomalies (99). 
It has shown that the risk of compromised neurodevelopmental outcomes (e.g. autism spectrum 
disorder, attention deficit-hyperactivity disorder, developmental delay, and 
emotional/behavioural problems) were significantly higher in children whose mother were 
overweight (OR = 1.17, 95% CI 1.11 to 1.24) or obese (OR = 1.51, 95% CI 1.35 to 1.69) prior 
to pregnancy than the risk in children with lean mothers (100). Another meta-analysis also 
indicated that the risk of cerebral palsy increased by 51% (95% CI 24% to 84%) among children 
born to overweight/obese mothers (101). 
Consistent findings indicated that maternal high pre-pregnancy BMI is significantly associated 
with the increased risk of LGA (OR = 2.42, 95% CI 2.16 to 2.72), macrosomia (OR = 2.17, 95% 
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CI 1.92 to 2.45) (102), childhood obesity (103), and cardiovascular and metabolic diseases in 
adulthood (104, 105). Another systematic review concluded that maternal high pre-pregnancy 
BMI is associated with altered offspring DNA methylation levels, which may contribute to the 
elevated life-long risk of metabolic syndromes in offspring (106). In addition, infants born after 
maternal bariatric surgery have significantly reduced fat mass and an elevated fasting insulin 
level, compared with their siblings born before surgery (106). 
 
Maternal dyslipidaemia 
Maternal circulating lipid levels, including TC, HDL-C, LDL-C, and triglycerides, slightly 
decreased in the first 6 weeks after conception, and then dramatically increased in line with the 
progression of pregnancy. After childbirth, maternal lipid levels gradually dropped to the level 
before pregnancy (Figure 1) (107).  
 
Maternal dyslipidaemia and maternal health 
Maternal lipid levels during pregnancy have been associated with the incidence of GDM, pre-
term delivery, as well as pre-eclampsia. Compared with non-GDM women, women who are 
diagnosed as GDM have a significant elevated triglycerides level throughout pregnancy and a 
significant reduced HDL-C level in the second and third trimesters (108). The latest systematic 
review concluded that women with either low or high lipid levels (TC, HDL-C, LDL-C, and 
triglycerides) during pregnancy might have an increased risk of preterm delivery (109). 
Moreover, a meta-regression analysis demonstrated that the elevated maternal TC and 
triglycerides levels throughout pregnancy and the decreased maternal HDL-C levels in the third 
trimester are associated with the incidence of pre-eclampsia (110).  
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Figure 1 The average concentrations of maternal lipid levels one year before, during, and 





Maternal dyslipidaemia and neonatal health 
Apart from maternal lipid levels during pregnancy, maternal pre-pregnancy weight, gestational 
weight gain, and glucose levels during pregnancy have been associated with a series of adverse 
neonatal health outcomes in previous literature (99, 102-104, 111-115). Although maternal lipid 
levels during pregnancy are associated with the increased risk of pre-term delivery and pre-
eclampsia (109, 116), evidence regarding the association between maternal lipid levels during 
pregnancy and neonatal health outcomes remains inconsistent and controversial (117-119), 
which needs to be appropriately addressed. No previous systematic review has produced a 
synthesis for the association between maternal lipid levels and neonatal health outcomes. 
Therefore, I conducted a systematic review to synthesis evidence on the association between 
maternal lipid levels during pregnancy and neonatal health outcomes, including birthweight, 
metabolic factors, and inflammatory parameters (Chapter 3). 
 
Gestational weight gain 
Gestational weight gain and maternal health 
A narrative review published in 2015 indicated that maternal excessive weight gain in the first 
and second trimester is an independent risk factor of impaired glucose tolerance during 
pregnancy, GDM, type 2 diabetes, gestational hypertension, and pre-eclampsia (120). 
Meanwhile, among women with obesity before pregnancy, inadequate GWG was also 
associated with decreased risk of gestational hypertension (OR = 0.70, 95% CI 0.53 to 0.93) 
and pre-eclampsia (OR = 0.90, 95% CI 0.82 to 0.99) (121). However, another systematic review 
(2017) including six studies on the association between GWG and GDM concluded that there 
is no sufficient evidence for this relationship (111).   
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Compared with women with optimal GWG, women with inadequate GWG have an increased 
risk of preterm delivery (OR = 1.70, 95% CI 1.32 to 2.20), while women with excessive GWG 
have a higher risk of caesarean section (OR = 1.30, 95% CI 1.25 to 1.35) and a lower risk of 
preterm delivery (OR = 0.77, 95% CI 0.69 to 0.86) (111). Evidence also indicates that women 
with obesity who gaining excessive GWG were at risk of preterm delivery as well (OR = 1.54, 
95% CI 1.09 to 2.16) (122). There is also a clear association between excessive GWG and 
maternal postpartum weight retention (123). 
 
Gestational weight gain and neonatal health 
It has been established that women with inadequate GWG are at a higher risk of having SGA 
babies (OR = 1.53, 95% CI 1.44 to 1.64), while women with excessive GWG are at a higher 
risk of having LGA babies (OR = 1.85, 95% CI 1.76 to 1.95) and macrosomia (OR = 1.95, 95% 
CI 1.79 to 2.11) (111). Maternal excessive GWG was also recognised as one of those leading 
risk factors for early childhood obesity (103).  
Maternal excessive GWG may be associated with neonatal fat mass and long-term metabolic 
health, but the quality of evidence was poor (120, 124). In addition, a genetic systematic review 
demonstrated that maternal GWG has no association with differentially methylated cord blood, 
which may imply that there is limited influence on neonatal metabolic health (106).  
 
Interventions for optimising gestational weight gain 
Concerted efforts have been made to optimise GWG in women for preventing adverse 
pregnancy outcomes but end up with conflicting results. A recent meta-analysis indicated that 
healthy diet and/or physical activity during pregnancy are effective in control of gestational 
weight gain (125). 
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A 2017 systematic review indicated that combining diet and exercise interventions during 
pregnancy and reduced GWG were associated with decreased risk of GDM and caesarean 
section, but have no clear association with gestational hypertension, mortality, LGA, perineal 
trauma, neonatal hypoglycaemia, and childhood adiposity (126). In the same year, an 
individual-patient-data meta-analysis concluded that diet and physical activity interventions 
during pregnancy only succeeded in reducing GWG and lowering the risk of caesarean section 
but has no effect on composite adverse outcomes in mothers and infants (127).  
In 2015, another systematic review concluded that exercise during pregnancy could help to 
reduce the risk of GDM (Risk ratio [RR] = 0.69) (128). In particular, for women with obesity, 
exercise during pregnancy could only help to reduce the risk of pre-term delivery (RR = 0.62, 
95% CI 0.41 to 0.95), but has no effect on the risk of GDM, caesarean delivery, low birthweight, 
macrosomia, and stillbirth (129). 
 
Gestational diabetes mellitus 
Gestational diabetes mellitus and maternal health 
It is well established that GDM has a major impact on the maternal short- and long-term health. 
Evidence indicates that the incidence of pre-eclampsia and gestational hypertension in women 
with GDM is higher than that it in women without GDM (112). During childbirth, women with 
GDM have an increased risk of pre-term birth, caesarean section, perineal trauma, shoulder 
dystocia, as well as induction of labour (38, 130, 131).  
Approximately 30% to 84% of women with a history of GDM tend to have a recurrence GDM 
in their next pregnancy (132). Almost half of those women who were diagnosed as GDM would 
develop to type 2 diabetes within ten years (133). Studies have also shown that women who 
were diagnosed as impaired glucose tolerance during pregnancy or GDM have a significantly 
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increased risk of developing cardiovascular disease within ten years after childbirth (134-136).  
Additionally, women with a history of GDM have a higher incidence of postpartum depression 
(RR = 1.67, 95% CI 1.22 to 2.28) and non-alcoholic fatty liver disease than women who have 
never experienced GDM (137, 138). 
 
Gestational diabetes mellitus and neonatal health 
Neonates born to mothers with GDM have an increased risk of macrosomia (OR = 1.71, 95% 
CI 1.52 to 1.94), LGA, neonatal hypoglycaemia, and a higher fat mass at birth (112-114, 139). 
Compared to neonates of non-GDM women, an increased incidence of anorectal malformations 
and congenital heart defects were observed in neonates born to women with GDM (115, 140). 
Maternal GDM seems to be associated with offspring’s higher BMI Z-Score and 2-hour plasma 
glucose level in their childhood. It remains unclear whether the association is independent of 
maternal BMI (141). Children born to mothers with GDM have a 62% higher risk of autism 
spectrum disorders, compared to that in children of non-GDM mothers (142). GDM seems to 
have a negative impact on neonatal cognitive development, but needs to be evidenced (143). In 
addition, GDM was found to significantly increase neonatal methylation levels, therefore might 
have life-long impacts on neonatal health (106). 
 
Interventions for glycaemic control in GDM women 
Treatments for GDM could significantly lower the risk of shoulder dystocia (OR = 0.40, 95% 
CI 0.21 to 0.75) and LGA (OR = 0.48, 95% CI 0.38 to 0.62) (112). Both acute and chronic 
prenatal exercise could effectively reduce the level of circulating blood glucose levels in women 
with GDM (144). Meanwhile, low glycaemic index diet was demonstrated to reduce the risk of 
macrosomia among women with GDM (145). If pharmacotherapy is needed for women with 
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GDM, evidence suggests that insulin and metformin are preferable choices, but not 
glibenclamide (146). GDM is also considered a disease with heterogeneous physiological 
characteristics, therefore individualized therapies to maximize the health outcomes of mother 
and neonates warrants further investigations (147).   
 
Gestational hypertension 
Gestational hypertension and maternal health 
Hypertensive disorders in pregnancy are closely associated with the incidence of pre-eclampsia 
(148). Recurrence of hypertensive disorders in pregnancy is associated with the increased risk 
of pre-term delivery (149). 
Although maternal blood pressure typically fall back to a normal level, vascular dysfunctions 
could even persist in women with a history of gestational hypertension postpartum (150). 
Evidence indicates that women with a history of gestational hypertension have an increased 
risk of a series of cardiovascular diseases after childbirth. It containing chronic hypertension 
(RR = 3.70, 95% CI 2.70 to 5.10), coronary heart disease (RR = 2.50, 95% CI 1.43 to 4.37), 
stroke (RR = 1.81, 95% CI 1.29 to 2.55), atrial arrhythmias (Hazard ratio [HR] = 1.48, 95% CI 
1.10 to 1.98), heart failure (RR = 4.19, 95% CI 2.09 to 8.38), as well as cardiovascular death 
(RR = 2.21, 95% CI 1.83 to 2.66) (151-153). However, there is no statistically significant 
differences in the level of lipids and glucose homeostasis parameters observed in women with 
or without a history of gestational hypertension (151). 
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Gestational hypertension and neonatal health 
Gestational hypertension is associated with an increased risk of hypospadias (OR = 1.68, 95% 
CI 1.46 to 1.93) and bronchopulmonary dysplasia (OR = 1.59, 95% CI 1.11 to 2.26) in offspring 
(154, 155). 
Neonates born to gestational hypertension mothers probably have higher risks of cardiovascular 
events (156), low cognitive ability (157), autism spectrum disorder, attention-deficit, 
hyperactivity disorder (158), schizophrenia, mental and behavioural disorders (159), and 
retinopathy of prematurity (160).  
 
Interventions for blood pressure control during pregnancy 
Antihypertensive drugs (such as oral nifedipine, labetalol, and methyldopa) are safe choices for 
treatment of gestational hypertension during pregnancy, but have no effect on reducing risk of 
neonatal cerebral palsy (161-163). Evidence indicates that calcium supplementation in women 
with the risk of gestational hypertension could potentially prevent preterm delivery (164). 
 
Maternal pre-pregnancy weight, gestational weight gain, and glucose concentration during 
pregnancy are associated with birthweight and neonatal metabolic health in previous 
observational studies (102, 111, 113). Meanwhile, maternal lipid levels during pregnancy have 
been recognised as an ignored metabolic risk factor (118). Most of previous studies only 
focused on one specific metabolic trait or on the number of metabolic disorders (165, 166). 
However, these metabolic risk factors highly interact with each other, therefore it is necessary 
to consider the underlying metabolic network when exploring the association between maternal 
metabolic risk factors and neonatal metabolic conditions. To address this we conducted an 
additive Bayesian network analysis to quantify the inter-dependency between maternal 
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metabolic risk factors and their association with birthweight and cord blood insulin level 
(Chapter 4). 
 
Low and high birthweight 
Birthweight and short- and long-term health outcomes 
There is a debate between the use of absolute birthweight and percentile charts. In 1999, a 
systematic review found that the overall mortality and morbidity is raised among neonates with 
birthweight less than or equal to the lowest 3rd percentile for their gestational age (65). Another 
systematic review (2014) found a significantly increased risk of mortality in very low 
birthweight (VLBW, < 1,500 g) neonates, but not in neonates with low birthweight percentile 
for gestational age (167). A recent Bayesian meta-analysis also indicates that SGA babies have 
a significantly higher risk of intrauterine foetal demise (OR = 7.8, 95% CI 4.2 to12.3), neonatal 
death (OR = 3.5, 95% CI 1.1 to 8.0), perinatal death (OR = 5.8, 95% CI 3.8 to 7.8) and neonatal 
intensive care unit admission (OR = 3.6, 95% CI 2.0 to 5.5), compared to non-SGA babies. 
There is no elevated risk of perinatal death, hypoglycaemia, and intensive care unit admission 
was observed in LGA babies (168). Evidence indicates that there is a mild association between 
childhood mobility and SGA (OR = 1.49, 95% CI 1.02 to 2.19), but not with LBW (169). 
Evidence indicates that birthweight might be associated with cognitive ability in childhood 
(170). Compared to AGA, SGA neonates have relatively lower scores on neurodevelopmental 
outcomes (171).  Similarly, VLBW neonates were found to be twice as likely to have anxiety 
problems in later life, compared to term non-VLBW neonates (172). In addition, impairment 
of motor function throughout childhood was also observed in those children with VLBW (173). 
Macrosomic babies were found to have an increased risk of obesity from childhood to early 
adulthood (66), while LBW babies were found to have an increased risk of cardiovascular 
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dysfunction (e.g. endothelial dysfunction, reduced arterial diameters, and altered vascular 
structure) in their later life (174). Compared to babies with appropriate birthweight (2,500 – 
4,000 g), both LBW (OR = 1.32, 95% CI 1.06 to 1.64) and macrosomic (OR = 1.27, 95% CI 
1.01 to 1.59) babies were found to associated with an increased risk of developing type 2 
diabetes (67). 
Babies born small-for-gestational-age (SGA) and large-for-gestational-age (LGA) are at similar 
risks of developing obesity, diabetes, and cardiovascular diseases (65-67). The metabolic 
profiles in SGA and LGA babies are largely unknown, therefore cannot reliably inform clinical 
practice and recommendations to avoid subsequent metabolic dysfunctions. The ectopic fat 
deposition is considered a common feature linking SGA/LGA babies to the risk of subsequent 
metabolic dysfunctions (175). However, it is hard to explain why SGA babies with moderate 
catch-up-growth still show impaired insulin sensitivity in their childhood (176). To investigate 
whether SGA and LGA babies have similar metabolic profile at birth that lead to subsequent 
adverse health outcomes, in Chapter 5 I have evaluated the association of birthweight with cord 
blood metabolic parameters (glucose, lipids, and insulin). 
 
Feeding infants with low or high birthweight 
Breastfeeding is the preferable way to feed all infants. Evidence indicated that human milk 
feeding in LBW babies could help to reduce the risk of late onset sepsis, retinopathy of 
prematurity and severe necrotising enterocolitis, but has no effect on neurodevelopment and 
bronchopulmonary dysplasia (177). 
Additionally, vitamin A supplementation in VLBW infants seems to have minor effects on 
reducing the risk mortality at one month of age and chronic lung disease, but has no effect on 
neurodevelopment (178). 
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1.4 Potential mechanism 
Obesity, insulin, glucose, and lipid metabolism 
Adipose tissue and insulin 
There are three kinds of adipose tissue in the human body: white, beige, and brown adipose 
tissue (179). Obesity is characterized by adipose tissue expansion, especially white adipose 
tissue (WAT) (180). WAT is a key endocrine organ that regulates metabolic homoeostasis. 
Both ‘too much’ and ‘too little’ adipose tissue have been associated with the risk of developing 
type 2 diabetes mellitus, non-alcoholic fatty liver disease, cardiovascular disease, polycystic 
ovary syndrome, as well as several cancers (180). Other than the amount of adipose tissue, the 
distribution of adipose tissue also does matter (181). For people with normal weight, the 
majority of adipose tissue is distributed in the subcutaneous tissue. Ectopic fat accumulation in 
visceral and other non-adipose tissues is considered to be more harmful than the subcutaneous 
adipose tissue (SAT), and plays an important role in development of metabolic dysfunction 
(182).  
Insulin is a peptide hormone secreted by β cells embedded in the pancreatic islets (183). It 
regulates an integrated anabolic metabolism by binding to the insulin receptor on the cell 
membrane of target cells (184). Insulin receptors are expressed in many somatic cells, including, 
but not limited to, WAT, skeletal muscle, liver, neurons, and glial cells (185, 186). Postprandial 
insulin secretion rises steeply, which is stimulated by the ingestion of glucose, amino acids, and 
fatty acids (183). The elevated insulin directly stimulates glucose uptake in skeletal muscle and 
WAT, promotes glycogen synthesis in skeletal muscle and liver, activates lipogenesis in liver 
and WAT, suppresses lipolysis in WAT, and blocks gluconeogenesis and glycogenolysis in the 
liver (187). Thereafter, the blood glucose level will fall gradually back to normal levels.  
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Insulin resistance (IR) occurs when somatic cells do not respond adequately to a normal insulin 
plasma levels  (183). As a result of a compensatory response, the pancreas must secrete more 
insulin into the bloodstream to achieve its previous anabolic effects (188). It is considered a 
pathological condition because the long-term IR is likely to induce β cells decompensation, and 
often eventually progress to type 2 diabetes mellitus (189). In general, chronic overnutrition is 
considered the most important reason for IR. 
As the major lipid-storage organ, the WAT is very sensitive to insulin (183). Stimulation of 
glucose/fatty acid transport and inhibition of lipolysis are the two major physiological function 
of insulin in WAT (190-192). As a consequence of insulin action and excessive nutrients supply, 
the size of individual adipocytes increases. As adipocyte grow, it gradually becomes resistant 
to insulin to avoid further expansion and lipid overload (191). Importantly, the WAT, especially 
the SAT, has limited capacity for hyperplasia (recruit preadipocyte) and hypertrophy 
(enlargement) in a given individual (180). The expansion capacity of SAT is likely determined 
jointly by genetic, epigenetic, and environmental factors (180).  
When lipids accumulation in adipocyte approaches its critical boundary, multiple cytotoxic 
stresses can trigger inflammatory signalling cascades, that results in necrosis of adipocytes (193, 
194). The contents of dead adipocytes, mainly lipids, are then released into the extracellular 
space (195). Chemo-attractants secreted by stressed adipocytes can drive macrophage 
infiltration, thereby inducing chronic inflammatory response locally (185, 191). Chronic 
inflammation has been shown to induce IR in WAT by ‘two-hit’ model, including macrophage 
activation and the secretion of proinflammatory cytokines (such as TNF-α,  IL-6, IL-1β and IL-
8) (185, 196). The elevated circulating proinflammatory cytokines levels will also induce 
chronic low-grade inflammatory response in non-adipose tissues, such as in coronary arteries, 
pancreases, and liver (185, 197). 
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Lipotoxicity and insulin resistance 
Increased lipolysis caused by insulin intolerance and net lipids egress from dead adipocytes 
contribute to the elevated free fatty acids (FFAs) and triglycerides in the blood plasma (185). 
Long-term lipids overload is considered to induce lipids accumulation in non-adipose tissue, 
which is known as ectopic lipid storage (180, 198). Excessive lipids accumulation in liver and 
skeletal muscle plays an important role in the development of IR and other metabolic 
dysfunctions (185). This whole process is referred as lipotoxicity (198). 
Chronic nutrients oversupply drives de novo lipogenesis (DNL) in liver through substrate-push 
(e.g. FFAs, glucose, and amino acids) mechanism that is independent of insulin signalling (199-
202). Lipids overflow from adipose tissue, DNL, together with dietary lipids, lead to elevated 
levels of intrahepatic lipids (203). Moreover, the chronic low-grade inflammation induced by 
proinflammatory cytokines could further contribute to the fat deposition in non-adipose tissues 
(197). 
The intracellular FFAs metabolism mainly occurs in mitochondria through β-oxidative pathway 
(197). Some bioactive lipid intermediates (e.g. diacylglycerol, ceramides, and acyl-carnitines), 
rather than inertly stored triglyceride, have been demonstrated to activate inflammatory 
signalling pathway, inducing the autocrine/paracrine secretion of proinflammatory cytokines, 
thereby enhancing inflammation locally and systemically (204). The accumulation of toxic lipid 
intermediates could also increase oxidative and endoplasmic reticulum stress, thereafter 
inducing mitochondrial dysfunctions (205). It is known that both low-grade inflammation and 
mitochondrial dysfunctions contribute to pathophysiology of IR and type 2 diabetes (185). 
Therefore, lipid intermediates are increasingly recognized as key components in the pathway 
linking the accumulation of lipids and IR (185).  
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Other than liver and skeletal muscle, evidence indicate that the ectopic fat deposition in 
pancreas might induce β-cell dysfunction and insulin resistance (206). Additionally, insulin 
resistance in neurons and glial cells might result in inability to suppress appetite, leading to 
diet-induced obesity (207). It is also indicated that gut-brain-liver axis, hypothalamic-pituitary-
adrenal axis, and brown adipose tissue may also participate in the glucose homeostasis, but  
these haven’t been thoroughly investigated in detail (185).  
 
Maternal metabolism and placental nutrient transport 
Maternal metabolism in pregnancy 
To meet the nutrient requirements of foetal growth and developments, maternal metabolism 
changes with the progression of pregnancy (208). Maternal normal metabolism during 
pregnancy is characterized by ’accelerated starvation’ and ‘facilitated anabolism’ (209). 
Accelerated starvation refers to an intensified response to overnight fasting in pregnant women 
compared to the response in non-pregnant women, including significantly decrease in glucose 
and amino acids, as well as elevated FFAs and ketones in plasma (208, 209). The process of 
maternal metabolism adaptation to ensure adequate nutrients supply to foetus is referred to as 
‘facilitated anabolism’ (209).  
It is well known that maternal fasting plasma glucose and amino acids concentrations decrease 
throughout pregnancy (210, 211). Pregnant women are considered to be in the lipogenesis state 
during the first half of pregnancy, and then switch into a catabolic state in the late pregnancy 
(212). Figure 1 showed that maternal circulating TC, LDL-C, and TG levels drop slightly in 
the first trimester and then enhance dramatically later on, while HDL-C concentration slightly 
increases with the progress of pregnancy (107). As the insulin sensitivity decreases gradually 
 57 
during pregnancy, the maternal fasting insulin concentration is about three times higher than it 
was before pregnancy (208, 212).  
 
Maternal fuels and its placental transfer 
As the principle nutrient substrate, glucose could be transported from maternal side to neonatal 
side freely by facilitated diffusion through the glucose transporter (GLUT) family members, 
especially the GLUT1 (213). Since gluconeogenesis in foetus is minimal, the entire foetal 
glucose is almost transported from the maternal side (214, 215).  
The vast majority of maternal circulating FFAs (98%) are stored as triglycerides in triglyceride-
rich lipoproteins in plasma (216). Triglycerides themselves cannot cross the placenta directly. 
They have to break down into FFAs and glycerol by lipases in placenta, and then transported 
to foetal side by specific transport proteins and diffusion (215). The lipid metabolites delivered 
from maternal side become the majority substrate for neonatal de novo lipogenesis in liver and 
muscle (216).  Evidence also indicates that human placenta could actively take up maternal 
lipoprotein cholesterol and dietary chylomicrons through specific lipoprotein receptors-
mediated transport or endocytosis (217, 218).   
The placenta can take up maternal circulating amino acid actively through amino acid 
transporters (219). Moreover, the amino acid concentration in foetus is normally higher than in 
mothers (220). Also maternal circulating insulin cannot cross the placenta, but it may 
significantly influence the efficiency of nutrient transport in the placenta (221).  
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Intrauterine nutritional programming 
Foetal origins hypothesis 
In 1990s, David Barker, a British epidemiologist, first proposed a hypothesis that intrauterine 
growth retardation may be the original causality for the development of cardiovascular diseases 
(222-225). This hypothesis is certainly limited in scope, but it has a profound impact on 
people’s understanding on the origins of chronic metabolic diseases.   
The foetal origin hypothesis, also known as ‘foetal programming’, has been widely recognised 
and supported by evidence from epidemiological and epigenetics studies (226). It proposes that 
the intrauterine environment, especially the nutritional environment, has a life-long impact on 
the developmental health and chronic metabolic conditions of the offspring (227). 
 
Nutritional programming 
The foetal programming starts from preconception period. Evidence shows the physiology of 
the gametes changed significantly in people with obese, compared with non-obese people (228). 
The quality and content of oocyte is significantly influenced by maternal diet and obesity 
through lipotoxicity and oxidative stress mechanism (229-231). Although evidence regarding 
the programming effects of paternal obesity is limited, some studies indicated that paternal BMI 
is significantly associated with DNA damage and methylation, altered miRNA content, 
spermatogenesis, and function in sperms (232-236). The preconceptional exposure to negative 
nutritional environments seems have persistent impact on the epigenetic and translation profile 
of the developing embryo, thereby leading to altered phenotypes in offspring (228).  
All organs of foetus are formed during pregnancy. Therefore, gestation period is recognised as 
a sensitive time window for foetal development. The structural or functional changes of tissues 
or biological system in response to different environmental input is referred to as ‘adaptive 
 59 
developmental plasticity’ (237, 238). The early developmental regulation events in foetus are 
particularly sensitive to the intrauterine nutritional environment. Stress induced by the deficient 
or overwhelming nutrient exposure in utero can systematically shape foetal development, 
leading to permanent changes of metabolic function in offspring (237).  
Compared to lean women, women with higher BMI tend to progress to lipid catabolic state 
earlier and often present with a more severe dyslipidaemia during pregnancy (239). In addition, 
evidence indicates that women with GDM have a significant higher triglycerides and lower 
HDL-C than non-GDM women throughout three trimesters (108). About 90% fat deposition in 
foetus occurs in the third trimester, coincident with the maximal lipids placental transport 
period (240).   
Evidence indicates that a steep concentration gradient across the placenta due to high levels of 
maternal circulating triglycerides can accelerate lipid placental transport rates, leading to fat 
deposition in foetus. A two-thirds alteration of placental gene expression in women with type 
1 diabetes or GDM is relevant to lipid pathways, while only 9% of which is relevant to glucose 
pathways (241). Meanwhile, the activity of lipid transport protein and lipoprotein lipases in the 
placenta could potentially be upregulated by maternal hyperinsulinemia and hyperglycaemia, 
resulting in elevated lipids placental uptake and transport (242). Additionally, just like other 
tissues, it seems that maternal obesity could induce low-grade inflammatory response in the 
placenta, resulting in possible functional changes (243). However, the underlying mechanism 
have not yet been well established.   
Excessive lipid exposures in uterus may potentially influence the development of foetal 
metabolic organs (e.g. liver, adipose tissue, muscle, brain and pancreas) through several 
pathways. First, the increased intrauterine FFAs exposures and its intracellular fatty acid 
intermediates could induce systematic chronic low-grade inflammation, leading to insulin 
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resistance in the foetus (244). Secondly, increased lipids input may induce ectopic fat deposition 
in non-adipose tissues (239). Thirdly, the ectopic lipid accumulation in foetal liver and muscle 
could result in oxidative stress and mitochondrial dysfunction (245, 246). Fourthly, the 
excessive FFAs exposure in utero may induce β-cell apoptosis in pancreas through endoplasmic 
reticulum stress pathway (247). Finally, the increased maternal circulating lipids could 
potentially change the feeding behaviour of their offspring through regulating appetite relevant 
neuronal genes and hypothalamic-pituitary-adrenal axis (248, 249).  
Glucose transported from maternal side could stimulate de novo insulin synthesis in the foetus. 
As insulin plays a central role in foetal growth and development, the additive effects of maternal 
hyperglycaemia may have a profound impact on metabolic health of offspring. GDM 
pregnancies have been linked with placental structural dysfunction, and increased inflammatory 
response as well as oxidative stress in placenta, thereby leading to chronic foetal hypoxia (250-
252). It is also indicated that neonates born to GDM mothers have reduced β-cell mass, because 
the development of pancreas in foetus is particularly sensitive to intrauterine hyperglycaemia 
(253). Compared to neonates with non-GDM mothers, neonates with GDM mothers were 
observed to have altered DNA methylation levels in their placenta and cord blood (254). It 
demonstrated that intrauterine hyperglycaemia exposure may have a persistent influence on 





The aim of this thesis was to determine the metabolic risk factors in mothers and their babies, 
and to investigate how these metabolic risk factors influence one another. Technical details will 
be presented in Chapter 2. Specifically, this project aimed to evaluate: 
1. The association between maternal lipid levels during pregnancy and adverse birthweight 
outcomes (Chapter 3) 
2. The interdependency between maternal metabolic risk factors and birthweight as well 
as cord blood insulin level (Chapter 4) 
3. The association between birthweight and cord blood metabolic parameters (Chapter 5) 
4. The association of birthweight and cord blood triglycerides with Interleukin 6, C-






Chapter 2 General Methods 
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In this chapter, I will present the systematic review protocol (2.1), then describe the BIGCS 
cohort study along with an overview of study designs (2.2), and finally, highlight the key 
statistical methods used in the analysis (2.3).  
 
2.1 How does maternal dyslipidaemia influence neonatal birthweight, 




Metabolic risk factors, including BMI, glucose, and dyslipidaemia, and its subsequent health 
outcomes have become one of the most important public health concerns globally. In vivo 
evidence indicates that maternal metabolic disorders, especially dyslipidaemia, might hold a 
key role in the process of foetal programming, which might increase the risk of metabolic 
dysfunctions or even further induce early onset of cardiovascular disease in offspring. The 
effects of intrauterine over-nutrition over the life-course might be a vicious cycle across 
generations. However, most of these metabolic risk factors are controllable and preventable. In 
this review, existing primary epidemiological evidence will be collected and synthesized to 




Electronic searches will be performed in the Embase (1974 to current), MEDLINE (1946 to 
current), PubMed (1950 to current), Scopus (1960 to current), PsycINFO (1967 to current), 
CINAHL Plus (EBSCO,1937 to current) and Cochrane Library (1974 to current) databases. 
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Secondary searches will be conducted in Grey literature, Open grey and google scholar for 




Study design: Longitudinal observational studies 
Population: Studies focused on general pregnant women, pregnant women with 
gestational diabetes mellitus or obesity are eligible for this review. 
Exposures: Maternal lipid levels during pregnancy (Total cholesterol, high-density-
lipoprotein cholesterol, low-density-lipoprotein cholesterol, very low-density-lipoprotein 
cholesterol, triglycerides, and free fatty acids). 
Outcomes: The primary outcome of this review is birthweight. The secondary outcomes 
include neonatal metabolic as well as inflammatory parameters. 
Comparators: Not applicable. 
 
Data extraction, quality assessment and analysis 
A designed data extraction form and the adapted Newcastle-Ottawa Scale (NOS scale) will be 
used in this review. The data extraction and quality assessment process will be undertaken by 
the first author and the second author independently. If any disagreement exists, a third 
individual (expert) will be invited to discuss it before reaching a final decision. Different format 
of data will be converted into same format if applicable. Meta-analysis method (random-effects 
model) will be used to synthesis the extracted data.  I2 statistics will be used to measure the 
degree of heterogeneity between studies for each outcome. Funnel plot will be used to detect 
the existence of publication bias visually. 
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Systematic review registration:  





Approximately 7% newborns in United States (2015) as well as in China (2011) are diagnosed 
as having macrosomia (255, 256). It has been well established that neonatal birthweight is 
related to the risk of developing subsequent obesity, type 2 diabetes and cardiovascular diseases 
in later life (66, 67, 257). Maternal metabolism during pregnancy has been demonstrated as a 
key component that might program foetal health systematically from the beginning of life (258, 
259). Apart from maternal glucose level during pregnancy, recent literature has shown that 
maternal lipid levels during pregnancy might also play an important role in the process of foetal 
programming (239, 260).  
 
Dyslipidaemia caused by obesity might further induce pre-diabetes status among non-pregnant 
population 
As a lipids storage organ, the buffering function of adipose tissue decrease when lipid 
accumulation exceeds its storage capacity, leading to elevated serum free fatty acids (FFAs) 
and triglycerides (TG) (261-263). This results in the net lipid flux to non-adipose organs, which 
is called ectopic fat stores (262). As obesity progresses, chemoattractants secreted by unhealthy 
and larger adipocytes could drive macrophage infiltration in adipose tissue (264, 265). When 
ectopic lipid accumulation occurs in liver, muscle and pancreas, pro-inflammatory cytokines 
produced by macrophages can directly engender insulin resistance (IR) in those organs and may 
result in diabetes through NFκβ, c-Jun N-terminal kinases and oxidation stress pathways (262, 
264, 266, 267). 
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How maternal dyslipidaemia might work on neonatal health? 
During the first half of pregnancy, pregnant women are mainly in lipogenesis state, then they 
switch to catabolic state (268-270). With the progression of pregnancy, women’s ability to 
inhibit lipolysis decrease as a result of relative insulin resistance, resulting in steep 
concentration gradient across the placenta. This results in lipids transport into foetus through 
placenta (239, 271). Compared to pregnant women with normal weight, obese women will not 
only progress to catabolic state earlier, but have severe hyperlipidaemia, which presents as 
lower high-density lipoprotein cholesterol (HDL-C) level and higher very low-density 
lipoprotein cholesterol (VLDL-C)/ free fatty acids (FFAs) levels (239), 
Human placenta could actively/passively take up maternal lipoproteins and dietary 
chylomicrons through specific lipoprotein receptors-mediated transport or endocytosis (217, 
272). The changes in maternal lipid profile could alter both the quantity and quality of 
transplacental lipids (217). In addition, Radaelli et al. reported that 67% of changes in placental 
gene expression in GDM women relates to lipids transport pathways, but only 9% to glucose 
transport pathways (241). In the placenta of obese mothers, it has been observed there is 
enhanced expression of proinflammatory cytokines and significant accumulation of 
heterogeneous macrophage population (243). This indicates that persistent low-grade 
inflammation in placenta might be one of the mechanisms of excessive lipids accumulation in 
pregnancy (239). 
In vivo evidence has shown that excess maternal intrauterine lipids exposure could affect the 
development of foetus organs systematically, such as skeletal muscle, adipose tissue, liver, 
pancreas, and brain, through several metabolic pathways (239).  It containing oxidative stress 
pathways, inflammatory pathway, Peroxisome Proliferator-Activated Receptor γ pathway, 
hypothalamic leptin pathway, and metabolic epigenetic programming pathway, which can alter 
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initial foetus metabolism and even feeding behaviours permanently (239). Foetus metabolic 
abnormalities mediated by maternal obesity and high-fat diet often manifest as increased body 
weight, fat mass, blood glucose, cholesterol, and blood pressure levels, as well as decreased 
insulin sensitivity, and ectopic lipid storage (239). 
 
Why it is important to do this review? 
Maternal dyslipidaemia during pregnancy and its consequent health outcomes have produced 
heavy burden on economy and health globally. However, these are controllable and preventable. 
One review proposed that the effects of intrauterine overnutrition over the life-course might be 
a vicious cycle across generations, likely increasing the risk and/or accelerating the onset of 
metabolic disorders like obesity and diabetes in the offspring (243). As an upstream risk factor, 
if the maternal dyslipidaemia is demonstrated as the key node of the whole metabolic pathway, 
early interventions on maternal lipids profile during pregnancy might be a viable option to 
reduce the risk of GDM and other related adverse health outcomes.  
There are several systematic reviews surrounded this topic, but none of them discussed the 
effect of maternal dyslipidaemia on neonatal health outcomes. Evidence around the impact of 
maternal dyslipidaemia on neonatal birthweight and metabolic condition is still inconclusive. 
Therefore, it is necessary to conduct a review to synthesis existing evidence systematically to 
have a better understanding. This review aims to investigate the relationship between maternal 




To investigate the association between maternal lipid levels in pregnancy and birthweight. 
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Secondary objectives 
1) To investigate the association between maternal lipid levels in pregnancy and neonatal 
metabolic parameters. 
2) To identify studies that might have tested the potential mechanisms linking maternal 




Electronic searches will be performed in the Embase (1974 to current), MEDLINE (1946 to 
current), PubMed (1950 to current), Scopus (1960 to current), PsycINFO (1967 to current), 
CINAHL Plus (EBSCO,1937 to current) and Cochrane Library (1974 to current) databases 
(273). The best study designs for causality studies are cohort study and randomized controlled 
trial (RCT), therefore, we limit our searches by using cohort and RCT study filters to identify 
the most robust evidence for this study.  
Secondary searches will be conducted in Grey literature, Open grey, and Google Scholar for 
potential grey literatures and relevant reviews. Abstracts, conference, and symposia proceeding 
from relevant organisations will be identified as well. References lists will be checked carefully 
to identify any available primary studies or reviews. Therefore, it is reasonable to believe that 
every eligible study in these three databases will be picked up through our primary and 
secondary searches.  
Screening for the search results will be undertaken by the first author (JW) and the second 
screener independently to confirm the accuracy of selection. If there is any disagreement of 
study selection after discussion, the third person (expert in this field) will be asked to resolve 
any issues. Non-English studies that eligible for this review will be translated into English by 
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an independent translation company to ensure there is no language restrictions in our searches. 
Results of search will be entered into EndNote X7 to facilitate record keeping, duplicate 
removal, study selection and document writing. 
Inclusion and exclusion criteria and selection strategy 
• Types of studies 
Longitudinal observational studies and secondary analysis of randomised controlled trials will 
be included in this review.  
• Types of participants 
Studies focused on general pregnant women, pregnant women with GDM (treated with either 
diet or insulin) or obesity are eligible for this review. The diagnostic criteria for GDM and 
obesity are different in different populations. Therefore, we accept the concept of GDM/obesity 
defined by the study author. Any studies focussing on population of pregnant women with 
diseases/conditions that could influence maternal metabolic status before pregnancy (hepatitis, 
polycystic ovary syndrome, familial hyperlipidaemia, human immunodeficiency virus [HIV] 
infection, type 1 & type 2 diabetes, hypertension, thrombophilia history of thromboembolism, 
rheumatologic disorders, cardiac dysfunction, or history of taking relevant lipid-lowering 
medicines) will be excluded. 
• Types of exposures 
Maternal lipid levels during pregnancy (TC, HDL-C, LDL-C, VLDL-C, TG and FFAs).  
• Types of outcome measures 
Subjects: all living neonates (less than three years old)  
The primary outcome of this review is birthweight, which should be measured in the 
first week after delivery. 
Secondary outcomes 
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1. Neonatal birthweight parameters, including low birth weight (LBW), small for 
gestational age (SGA), large for gestational age (LGA) and macrosomia (as defined by the 
study author) 
2. Neonatal metabolic status 
a) Anthropometric indicators (weight gain, BMI, skinfold thickness) 
b) Circulating metabolic parameters (glucose, TC, HDL-C, LDL-C, VLDL-C, 
triglycerides, FFAs, and insulin) measured in cord blood or blood samples taken from neonates.  
3. Inflammatory factors level, involving Monocyte Chemoattractant Protein-1, 
interleukin 6, tumour necrosis factor-alpha and 11-beta-Hydroxysteroid Dehydrogenase Type 
1, and C-reactive protein, measured in cord blood or blood samples taken from neonates. 
4. Leptin level measured in cord blood or blood samples taken from neonates.  
• Types of comparators 
Currently, there is no guideline mentioned about what is the ‘normal’ range of maternal lipid 
levels during pregnancy clearly. Given the knowledge of maternal lipid levels changes with 
progression of pregnancy, no comparator limitation will be applied in this review.  
 
Data extraction and quality assessment strategy 
The designed form for data extraction will be applied in this review. To evaluate the quality of 
included cohort studies under our topic, an adapted ‘star system’ quality assessment tool, the 
NOS scale will be used in this review (274). Both the data extraction and quality assessment 
process will be conducted by the first author and the second screener independently. Where 
disagreements exist, the third individual (expert) will be invited to review and discuss the issue 
before reaching a final decision. 
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Methods of analysis/synthesis 
• Measures of effect size 
For continuous outcomes (insulin, glucose, lipids, inflammatory factor and leptin levels, and 
early postpartum weight gain), results will be summarised and represented with tables in its 
original format. For categorical outcome variables with clear gold-standard cut-off point (e.g. 
macrosomia, LGA, AGA and SGA), odds ratios will be used for pooling.  
• Dealing with missing data 
A comprehensive strategy has been developed for dealing with missing data. For all included 
studies, the percentage of missing data and its reasons will be recorded in data extraction form. 
Authors will be contacted for unreported results. Sensitivity analysis will also be conducted to 
evaluate the impact of including or excluding potentially unreliable results due to missing data. 
• Assessment of heterogeneity 
I2 statistics will be used to measure the degree of heterogeneity between studies for each 
outcome (275). Once heterogeneity is identified (I2-value ≥ 50%), reasons behind it will be 
discussed based on the baseline characteristics of study design (276). 
• Assessment of reporting biases 
Funnel plot, a scatterplot of common effect against measure of study size, will be used to detect 
the existence of publication bias visually (277, 278). Theoretically, a symmetric funnel shape 
indicates low risk of publication bias (277). Conversely, asymmetric funnel indicates the 
existence of publication bias and substantial heterogeneity. Therefore, a result with an 
asymmetric funnel should be explained carefully (279, 280). Otherwise, a funnel plot will be 
used only for over 10 studies in this review (281). 
• Data synthesis 
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Random-effects model will be performed to compare dichotomised outcomes (odds ratio). 
Meta-analytic software (Review Manager 5.3) will be used for calculating and combining data 
(282). Variability among effect sizes will be evaluated by the Q statistics and the I2 index. For 
dichotomous data, the result of random-effects analysis will be presented as the average effect 
size with 95% confidence intervals, and the estimate value of I2. 
• Subgroup analysis and investigation of heterogeneity 
We plan to conduct subgroup analysis among obese GDM group, obese non-GDM group, lean 
GDM group and lean non-GDM group. Once substantial heterogeneity is identified, subgroup 
analysis will be performed based on its study characteristics. Additionally, the effect of 
maternal dyslipidaemia on different ethnic populations will also be analysed through subgroup 
analysis. To avoid selective reporting biases, all planned analyses will be presented in this 
protocol. Any additional analyses will be marked as ‘post’. 
• Sensitivity analysis 
Sensitivity analysis will be performed based on methodological quality, ethnic populations, 
publication status and sample size scale. 
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2.2 The association between maternal metabolic risk factors and neonatal 
anthropometric and cord blood metabolic parameters: A research proposal 
 
Abstract 
Background and objective 
Maternal pre-pregnancy body mass index (BMI), gestational weight gain (GWG), and 
gestational diabetes mellitus are independent risk factors for macrosomia. Current clinical 
guidelines provide pregnant women advice on diet and exercise for reducing the risk of adverse 
metabolic pregnancy outcomes. However, recent evidence shown that life style changes during 
pregnancy achieved limited success in reducing GWG and did not have any effect on composite 
maternal and foetal outcomes. The aim of study is to investigate the interdependent association 
of maternal metabolic risk factors with birthweight and cord blood insulin, and to explore the 
association between birthweight and cord blood metabolic parameters.  
 
Methods and analysis 
Data from the Born in Guangzhou Cohort study (BIGCS), an ongoing prospective longitudinal 
birth cohort, will be used in this study. Primiparous women with a singleton pregnancy and 
their offspring who participant in BIGCS study are eligible for this study. Maternal fasting 
blood samples and cord blood samples will be assayed for metabolic parameters. Other relevant 
information will be extracted either from the clinical records or questionnaires. Descriptive 
analysis followed by multivariable regression model, Bayesian network analysis, as well as 
generalised additive model will be applied to analyse the data.  
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Ethics and dissemination 
The protocols for this study of BIGCS will be reviewed and approved by the Institutional Ethics 




Metabolic disorders have become a serious health concern in China 
Metabolic risk factors, including central obesity, dyslipidaemia, hypertension, and impaired 
glucose tolerance, that might progress to diabetes mellitus, cardiovascular diseases, and certain 
cancers in later life (283, 284). Apart from the long-term effect of these metabolic risk factors 
among the adult population, evidence indicates that metabolic dysfunctions before and during 
pregnancy in mothers, such as diabetes mellitus, obesity, and dyslipidaemia, might significantly 
influence neonatal metabolic conditions (285, 286). The effect of intrauterine overnutrition and 
its subsequent long-term health outcomes might become a vicious cycle across generations for 
human (287).  
Around 27.9% of Chinese female in childbearing age (18 - 44 years old) were overweight or 
obese, and 29.7% of the female population were found to have hypertriglyceridemia (288-290).  
On the other hand, studies have shown that increased neonatal birth weight might be related to 
increased adiposity and early on-set metabolic disorders (66, 291, 292). Data from the China 
Health and Nutrition Survey showed that the standardized incidence of overweight (new cases 
between 1991 and 2000, and between 2000 and 2011) of children aged 2-6 years old across two 
decades increased from 2.3% to 8.3% (293). These data indicate that metabolic disorders of 
mothers and their offspring have become one of the most important public health concerns in 
China currently.  
 
The altered maternal metabolism in pregnancy 
Once women become pregnant, their energy homeostasis is challenged by the increased 
demands of pregnancy when suboptimal adaptive responses may be noted. Consequently, the 
glucose/lipid levels and weight of pregnant women change dramatically during pregnancy, 
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which might in turn influence the metabolism of their offspring from the early beginning of 
their life. In 2008, the prevalence of GDM was 6.2% among women living in urban Tianjin 
(China) (294). A systematic review published in 2015 demonstrated that dyslipidaemia in 
pregnancy might be an independent risk factor for GDM, although there is no clear definition 
for gestational dyslipidaemia to date (108). 
 
Maternal metabolic disorders are critical for foetal programming 
It has been established that maternal pre-pregnancy body mass index (BMI), gestational weight 
gain (GWG), and GDM are independent risk factors for macrosomia, but recent studies also 
indicated only a quarter of the difference of birth weight in multivariate models could be 
explained by maternal hyperglycaemia (239, 295, 296). Among GDM women with well-
controlled glucose level, researchers found that maternal fasting serum TG and free fatty acids 
(FFAs) level may be independent risk factors for neonatal high birth weight and fat mass (166, 
297). Therefore, we hypothesised that maternal metabolic conditions, including obesity, 
glucose, and lipid levels, might play important role in the process of foetal programming jointly 
(295, 298). 
 
It is necessary to investigate the association between maternal metabolic risk factors and 
neonatal health 
Epidemiological studies have demonstrated that maternal metabolic risk factors (high pre-
pregnancy BMI, excessive GWG, and GDM) could results in high birth weight of their 
offspring (299-302). However, none of these studies investigated the impact of maternal 
metabolic disorder on neonatal metabolism. Importantly, an individual patient data meta-
analysis concluded that diet and lifestyle interventions in pregnancy only achieved modest 
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success in reducing gestational weight gain and had no effect on composite maternal and foetal 
outcomes (303). Meanwhile, gestational dyslipidaemia is gaining attention from researchers 
and clinicians, and has been considered as an ignored risk factor for adverse pregnancy 
outcomes. Evidence show that excessive intrauterine lipids exposure can affect the 
development of foetus organs systematically through oxidative stress and also by inflammatory 
and metabolic epigenetic programming pathways (239). If we could figure out how maternal 
metabolic parameters influence neonatal birthweight and metabolism, then early optimal 
interventions on the most critical risk factors might be a viable option to avoid subsequent 
adverse health outcomes. Therefore, the aim of this study is to disentangle the association and 
interdependency of maternal metabolic risk factors during pregnancy with neonatal 
anthropometric parameters and metabolic markers in cord blood through a large well 




To investigate the association of maternal metabolic risk factors (pre-pregnancy BMI, mid-
pregnancy glucose, total cholesterol, HDL-C, LDL-C, and triglycerides) with birthweight. As 
insulin plays a central role in the foetal growth and development, the association between 
maternal risk factors and cord blood insulin will be further explored as well. 
 
Secondary objectives 
1. To investigate the interdependency of maternal metabolic risk factors and their 
association with birthweight as well as cord blood insulin; 




Setting: The BIGCS study 
 What is the BIGCS study 
The Born in Guangzhou Cohort Study (BIGCS) is an ongoing prospective longitudinal birth 
cohort study, which was established to investigate the short- and long-term health consequences 
in the younger generation, whose parents have experienced one of the world’s most rapid 
societal and epidemiological transition in their lifetime. It aims to recruit 20-30,000 pregnant 
women in Guangzhou within 5-10 years from 2011 and follows them and their offspring. The 
main investigations of BIGCS include maternal lifestyle, nutrition, psychosocial stress, medical, 
and environmental conditions before, during, and after pregnancy as well as neonatal health 
conditions in early and late childhood. 
 Design of the BIGCS study 
Participants: All pregnant women attending the maternity units in Guangzhou Women and 
Children’s Medical Centre (GWCMC) are eligible for the study. Pregnant women who do not 
live in Guangzhou or plan to leave Guangzhou within 3 years are excluded from this study. 
Women who attend pregnant routine antenatal examinations or come for the first pregnancy 
visit (usually during weeks 6 - 16) were invited to participate in the BIGCS.  
Follow-up: The schedule for collection of data and biological samples is attached below in 
Table 6.  
Funding: The establishment of the BIGCS has been supported by grants from Guangzhou 
Municipal Government and Guangzhou Women and Children’s Medical Centre. 
 Implementation of the BIGCS 
Since then to date it has recruited 30,000 number of patients. 
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Table 6 Schedule for collection of data and biological samples 





Antenatal    
Before week 11 Early pregnancy clinic visit   
Weeks 11-16 
First trimester clinic visit/ 
Down Syndrome screening 
Q1 Parental blood 
Weeks 20-24 Second trimester clinic visit 
Q2 (food frequency 
questionnaire) 
Maternal blood 
Weeks 30-33 Third trimester clinic visit Q3 Maternal blood, urine 
At birth Delivery at hospital Q4 
Maternal blood, cord 
blood, placenta and 
umbilical cord tissues 
Postnatal    
3 months Telephone interview / home visit Q5  
6 months Telephone interview / home visit Q6  
12 months Children’s health care visit Q7 Blood, urine 
18 months Telephone interview / home visit Q8  
36 months Children’s health care visit Q9 Blood 





All healthy adult (aged over 18 years old) primiparous women with a singleton pregnancy who 
have fasting blood samples collected during the second trimester in BIGCS study are eligible 
for this study. Women with conditions that influence their metabolic response during pregnancy 
were excluded from the study. Conditions excluded were liver diseases, kidney diseases, 
pancreas diseases, polycystic ovary syndrome, immune system diseases (human 
immunodeficiency virus infections or erythematosus), inherited metabolic diseases (familial 
hyperlipidaemia or 21-hydroxylase deficiency), type 1/ type 2 diabetes, thyroid dysfunction, 
hypertension, thrombophilia, history of thromboembolism, rheumatologic disorders cardiac 
dysfunction, history of organ transplant before pregnancy,  records of Intrauterine infections, 
miscarriage and stillbirth during this pregnancy/labour, have neonatal with inherited metabolic 
diseases and congenital abnormalities, have missing samples of cord blood, or dropped out 
before labour.  
 
Sample size 
We powered the study for the potentially least associated maternal metabolic risk factor (TG) 
for birthweight. Knopp et al. reported a correlation between maternal TG and birthweight of r 
= 0.09 (p < 0.05) in non-GDM women (304). We conservatively assumed an effect size of 0.08. 
Stata 14.0 was used to calculate the sample size. After using ‘Fisher’s z tests comparing one 
correlation to a reference value’ tool, a sample of 1,225 will give 80% power to detect a 
correlation of 0.08 at 5% significance level (two-sided). We conservatively assumed 20% 
attrition rate due to missing data and loss to follow up, thus giving a sample size of 1,531.   
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Samples collection and storage 
Maternal fasting blood samples are collected (for OGTT test and storage) in the second 
trimester clinic visit. The umbilical cord vein blood samples are collected after labour. All 
samples are taken into an Ethylenediaminetetraacetic acid (EDTA) tube for serum and plasma 
separately, which are stored in the biobank at -80°C until analysis. 
 
Exposures  
Once pregnant women are enrolled into the BIGCS study, baseline information (such as 
maternal age, height, pre-pregnancy weight, ethnicity, education level, marital status, social-
economic level, working status, family and housing environment, smoking status, alcohol use 
and medicine history) would be collected via the Q1 questionnaire (self-completed).  
Participants were routinely given a 75g, 2h OGTT for GDM screening in a prenatal care visit 
(20 - 28 weeks). The diagnosis of GDM is made when any of the following blood glucose 
values is met or exceeded based on the criteria developed by the International Association of 
Diabetes and Pregnancy Study Groups: fasting, 5.1 mmol/l; 1h, 10.0 mmol/l; 2h, 8.5 mmol/l 
(40).  
Maternal pre-pregnancy BMI and paternal BMI are calculated using the weight in kilograms 
and the height in metres (305). Based on the recommendations of the China Obesity Task Force 
of the Chinese Ministry of Health, pre-pregnancy BMI is classified as two groups: lean group 
(< 23.9 kg/m2) and overweight group (≥ 24 kg/m2) (306). Gestational weight gain is defined as 
the increase in maternal weight during pregnancy, which is calculated by maternal terminal 
weight minus pre-pregnancy weight. 
Maternal fasting blood samples will be analysed for lipids profile, which including total 
cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C) and TG. Automated 
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clinical chemistry analyser, which is based on enzymatic colorimetric assays, will be used to 
perform samples analysis. Evidence have shown that there is no significant changes in the 
stability of lipids profile test measurements based on samples stored at -80°C for a period up to 
24 months (correlation between fresh plasma and samples stored for 24 months are 0.990 for 
TC and HDL-C, and 1.000 for TG). Multiple freezing and thawing of plasma samples have no 
influence on the measured studied lipids profiles as well (307, 308).  
 
Outcomes 
 Primary outcome 
The primary outcome of this study is birthweight and cord blood insulin concentrations. The 
value of birthweight will be extracted from clinical records. On the basis of Intergrowth 21st 
Newborn Size Standard and Tools, newborns will be classified into large for gestational age 
(LGA, birthweight ≥ 90th percentile for gestational age), appropriate for gestational age (AGA, 
birthweight ＞ 10th or ＜ 90th percentile for gestational age) and small for gestational age (SGA, 
birthweight ≤ 10th percentile for gestational age)(309). Macrosomia is defined as birthweight 
over 4000g (310). In China, the overall prevalence of macrosomia in 2011 was 7.3%. The 
prevalence of macrosomia in southern China is 5.6%, which is much lower than in northern 
China (8.5%) (256). Cord blood insulin will be measured by monoclonal antibody-based 
sandwich enzyme-linked immune sorbent assay (ELISA) (311).  
 Secondary outcomes 
The secondary outcomes of this study are glucose and lipids concentrations in venous cord 
blood. The concentrations of plasma glucose in venous cord blood samples will be assayed 
using automatic biochemistry analyser. The analytical stability of glucose level will not be 
influenced by numerous freeze-thaw and up to 3 months -20℃ storage (312). Venous cord blood 
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samples will be analysed for TC, HDL-C, LDL-C and TG, using automated clinical chemistry 
analyser. There is scarce literature reporting lipid profile distribution in cord blood. In one study 
conducted in Iran (n = 442), the reported distribution of lipids profile in cord blood was TC 
76.9mg/dL (SD = 28.9 mg/dL), HDL-C 30.1mg/dL (SD = 28.9 mg/dL), LDL-C 34.1mg/dL 
(Standard deviation [SD] = 11.7 mg/dL) and TG 67.5 mg/dL (SD = 20.1 mg/dL) (313). 
 
Covariates 
Information on maternal terminal weight, parturition methods (caesarean section, assisted 
delivery or eutocia), preterm birth (defined as birth of newborns less than 37 weeks gestational 
age), pre-eclampsia and eclampsia, intrauterine growth restriction and neonatal gender will be 
extracted from clinical records of subjects in BIGCS study.  
 
Statistical analysis 
Data analysis will be performed using Stata 14.0. The following analyses will be included: 
1. Descriptive analysis 
2. Multivariable regression model (to qualify the linear associations between independent 
variables and dependent variables) 
3. Generalized additive model (to explore the potential non-linear associations between 
independent variables and dependent variables) 
4. The Bayesian Net-work analysis (to identify potential pathways of action if there were 
to be a positive relationship between maternal metabolic risk factors and neonatal 
outcomes linked to or predisposing to metabolic dysfunctions) 




The protocol for this study in BIGCS was reviewed and approved by the Institutional Ethics 
Committees at the women and children centre at Guangzhou. Written, informed consent was 
obtained from all participants. All participants were voluntarily joining BIGCS and can 
withdraw their consent at any time. The identity of participants was covered by a unique number. 
This number was used to links all data acquired from the participant, her partner (biological 
father of the offspring), and her offspring (including multiple births). All records and biological 
samples used for this study have been collected by researchers in BIGCS.  
 
Discussion 
The BIG study is a unique large prospective birth cohort resource for disentangling the effect 
of maternal metabolism on neonatal health outcomes during pregnancy (272). To our 
knowledge, it is the first study trying to elaborate a comprehensive disease casual network of 
maternal and neonatal metabolisms in the same population.  
The BIG study is conducted in Guangzhou, a Southern Chinese city, where there are less obese 
women (18.4%, BMI ≥ 25, 2001) than Northern city in China (36.9%, BMI ≥ 25, 2001) and 
Western countries (33.3%, BMI ≥ 30, 2001) (314, 315). The dietary habits, lifestyle and climate 
environments have distinct differences compared with other populations (315). As a tertiary 
hospital-based cohort study, the population of this study mainly come from urban areas, with 
features of modern lifestyle. We are unsure how these features will influence our results.  
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2.3 Introduction to statistical methods 
Multivariable regression model 
Multivariable regression model refers to a statistical method that can be used to determine the 
relationship between one dependent variable and a number of independent variables (316).  
There are three multivariable regression models that are commonly used in the public health 
literature: multivariable linear regression, multivariable logistic regression, and multivariable 
Cox proportional hazards regression (317). A multivariable linear regression model could be 
defined by this equation: Y= α + X1β1 +X2β2 + … + Xkβk + ε (316). 
The model structures of logistic regression and Cox proportional hazards regression are similar 
to the linear regression model. The multivariable logistic model could be used to assess the 
association between a dependent binary outcome and more than one independent variables 
(318). The multivariable Cox proportional hazards regression model could be used to 
investigate the association between several independent variables and the time at which a 
specific event occurs (319).  
 
Additive Bayesian Network analysis 
A Bayesian network is a probabilistic graphical model that represents a set of variables and 
their conditional dependencies via directed acyclic graphs (DAGs) (320). It is a well-established 
unsupervised machine learning methodology that is typically referred to as structure discovery 
model for dealing with multidimensional data (321). Unlike other widely used multivariate 
approaches, such as principal component analysis, propensity score matching analysis and 
multivariate regression model, graphical modelling does not involve any dimension reduction. 
Most graphical models, including path analysis and structural equation modelling, rely on a 
pre-specified structure, whereas Bayesian network is entirely data driven. 
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Unlike the contingency table parameterization in standard Bayesian network models, Additive 
Bayesian networks (ABN) allow us to obtain interpretable DAGs where each node in graph 
comprises a generalized linear model (GLM) or a generalized linear mixed model (GLMM, if 
binary variable involved) (322, 323). There are two mutually dependent parts in ABN model: 
a network structure (i.e. the DAG) and a set of parameters. Each node (corresponding to the 
variables in the dataset) in the DAG is the equivalent of a potential dependent variable in a 
Bayesian GLM or GLMM regression model. While other DAG nodes where relevant as 
identified by the unsupervised learning act as covariates, having a role of corresponding 
parameters. Therefore, an ABN model is ideally suited to analysing highly complex 
epidemiological data comprising many inter-dependent variables. 
 
Generalized additive model 
The generalized additive model (GAM) is a combination of GLM and additive model (324).  
Unlike the general linear regression model, the dependent variable of GLM does not have to be 
normally distributed or be continuous (325). A multivariable linear regression model could be 
considered a special case of GLM.  It could be described as: Y= g (α + X1β1 +X2β2 + … + Xkβk 
+ ε), where g (…) is an identity function. A link function (gi), the inverse function of g (…), is 
used to connect the association between independent variables and dependent variable in GLM: 
gi (muY) = α + X1β1 +X2β2 + … + Xkβk + ε, where muY represents the expected value of Y. 
The general regression model also has the nature of an additive model. Instead of using the 
linear equation (Xkβk), the non-parametric function fk (Xk) of each independent variable is used 
to achieve the best prediction of the dependent variable value. The additive model could be 
described as a formula like this: Y = α + f1(X1) +f2(X2) + … + fk(Xk). 
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The form of GAM is gi (muY) = ∑𝑘(fk(Xk)), which assumes the link functions are additive and 
its components are smooth (324). GAM allows us to explore non-linear, linear, and non-






Chapter 3 Gestational Dyslipidaemia and 
Adverse Birthweight Outcomes: a systematic 





Low and high birthweight is known to increase the risk of acute and longer-term adverse 
outcomes, such as stillbirth, infant mortality, obesity, type 2 diabetes and cardiovascular 
diseases. Gestational dyslipidaemia is associated with a numbers of adverse birth outcomes, but 




The aim of this study was to explore the relationship between maternal gestational 




We searched systematically Embase, MEDLINE, PubMed, CINAHL Plus and Cochrane 
Library up to 1 August 2016 (with an updated search in MEDLINE at the end of July 2017) for 
longitudinal studies that assessed the association of maternal lipid levels during pregnancy with 
neonatal birthweight, or metabolic and inflammatory parameters up to 3 years old. 
 
Results 
Data from 46 publications including 31,402 pregnancies suggest that maternal high 
triglycerides and low high-density-lipoprotein cholesterol levels throughout pregnancy are 
associated with increased birthweight, higher risk of large for gestational age and macrosomia 
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and lower risk of small-for-gestational age. The findings were consistent across the studied 
populations, but stronger associations were observed in women who were overweight or obese 
prior to pregnancy. 
 
Conclusions 
This meta-analysis suggested that the potential under-recognized adverse effects of intrauterine 
exposure to maternal dyslipidaemia may warrant further investigation into the relationship 







Low and high birthweight has been linked to the risk of stillbirth and infant mortality (65). In a 
longer life course, both low birthweight or small for gestational age (SGA), and large for 
gestational age (LGA) or macrosomia are known to increase the future risk of obesity, type 2 
diabetes and cardiovascular disease (66, 67). The estimated prevalence of macrosomia in 
developed countries varies from 5% to 20%, and a parallel increase in macrosomic births was 
observed in both developed and developing countries over the last two to three decades (73). 
These life course associations have often been attributed to the impact of an adverse intrauterine 
environment, particularly fuels (glucose, lipids and amino acids) transported from the maternal 
end (326). Previous reviews have shown that maternal obesity and gestational diabetes mellitus 
(GDM) are two identified risk factors of low and high birthweight (95, 327, 328). However, as 
one of common metabolic disorders, the adverse effects of gestational dyslipidaemia on 
neonates' birthweight/birthweight centiles are not widely recognized in clinical practice. 
Dyslipidaemia has been considered a risk factor for a number of adverse health outcomes, in 
particular cardiovascular disease and type 2 diabetes (329, 330). Previous reviews have shown 
that dyslipidaemia during pregnancy are associated with increased risk of GDM, pre‐
eclampsia and pre‐ term delivery (108, 331, 332), but epidemiological evidence on birthweight 
is conflicting (117-119). Furthermore, previous evidence indicates that excessive maternal 
intrauterine lipid exposures may program the development of foetal organs from early life, 
resulting in metabolic dysfunction (239, 333). If maternal dyslipidaemia is a significant 
contributor to birthweight and implicated in neonatal metabolic dysfunction, then interventions 
before and during pregnancy to mitigate dyslipidaemia might improve offspring's adverse birth 
and metabolic health outcomes. 
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We performed a comprehensive systematic review and meta‐ analysis to explore the 
association and quantify the magnitude of effect between maternal dyslipidaemia and neonatal 
outcomes, namely, birthweight, metabolic factors and inflammatory parameters. 
 
Methods 
Search strategy and selection criteria 
The protocol for this review was registered on PROSPERO (CRD42016048568), and the 
review is reported in accordance with the Preferred Reporting Items for Systematic reviews and 
Meta‐ analyses (PRISMA) (334) and Meta‐ analysis Of Observational Studies in 
Epidemiology (MOOSE) (335) guidelines. We searched systematically Embase, MEDLINE, 
PubMed, Scopus, CINAHL Plus and Cochrane library (CENTRAL) up to 1 August 2016, 
without language or year restrictions. An updated search was made in MEDLINE before 
manuscript submission until the end of July 2017. The search of bibliographic databases 
combined index and free‐ text terms relating to lipids (e.g. ‘lipids’, ‘lipoproteins’, ‘fatty acids’, 
‘triglycerides’ and ‘cholesterol’) with those relating to pregnancy (e.g. ‘pregnan*’, ‘gestation*’, 
‘gravidity’ and ‘mothers’) and birthweight (e.g. ‘birth weight’, ‘small for gestational age’, 
‘large for gestational age’ and ‘macrosomia’). The full strategies are provided in 
Supplementary material S1. Cohort and randomized controlled trial (RCT) filters were used to 
target longitudinal observational studies and the secondary analysis of RCT studies (336). 
Additional searches were conducted in Grey Literature Report and Open Grey. Reference lists 
of included studies were screened and checked for relevance. 
Search results, after removal of duplicates, were screened for relevance using title and abstract 
information. Full texts of relevant articles were assessed for eligibility against the selection 
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criteria. Screening and selection were undertaken by two reviewers independently in 
consultation with a third reviewer when required. 
This review included studies of healthy pregnant women and pregnant women with GDM or 
obesity, which investigated the association between maternal lipid levels during pregnancy 
(total cholesterol [TC], high‐ density lipoprotein cholesterol [HDL‐ C], low‐ density 
lipoprotein cholesterol [LDL‐ C], very‐ low‐ density lipoprotein cholesterol [VLDL‐ C], 
triglycerides [TG] and total free fatty acids [FFAs]) and neonatal anthropometric, metabolic 
and inflammatory parameters. 
Studies of pregnant women with conditions that could influence maternal metabolic status 
before pregnancy (hepatitis, polycystic ovary syndrome, familial hyperlipidaemia, acquired 
immunodeficiency syndrome, type 1 and type 2 diabetes, hypertension, thrombophilia, history 
of thromboembolism, rheumatologic disorders, cardiac dysfunction or history of taking relevant 
lipid‐ lowering medications) were excluded. 
The primary outcome was birthweight measured within the first week after delivery. Neonatal 
anthropometric parameters, including low birthweight, SGA, LGA and macrosomia, were 
considered as different indexes of birthweight. Secondary outcomes included the following: 
anthropometric parameters in children younger than 3 years (e.g. weight gain after delivery, 
body mass index [BMI] and skinfold thickness), biological indicators (glucose, TC, HDL‐ C, 
LDL‐ C, VLDL‐ C, TG, FFAs and insulin levels; and insulin resistance) and neonatal 
inflammatory factors (monocyte chemoattractant protein‐ 1, interleukin 6, tumour necrosis 
factor alpha and 11‐ beta‐ hydroxysteroid dehydrogenase type 1 and C‐ reactive protein, as 
well as leptin levels) measured in cord blood or blood samples taken from neonates (< 3 years 
old). Owing to the diverse definition of GDM, obesity, SGA, LGA and macrosomia in different 
populations, we accepted the definition specified by authors. 
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Data extraction and quality assessment 
A STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)‐ based 
pre‐ designed form (337) was used for data extraction, including the following information: 
study characteristics (study name, design, language and location), participants (setting, 
eligibility/exclude criteria and sample size), maternal characteristics (age, parity, pre‐
pregnancy BMI and gestational length), follow‐ up (enrolment time, length of follow‐ up, data 
collection methods and loss to follow‐ up rate), exposures (definition, fasting status, measured 
gestational weeks and measurement methods) and outcomes (definition and measurement time 
point) (Supplementary material S2). 
The Newcastle–Ottawa Scale was used to characterize and stratify the methodological quality 
of included studies (Supplementary material S3) (274). Studies' quality was classified as ‘low’ 
(≤ 5), ‘medium’ (6 and 7) or ‘high’ (8 and 9). In addition, domains relating to sample selection, 
comparability between groups and method of outcome assessment were considered separately. 
Data extraction and quality assessment were conducted by two reviewers independently in 
consultation with a third reviewer when required. Missing information was requested from 
authors by email. 
 
Data synthesis 
Included studies were categorized by trimester on the basis of the mean/median gestational age 
for the lipid measurement (first trimester [T1], 1 – 13; second trimester [T2], 14 – 27; and third 
trimester [T3], ≥ 28 gestational weeks). For studies reporting lipid levels multiple times within 
one trimester, data from the trimester with the largest sample size were adopted. Studies with 
different types of population (example GDM or obesity) were divided into two or three subsets 
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to enable us to assess and report separately. Lipid measurements reported in milligrams per 
decilitre were converted to millimoles per litre using standard unit conversion factors (338). 
Results of birthweight were reported in various ways, e.g. regression coefficients (RC) and 
correlation coefficients. Findings were summarized in tables and visually represented as 
horizontal histogram, displaying the direction as well as statistical significance of results 
comprehensively (post‐ analysis). 
Summary estimates were pooled using random‐ effects meta‐ analysis, according to 
assessment of outcomes (birthweight, LGA, SGA and macrosomia), timing of lipids 
measurement (T1/T2/T3) and statistic reported in the primary study (RC, odds ratio [OR] or 
mean difference). Unadjusted and adjusted estimates reported in the articles were entered into 
random‐ effects models separately. Confounding factors that were adjusted (maternal age, 
pre‐ pregnancy BMI, gestational weight gain, gestational glucose level, pre‐ term birth, 
gestational lipid levels, gestational age and neonatal gender) for each result were recorded for 
further sensitivity analyses. The I2 statistic was used to quantify the degree of heterogeneity 
beyond that expected by chance in each analysis (275). The potential for publication bias could 
not be assessed via funnel plots as the requirement for 10 or more studies per meta‐ analysis 
was not met (281). Owing to the heterogeneity in baseline characteristics of included studies, 
we were not able to compare non‐ GDM women with GDM women. Sensitivity analysis was 
performed by choice of covariates controlled for in the model. All analyses were conducted 
using Review Manager version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark) and R 





Of the 13,705 unique records identified by the searches, 46 publications (117-119, 165, 166, 
297, 301, 339-377) reporting from 42 studies were included in the review (Figure 2). These 
studies included 31,402 pregnancies. Of the 46 included publications, 16 contributed to the 
quantitative analysis owing to the diversity of reporting formats (RC, correlation coefficients, 
mean differences, trend analyses or without exact effect estimates) and lack of data required for 





Figure 2 Flow-chart 
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Characteristics of included studies 
Table 7 describes the baseline characteristics of the 46 included publications. Most articles 
were published in English language and as full text articles with only one 44 study written in 
German and one 43 published as an abstract. The studies were published between 1985 and 
2016. The number of pregnancies ranged from 38 to 5,535. On the basis of the World Bank 
Income Classification of countries (378), 25 out of 42 studies were from high‐ income 
economies (117, 119, 166, 297, 340-347, 350-353, 355, 358-360, 367, 368, 370, 373, 374), 16 
from upper‐ middle‐ income economies (118, 165, 301, 339, 348, 349, 354, 356, 357, 363-366, 
369, 376, 377) and 1 from middle‐ income economies (372). Forty studies were prospective 
cohorts (118, 119, 165, 297, 301, 339-341, 343-346, 348-365, 367-372, 374-377), three were 
retrospective cohorts (347, 366, 373) and three were secondary analyses of cohorts in RCTs 
(117, 166, 342). 
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Table 7 Baseline characteristics of included studies 
Study ID Study design Locations 
Population 
(N) 
TC HDL LDL TG VLDL FFAs Tri. Outcomes 






√ √ √ √   3 
Birthweight 
LGA, SGA 






√ √ √ √   2 Birthweight 






√ √  √  √ 2,3 Birthweight 






   √   2,3 Birthweight 






√ √  √   2,3 Birthweight 






√   √   1 LGA, SGA 






√ √ √ √   3 
Birthweight 
LGA 






√ √ √ √   3 LGA 






√ √  √   3 
Infant weight 
gain at 3 months 







√ √ √ √   3 
Birthweight 
LGA 






√   √   3 
Birthweight 
LGA 






√ √ √ √   2 
Birthweight 
LGA 





√ √ √ √ √ √ 3 
Birthweight 
Couch et al.1998(2) Non-GDM (n=20) 
Cord vein lipids 
profile 

















√ √  √   1-3 
Mixed venous-
arterial cord blood 
lipids profile 
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Study ID Study design Locations 
Population 
(N) 
TC HDL LDL TG VLDL FFAs Tri. Outcomes 
Schaefer-Graf et al. 
2008 





√   √  √ 3 
Birthweight,  
cord blood lipids 
LGA 







√ √ √ √   3 Birthweight 






√ √ √ √   3 
Birthweight,  
sum of skinfolds 






√ √ √ √   3 
Birthweight 
LGA, SGA 






√ √ √ √   3 
LGA, 
macrosomia 






√ √ √ √   2 Birthweight 






√ √ √ √   2 Macrosomia 
















√ √ √ √   1-3 Birthweight 
Vinod et al.2011(2) 
Normal weight 
(n=72) 






 √  √   2 
Birthweight 
Macrosomia 






√ √ √ √   2 Macrosomia 






√      2,3 Birthweight 




GDM + lean 
(n=128) 
√ √  √   2,3 Birthweight Olmos et al.2014(2) 
GDM + overweight 
(n=105) 
Olmos et al.2014(3) 
GDM + obese 
(n=46) 
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Study ID Study design Locations 
Population 
(N) 
TC HDL LDL TG VLDL FFAs Tri. Outcomes 






√ √ √ √   3 
Birthweight, 
infant weight at 
3 months 






√ √ √ √   2 Birthweight 
Brunner et al. 2013 

















   √   3 Birthweight 






 √ √  √ √ 3 Birthweight 


















   √   1 Birthweight 






   √   ND Macrosomia 






√ √  √  √ 3 Birthweight 






 √  √   2 LGA, SGA 






√   √  √ 3 
Birthweight 
LGA 










Geraghty et al. 2016 





√ √ √ √   2,3 
Birthweight 
Postpartum 
growth, sum of 
skinfolds 










Study ID Study design Locations 
Population 
(N) 







 √ √  √  2 
Cord blood 
lipids profile 






   √  √ 1 Birthweight 






√      2 Birthweight 







√ √ √ √   3 Birthweight 
Oral Glucose tolerance test (OGTT), Negative screenees of OGTT test (NS-), Positive screenees of OGTT test but reach GDM diagnostic 
threshold value (PS+), No documented (ND). 
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Quality of included studies 
Forty‐ five publications, excluding the abstract (365), were assessed for methodological quality. 
Ten, 21 and 14 studies were assessed as methodologically high (118, 343, 344, 346, 350, 352, 
355, 362, 375, 377), moderate (117, 119, 301, 339, 341, 342, 345, 347, 351, 354, 357-361, 363, 
364, 366, 367, 374, 376) and low quality (165, 166, 297, 340, 348, 349, 353, 356, 368-373), 
respectively (Supplementary material S4). Three (7%) of 45 included studies had low risk for 
study selection while 40 (93%) had medium risk. For comparability bias, 15 (33%) had low 
risk, 13 (29%) had medium risk and 17 (38%) had high risk. Sixteen (36%) studies were 
regarded to have a low risk of outcome assessment bias, with the rest (29 studies) having 
medium risk. 
 
Maternal lipid levels during pregnancy and birthweight 
Figure 3 shows the relationship between maternal lipid levels during pregnancy and 
birthweight (Supplementary material S5). There were strong associations noted for HDL‐ C 
and TG throughout pregnancy with birthweight. For HDL‐ C, both studies 55 reporting in T1, 
6 (117, 118, 346, 365, 374, 376) out of 11 (117, 118, 165, 297, 301, 346, 358, 366, 374, 376) 
studies reporting in T2 and 11 (118, 119, 343, 346, 348, 351, 360, 370, 374, 377) out of 18 
(117-119, 301, 343, 345, 346, 348, 349, 351, 360, 369, 370, 372-374, 377) studies reporting in 
T3 showed an inverse association with birthweight, while 1 (118) in T2 and 1 (117) in T3 
reported a positive association. For TG, 4 (367, 374, 375) out of 5 (353, 367, 374, 375) studies 
reporting in T1, 10 (118, 165, 297, 346, 355, 358, 366, 374, 376) out of 12 (117, 118, 165, 297, 
301, 346, 355, 358, 366, 374, 376) studies reporting in T2 and 20 (117, 118, 301, 339, 343, 345, 
346, 348, 349, 351, 355, 359, 361, 372-374, 377) out of 27 (117-119, 166, 301, 339, 342, 343, 
345, 346, 348, 349, 351, 355, 359, 361, 369-374, 377) studies reporting in T3 found a positive 
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association with birthweight, while 3 (119, 342, 370) studies in T3 reported an inverse 
association. Of the seven studies reporting the association between maternal FFAs level in T3 
and birthweight (166, 345, 346, 351, 359, 360, 371), four reported a positive association (346, 
359, 360, 371), while none reported inverse association. For TC, 7 (117, 118, 346, 347, 350, 
366, 374) out of 12 (117, 118, 297, 301, 346, 347, 350, 358, 366, 374, 376) studies in T2 and 8 
(117, 118, 339, 348, 350, 359, 374, 377) out of 22 (117-119, 166, 301, 339, 343, 345, 346, 348-
351, 359, 368-374, 377) studies in T3 reported a positive association, while 1 (374) in T2 and 
3 (343, 370, 374) in T3 found an inverse association. There was no evident association between 
maternal LDL‐ C level and birthweight (117, 119, 297, 301, 343, 345, 348, 349, 358, 360, 366, 





Figure 3 Results summary of the association of maternal lipid levels with birthweight 
throughout pregnancy. 
The numbers in parenthesis are the number of studies shown in this figure/the overall number of studies reporting 
the target associations. Studies reporting statistically insignificant results without its direction or those that did not 
report their results are not shown in the figure. FFAs, total free fatty acids; HDL‐ C, high‐ density lipoprotein 
cholesterol; LDL‐ C, low‐ density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; VLDL, very‐




Figure 4 shows the pooled estimates for the effect of maternal lipids throughout pregnancy on 
birthweight using all available data (Supplementary material S5). In general, the results of 
meta‐analyses are consistent with the overall results summary (Figure 3). Maternal HDL‐C 
was inversely associated with birthweight, particularly in T3 (adjusted RC, 
−70.17 g mmol−1 L−1, p < 0.001). Increased maternal TG levels were significantly associated 
with birthweight for T1 (adjusted RC, 86.72 g mmol−1 L−1, p < 0.001) and T3 (adjusted RC, 
89.58 g mmol−1 L−1, p = 0.01). Positive associations between TC and birthweight were observed 
in T1 (adjusted RC, 22.67 g of birthweight per mmol L−1 maternal lipid, p = 0.02), T2 (adjusted 





Figure 4 Summary of findings of meta‐ analysis for the associations between maternal 
lipids and birthweight throughout pregnancy. 
The number of participants (studies) included into quantitative analysis/overall number of participants (studies) 
that reported the outcome of interest. HDL‐ C, high‐ density lipoprotein cholesterol; LDL‐ C, low‐ density 




Stronger associations were observed among pregnant women with pre‐ pregnancy overweight 
or obesity in the two relevant studies (Appendix S5) (301, 374). The degree of heterogeneity 
within all meta‐ analyses in T3 was detected with I2 values ranging from 0% to 93%. The 
heterogeneity decreased markedly when studies controlled for pre‐ pregnancy BMI, gestational 
weight gain, glucose level and gestational age (Supplementary material S5). 
 
Maternal lipid levels during pregnancy and LGA, SGA and macrosomia 
Figure 5 shows the pooled adjusted OR for LGA as well as SGA, according to each type of 
maternal lipids in T3 (Supplementary material S6 and S7). Pooled estimates for rising maternal 
HDL‐ C level revealed potentially decreased odds of LGA (OR, 0.77; 95% CI, 0.59 to 1.01; p 
= 0.06) and significantly increased odds of SGA (OR, 1.96; 95% CI, 1.04 to 3.71; p = 0.04). In 
contrast, increased maternal TG levels were associated with increased odds of LGA (OR, 1.08; 
95% CI, 1.01 to 1.15; p = 0.02) and decreased odds of SGA (OR, 0.66; 95% CI, 0.49 to 0.90; 
p = 0.007). In addition, 10 (166, 339, 348, 354, 357, 359, 363, 372, 373, 377) out of 11 (119, 
166, 339, 348, 354, 357, 359, 363, 372, 373, 377) studies reporting the association between 
maternal TG and LGA in T3 reported positive statistically significant associations. Of six 
studies investigating the relationship between maternal HDL‐ C and macrosomia (165, 344, 
348, 356, 357, 363), four studies reported decreased risk of macrosomia (three statistically 
significant) (165, 344, 356, 357), especially for T2 with higher HDL‐ C (Supplementary 
material S8). For the relationship of TG with macrosomia, five (344, 356, 361, 363, 365) out 
of six (344, 356, 357, 361, 363, 365) studies reported statistically significant positive OR values 
across three trimesters. No association was observed between maternal TC as well as LDL‐ C 
levels and LGA, SGA and macrosomia. 
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Figure 5 Summary of findings of meta‐ analysis for the associations between maternal 
lipids and LGA/SGA in the third trimester. 
The number of participants (studies) included into quantitative analysis/ overall number of participants (studies) 
that reported the outcome of interest. HDL‐ C, high‐ density lipoprotein cholesterol; LDL‐ C, low‐ density 





Maternal lipid levels during pregnancy and other outcomes of interest 
For secondary outcomes, positive correlations were found by all six publications investigating 
the association between different maternal lipids and different cord blood lipids, but results are 
inconsistent with each other (166, 340, 341, 345, 368, 371). No association was observed 
between maternal lipids and infant post‐ natal weight, weight gain or sum of skinfold thickness 
up to two years old (117, 342, 362, 375). No study investigated the relationship of maternal 
lipid levels during pregnancy with neonatal glucose, insulin, inflammatory factors and leptin 
levels in our searches. 
 
Discussion 
Summary of the findings 
This is the first systematic review pooling data from 40 longitudinal observational studies and 
two RCT secondary analysis studies providing quantitative estimates of the magnitude of 
association between maternal lipid levels at various stages of pregnancy and neonatal health 
outcomes. Throughout pregnancy, low maternal HDL‐ C and high TG levels are associated 
with increased birthweight. Low HDL‐ C and high TG increased the risk of LGA/macrosomia 
and lowered the risk of SGA babies. Maternal TC level throughout pregnancy and FFAs level 
in the third trimester are positively associated with a small increase in birthweight. Associations 
are stronger among populations with pre‐ pregnancy obesity. The findings provide evidence 
for the critical role of dyslipidaemia in gestational metabolism and neonatal health and will 




The results are mostly consistent with previous published evidence. Maternal lipid metabolism 
is mainly in lipogenesis state in the earlier half of pregnancy, but then switches into catabolic 
state (269, 270). When the lipid accumulation exceeds the storage capacity of adipose tissue, 
the buffering function of the adipocytes is decreased, leading to elevated serum FFAs and TG 
(261, 263, 379). Compared with pregnant women with smaller pre‐ pregnancy BMI, women 
who are overweight or obese not only will progress to catabolic state earlier but also have less 
capacity to inhibit lipolysis (239). Women with obesity prior to pregnancy usually present with 
more central adipose accumulation and severe dyslipidaemia (380, 381), resulting in steep 
concentration gradient across the placenta (271). 
Both in vivo and epidemiological evidence suggest that excessive maternal intrauterine lipid 
exposure could affect the development of foetal organs systematically, which can then alter 
initial foetal metabolism and feeding behaviours permanently (239, 382). Previous animal 
studies observed that foetal metabolic abnormalities mediated by maternal obesity and high‐
fat diet often manifest as increased body weight, fat mass, blood glucose, cholesterol and blood 
pressure levels and decreased insulin sensitivity and ectopic lipid storage in newborns (239). 
The latest multi‐ ancestry genome‐ wide association study meta‐ analysis also demonstrated 
that cholesterol biosynthesis is one of the most important metabolic pathways involved in 
birthweight (333). 
 
Strengths and weaknesses 
The major strengths of this study are the comprehensive searches, adherence to robust review 
methodology and thorough analyses. Special care was taken in the handling of missing data, 
which was addressed by personal contact with the authors in an attempt to minimize reporting 
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bias. The inclusion of longitudinal studies ensured the temporal association between exposures 
and outcomes, which also permitted a trimester‐ specific analysis. The major limitation of the 
study was the substantial heterogeneity, possibly owing to the diversity of settings, study 
populations, lipid measurement methods and diverse gestational age of the studied populations. 
However, this heterogeneity was addressed by subgroup analysis. 
It would be intriguing to explore the effects of maternal dyslipidaemia independent of maternal 
hyperglycaemia. Unfortunately, this was not feasible owing to the nature of data reported in 
individual study. GDM women are known to have higher TG levels and lower HDL‐ C levels 
than do non‐ GDM women (108). However, elevated maternal TG levels and lower HDL‐ C 
levels are associated with the risk of LGA and macrosomia in both GDM women (166, 363, 
373) and non‐ GDM women (339, 354, 357, 372, 375, 377). For women with type 1 
diabetes/GDM, maternal hyperglycaemia is not the sole contributor to increased birthweight 
because foetuses may develop LGA despite them having optimal glycaemic control 80. Several 
other studies found that lipid levels during pregnancy, similar to glucose levels, are also strong 
metabolic determinants for foetal growth (118, 166, 343, 344, 351, 353, 359, 361, 362, 364, 
366, 376). Our sensitivity analyses result has also shown that there is little effect on the 
relationship between gestational HDL‐ C/TG levels and birthweight when removing those 
studies controlled for glucose (Appendices S7.13 and S7.23). Collectively, this evidence 
suggests that maternal dyslipidaemia may be an independent, unrecognized risk factor of 
LGA/macrosomia. 
Unfortunately, paucity of the required primary data prevented the pre‐ specified subgroup 
analyses on the basis of different definitions used for GDM and obesity across studies. Thus, 
this should be acknowledged as a source of clinical heterogeneity when interpreting the findings 
of the present study. Another limitation of this study is that we are unable to control for the 
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effect of GDM treatment on lipid levels. However, it has been noticed that initiation of therapy 
(diet control, insulin or metformin) may modestly influence TG levels (383), yet to a direction 
that would obscure rather than magnify differences between normal and GDM pregnancies. 
Similarly, our sensitivity analyses show a moderate decrease on TG effect estimate when 
removing studies that excluded pre‐ term births (Appendix S7.25). 
It should be acknowledged that our primary outcome, birthweight, is a quite inexact measure 
of foetal growth, although it has been widely measured and utilized in clinical and research 
areas. We tried to extend our target outcomes from birthweight parameters to other neonatal 




Our results provide compelling evidence on the role of maternal circulating HDL‐ C and TG 
levels on birth outcomes and suggest that the under‐ recognized adverse effects of intrauterine 
exposure to maternal dyslipidaemia may need further investigation in large prospective cohorts 
or in randomized trials. Although the importance of screening for preconceptional 
dyslipidaemia has been noted in recent guidelines to alert for risk assessment for GDM (384, 
385), its independent adverse effects remain largely underestimated in routine clinical practice, 
and recommendations regarding the management of dyslipidaemia preconceptionally or during 
pregnancy are still lacking. Our findings do question the current clinical practice and support 
the monitoring of gestational dyslipidaemia before or during pregnancy. Moreover, our findings 
may be a call for action regarding the implementation of strategies to address maternal 
dyslipidaemia (such as carefully planned dietary interventions, increasing physical activity 
and/or omega‐ 3 fatty acid supplementation). Meanwhile, gestational dyslipidaemia, as an 
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important feature of obesity and GDM, might be a potential treatment target for clinical 
interventions. These steps need to be evaluated by global health policy makers through RCTs, 
evidence synthesis and consensus (272, 386, 387). 
 
Conclusion 
Our findings demonstrate that maternal low HDL‐ C and high TG levels are positively 
associated with neonatal birthweight. No effect was documented for total or LDL‐ C. Findings 
are of clinical importance in considering the management of gestational dyslipidaemia, e.g. 






Chapter 4 Inter-dependency between maternal 
metabolic risk factors and their association with 






Maternal obesity, gestational diabetes mellitus, and excessive gestational weight gain (GWG) 
are associated with adverse pregnancy outcomes. However, lifestyle interventions during 
pregnancy do not confer significant benefits for composite maternal and neonatal health 
outcomes. Meanwhile, gestational dyslipidaemia has been recognised as an ignored metabolic 
risk factor. This study aims to quantify the inter-dependency between those maternal metabolic 
risk factors and their association with birthweight and cord blood insulin level. 
 
Methods 
We used data from 1,522 mother-child pairs from the Born in Guangzhou Cohort Study. 
Multivariable linear regression (MLR) and Additive Bayesian Network (ABN, a data-driven 
causality inference model) were used to investigate the association of maternal metabolic risk 
factors and their interdependency in predicting birthweight and cord blood insulin 
concentrations. Metabolic risk factors studied were maternal pre-pregnancy body mass index 
(BMI), fasting glucose, lipid profile (total cholesterol [TC], high-density lipoprotein cholesterol 
[HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides), and early GWG.  
 
Results 
High maternal pre-pregnancy BMI was associated with neonatal birthweight (standardized 
adjusted regression coefficient [βstd] = 0.27, 95%CI 0.22 - 0.32) directly; and indirectly with 
cord blood insulin in ABN. Maternal fasting glucose was positively associated with increased 
birthweight(adjusted regression coefficient [βadj] = 84, 95%CI 43 – 126 g per mmol/L) and cord 
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blood insulin (βadj = 2.23, 95%CI 0.89 - 3.57 µU/mL per mmol/L) in MLR, but only with cord 
blood insulin (βstd =0.12, 95%CI 0.07 - 0.17) in ABN. Maternal GWG was associated with 
birthweight, but not with cord blood insulin in ABN. ABN suggested none of the maternal 
lipids profile was independently associated with birthweight or cord blood insulin.  
 
Conclusions 
High maternal pre-pregnancy BMI is the most influential upstream metabolic risk factor for 
both maternal and neonatal metabolic health, therefore weight management should be 
addressed from preconception period. Maternal hyperglycaemia drives neonatal 
hyperinsulinemia and may lead to adipose tissue accumulation in neonates. Maternal 
dyslipidaemia appears to be secondary to maternal metabolic dysfunction with no clear links to 
metabolic adverse outcomes in neonates. 
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Manuscript (Under review) 
Introduction  
High fasting plasma glucose, hypercholesterolemia, and high body-mass index (BMI) remain 
leading risk factors for mortality and morbidity worldwide (11). In pregnancy, poor maternal 
metabolic health is known to induce adverse outcomes for both mothers and babies. These 
include: stillbirth, pre-term delivery, low or high birthweight, pre-eclampsia, and maternal 
postnatal diabetes/cardiovascular disease (388, 389). The prevalence of gestational diabetes 
mellitus (GDM) varies from 2% to 25% worldwide, and has increased over the last decades in 
parallel with the increasing obesity prevalence of women in child-bearing age (390, 391). 
Evidence has shown that offspring born to mothers with obese, GDM, and/or gestational 
dyslipidaemia have increased risk of high birthweight (286, 392, 393). However, evidence 
regarding the association between maternal metabolic disorder and neonatal metabolic 
programming remains controversial. Previous observational studies reported that maternal 
obesity and GDM might contribute to an increased risk of short- and long-term metabolic 
dysfunction (e.g. obesity and diabetes) in offspring with inconsistent results (394-396). This 
could be explained by the heterogeneity of study settings and inadequate adjustment for 
confounding factors. Meanwhile, interventions based on diet and physical activity in pregnancy 
have had limited success in decreasing the risk of adverse pregnancy outcomes such as pre-
term birth, macrosomia, and foetal adiposity (303, 397).   
The mechanism of how maternal metabolic dysfunction is linked with neonatal health remains 
uncertain, however, the majority of researchers believe it may be explained by the foetal 
programming hypothesis of intrauterine over-exposure to macronutrients (glucose, free fatty 
acids, and amino acids) (196, 398). Previous studies mainly focused on one specific metabolic 
trait or on the number of metabolic disorders, without assessing the underlying interacted 
 120 
effects of the natural metabolic network. This is due to the limited analytical ability of classical 
statistical methods to analyse multidimensional data. Understanding how the metabolic 
network influences neonatal health is crucial to future interventional studies and potentially to 
antenatal/pre-natal advice.   
In this study, we investigated the association of maternal metabolic traits with birthweight and 
cord blood insulin in the Born in Guangzhou Cohort Study (BIGCS). To give new insights from 
data, we further mapped the inter-dependency of metabolic factors on both mothers and their 
offspring, using Additive Bayesian Network (ABN) analysis, a robust unsupervised machine 
learning method, which has been widely used in other disciplines (321, 399).   
 
Research Design and Methods 
Participants 
The design and methods of BIGCS have been described previously (400). In brief, eligible 
women with Chinese nationality, living in Guangzhou who are < 20 weeks gestation and who 
intend to deliver at one of the two Guangzhou Women and Children’s Medical Centre 
(GWCMC) campuses were recruited into BIGCS. This study was conducted in a subgroup of 
BIGCS in whom maternal and cord blood were analysed for metabolic parameters separately. 
Pregnant women attending BIGCS with a singleton pregnancy who delivered at GWCMC 
between Jan 2015 and Jun 2016 and had umbilical cord blood retained are eligible for this study. 
Women were excluded if: 1) maternal blood samples unavailable at 14-27 gestation week; 2) 
no records of maternal fasting glucose at 20 - 28 gestation week; 3) lacking maternal 
demographic information; 4) diagnosed with health condition prior to pregnancy, including 
type 1 or type 2 diabetes, thyroid dysfunction, hypertension, virus hepatitis, and renal diseases. 
The study was powered for the association between maternal triglycerides (the potential 
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weakest risk factors among maternal metabolic traits) with birthweight according to literature 
(Supplementary material S9). The eligible mother-child pairs were then selected into this study 
by computer generated randomization. Ethical permission for the study was granted by the 
GWCMC Ethics Committee.  
 
Study Procedures 
Maternal demographic data, including anthropometric measures, socioeconomic status, family 
and personal medical history, were collected through a semi-structured questionnaire (Q1) at 
recruitment. Maternal overnight fasting blood samples were collected during second trimester. 
At 22 - 28 weeks gestation, women attending their second prenatal visit underwent a standard 
2h 75g oral glucose tolerance test (OGTT). Women with OGTT results which met or exceeded 
at least one threshold of the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) criteria (FPG ≥ 5.1 mmol/L, 1h glucose ≥ 10.0 mmol/l, and 2h glucose ≥ 8.5 mmol/L) 
were diagnosed as having gestational diabetes mellitus (GDM) (401). For participating children, 
birth information, including birth characteristics, delivery mode, and perinatal outcomes were 
obtained from routine medical records. Umbilical cord blood samples were collected by 
midwives at birth.  
 
Demographic Data 
Maternal demographic information (age, height, pre-pregnancy weight, parity, date of last 
menstrual period, monthly income, education levels, and ethnicity) were collected through Q1 
questionnaire. BMI was calculated by dividing weight in kilograms by height in meters squared. 
Based on the recommendations of the China Obesity Task Force of the Chinese Ministry of 
Health, maternal pre-pregnancy BMI is classified into two groups: lean group (< 24 kg/m2) and 
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overweight group (≥ 24 kg/m2) (6). Maternal second trimester weight was measured to the 
nearest 0.1 kg using an electronic scale. Maternal early gestational weight gain (GWG) was 
calculated by subtracting pre-pregnancy weight from maternal second trimester weight, with 
documentation of the gestational age at measurement. Maternal fasting glucose concentration 
was obtained from OGTT test zero-time value in hospital records. 
 
Biochemical Test 
Sample collection, delivery, pre-treatment, and measurements were blinded. All blood samples 
were stored and delivered to pre-treatment laboratory centre. Blood samples were then 
separated to serum and plasma by immediate centrifugation, and were stored in EDTA tube in 
the bio-bank at -80℃ until analysis. Plasma lipids (TC, HDL-C, LDL-C, and TG) and insulin 
levels were measured using commercial kits in fully automated clinical analyser (Roche 
Diagnostics, Mannheim, Germany). Intra- and inter-day coefficients of variation (CVs) were 
consistently less than 2% for all assays. 
 
Neonatal anthropometry 
Gestational age was estimated from ultrasound examination during the first- or second-
trimester. Birthweight and other information, including gestational age at delivery, mode of 
delivery, neonatal sex, and pregnancy complications were obtained from hospital records. 
Birthweight was measured to the nearest 50g using an electronic scale by midwives 
immediately after delivery. Birthweight Z-Score and percentile(adjusted for gestational age at 
delivery and neonatal sex) were calculated using Intergrowth 21st Newborn Size Standard and 
Tools (309). Large for gestational age (LGA) was defined as a birthweight larger than the 90th 
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percentile for gestational age by sex, while Small for gestational age (SGA) was defined as a 
birthweight smaller than the 10th percentile based on the same birthweight reference.  
 
Statistical Analysis 
Classic statistical methods 
For the baseline table data are summarized as mean ± Standard Deviation (SD), median (Inter 
Quartile Range, IQR), or counts with percentages. Pearson correlation was used to assess the 
impact of the long-term -80 °C storage on insulin concentrations in EDTA tube. Adjustments 
were then made to account for any degradation by correcting the initial value using linear 
regression methods (Supplementary material S10). Similarly, maternal lipid levels were 
adjusted for gestational age using regression model to account for timing of blood sampling 
(Supplementary material S11) (347).  
Initially, linear and logistic regression were used to estimate the association between maternal 
metabolic parameters and neonatal continuous and binary outcomes, respectively. Further 
analyses using linear regression model were performed after all exposures were transformed to 
Z-Scores. This was to enable comparison of the effect size each maternal metabolic parameter 
had on birthweight Z-Score and cord blood insulin Z-Score. cord blood insulin and maternal 
triglycerides were log-transformed prior to standardization. Multiple imputation was used to 
handle missing data (Supplementary material S12). Subgroup analyses were conducted in boys 
and girls respectively. Sensitivity analyses were conducted to compare the estimate differences 
between GDM and non-GDM participants, fasting blood samples and non-fasting samples, 
primiparous women and non-primiparous women, lean and overweight group, as well as before 
and after multiple imputation (Supplementary material S13). All statistical tests were two-
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tailed and a P-value <0.05 was considered statistically significant. Statistical analyses were 
performed in Stata version 14.0 (College Station, Texas, USA). 
 
Additive Bayesian Networks (ABN) analysis 
To further assess the inter-dependency between maternal metabolic risk factors and their 
association with birthweight and cord blood insulin, Additive Bayesian Network (ABN) model 
- an unsupervised machine learning method - was conducted. Bayesian network analysis is a 
form of structure discovery statistical modelling that derives, from empirical data, a graphical 
network describing the dependency structure between variables, shown as directed acyclic 
graphs (DAGs) (321). ABNs comprise of DAGs where each node in the graph comprises a 
generalized linear model (GLM) or a generalized linear mixed model (GLMM). ABN model is 
suitable for analysing highly complex epidemiological data comprising many inter-dependent 
variables (399).  
Ten variables were chosen for ABN based on prior knowledge gained from literature and 
findings of the classical statistical analyses. These ten variables were maternal age, maternal 
pre-pregnancy BMI, maternal fasting glycaemia in OGTT, early GWG, maternal fasting plasma 
HDL-C and triglycerides in the second trimester, birthweight Z-Score, cord blood insulin, 
gestational age at delivery, and neonatal sex. GWG was adjusted for gestational age at weight 
measurement in mid-pregnancy. Cord blood insulin was adjusted for sample storage duration. 
All continuous variables were standardized to Z-Scores to eliminate the influence of different 
measurement units. Mother-child pairs with missing data were excluded (n = 93/1,522, 6%).  
Firstly, an optimal DAG with the best goodness of fit (highest log marginal likelihood) was 
identified. Next, parametric bootstrapping (12,800 samples) was performed to address the 
potential overfitting. Full technical details are provided in the Supplementary material S14. 
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ABN analysis was conducted in R 3.4.4 (The R Foundation for Statistical Computing) using 
‘abn’ package (399).  
 
Results 
A total of 5,497 women who gave birth between January 2015 and June 2016 were initially 
included in this study. Blood samples in the second trimester were successfully collected from 
4,595 (83.59%) mothers. We excluded women with pre-pregnancy health conditions known to 
influence metabolism (thyroid dysfunction, n = 106; viral hepatitis, n = 45; renal diseases, n = 
20; type 1 or 2 diabetes, n = 5; known hypertension, n = 5), and women without baseline 
characteristic information (n = 39, 0.7%). Of the 4,039 eligible mother-child pairs, 1,522 were 
randomly selected as the sub-cohort for additional blood metabolic parameter measurements 






Figure 6 Flow chart 
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The baseline characteristics of participants are shown in Table 8. The majority (91.20%) of 
maternal blood samples were collected after overnight fasting. Maternal mid-pregnancy weight, 
fasting glucose, and lipids profile were measured at a mean of 20.0 (SD = 4.0), 24.6 (SD = 1.4), 
and 20.5 (SD = 3.5) gestation weeks, respectively. Cord blood samples were stored for a median 








Maternal baseline information  
Maternal age at enrolment (years) 29.50 ± 3.30 
Ethnic Han 1,486 (97.70) 
Primiparous 1,223 (80.35) 
Spontaneous delivery 1,239 (81.41) 
Early pregnancy cigarette exposure  436 (28.68) 
Maternal metabolic profile  
GDM 181 (11.89) 
Glucose(mmol/L) 4.25 ± 0.42 
Gestational age of OGTT test (weeks) 25.60 (1.38) 
Pre-pregnancy BMI (kg/m2) 20.47 ± 3.85 
Early gestational weight gain (kg) 4.21 ± 8.42 
Total cholesterol (mmol/L) 5.47 ± 0.90 
HDL-C(mmol/L) 2.07 ± 0.43 
LDL-C(mmol/L) 3.06 ± 0.77 
Triglycerides(mmol/L) * 1.71 (1.39-2.15) 
Gestational age of blood sampling (weeks)* 19 (17-24) 
Neonatal information  
Gestational age (days)* 275 (270-281) 
Preterm delivery 66 (4.34) 
Male 820 (53.88) 
Birthweight (g) 3,203 ± 411 
LGA 96 (6.31) 
SGA 106 (6.96) 
Cord blood insulin (μU/mL) * 7.43 (4.34-12.61) 
Data are mean ± SD or n (%). *Median (Inter Quartile Range) 
GDM, gestational diabetes mellitus; OGTT, the oral glucose tolerance test; BMI, body 
mass index; HDL-C, high-density lipoprotein cholesterol ; LDL-C, low-density 




Association between maternal metabolic parameters and birthweight 
Table 9 presents the associations between five maternal main metabolic parameters (pre-
pregnancy BMI, GWG, fasting glucose, HDL-C, and TG levels) and neonatal outcomes. Pre-
pregnancy BMI (adjusted β = 29.25, 95%CI: 22.77 to 35.73 g per kg/m2), GWG (adjusted β = 
18.75, 95%CI: 13.06 to 24.43 g per Kg), fasting glucose (adjusted β = 84.32, 95%CI: 42.65 to 
125.98 g per mmol/L), and triglycerides (adjusted β = 67.97, 95%CI: 42.38 to 93.55 g per 
mmol/L) were positively associated with birthweight. Higher maternal HDL-C was 
significantly associated with lower birthweight (adjusted β = 45.78, 95%CI: 5.59 to 85.97 g per 
mmol/L). There was no evidence of an association between maternal TC and LDL-C levels and 
birthweight (Supplementary material S15). 
Elevated maternal pre-pregnancy BMI, early GWG, fasting blood glucose and triglycerides 
level were significantly associated with an increase in the odds of LGA. The risk was 
particularly high for fasting glucose (OR = 2.06, 95%CI 1.31 to 3.24). Higher pre-pregnancy 
BMI and triglycerides were significantly associated with lower odds of SGA. There was no 
evidence of an association between maternal HDL-C level and risk of LGA/SGA. 
 
Association between maternal metabolic parameters and cord blood insulin 
Maternal fasting glucose (adjusted β = 2.23, 95%CI: 0.89 to 3.57 μU/ml per mmol/L) and 
triglycerides levels (adjusted β = 0.88, 95%CI: 0.05 to 1.71 μU/ml per mmol/L) were 
significantly associated with higher cord blood insulin. Pre-pregnancy BMI, GWG, TC, and 
LD L-C levels did not show an association with cord blood insulin (Table 9 and Supplementary 




Table 9 Multivariate analyses of maternal metabolic risk factors with birthweight and 
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∆ Adjusted for maternal age, ethnic group, parity, gestational age, neonatal sex, and early pregnancy cigarette exposures. For 
gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight measurements 
during pregnancy. 
¶ Adjusted for maternal age, ethnic group, parity, gestational age, neonatal sex, early pregnancy cigarette exposures, delivery 
mode, and sample storage duration. For gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational 
age of maternal weight measurements during pregnancy. 
§ Adjusted for maternal age, ethnic group, parity, and early pregnancy cigarette exposures. For gestational weight gain, model was 
further adjusted for pre-pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; LGA, 




Association between maternal metabolic parameter Z-score and birthweight Z-score  
Table 10 shows the estimates of the association between maternal metabolic parameter Z-
Scores and birthweight Z-Score as well as cord blood insulin Z-Score, and subgroup estimates 
for boys and girls. Maternal pre-pregnancy BMI (adjusted β = 0.20, 95%CI 0.15 to 0.24) and 
early GWG (adjusted β = 0.17, 95%CI 0.12 to 0.22) Z-scores had the strongest association with 
birthweight Z-Score. Both maternal triglycerides (adjusted β = 0.12, 95%CI 0.08 to 0.16) and 
glucose (adjusted β = 0.08, 95%CI 0.04 to 0.12) Z-scores were also positively associated with 
birthweight Z-Scores. Maternal HDL-C Z-Score showed a statistically significant negative 
association with birthweight Z-Score in boys (adjusted β = -0.06, 95%CI -0.12 to -0.01) only. 
The association of maternal pre-pregnancy BMI Z-Score, GWG Z-Score, Glucose Z-Score as 
well as triglycerides Z-Score with birthweight Z-Score remained statistically significant after 




Table 10 Multivariate analyses of maternal metabolic parameter Z-Scores with 













Model 1 (All) 0.20(0.15, 0.24) 0.17(0.12, 0.22) 0.08(0.04, 0.12) -0.05(-0.09, -0.00) 0.12(0.08, 0.16) 
Boys 0.18(0.12, 0.23) 0.18(0.10, 0.25) 0.07(0.02, 0.12) -0.07(-0.12, -0.01) 0.14(0.09, 0.19) 
Girls 0.22(0.15, 0.29) 0.16(0.09, 0.24) 0.09(0.02, 0.16) -0.03(-0.09, 0.04) 0.10(0.03, 0.16) 
Model 2 (All) 0.20(0.15, 0.24) 0.16(0.11, 0.22) 0.04(0.00, 0.09) 0.01(-0.03, 0.06) 0.07(0.03, 0.12) 
Cord blood insulin Z-Score 
Model 3 (All) 0.10(0.05, 0.15) 0.05(-0.01, 0.12) 0.13(0.08, 0.18) -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
Boys 0.13(0.07, 0.20) 0.04(-0.04, 0.13) 0.14(0.08, 0.21) -0.04(-0.11, 0.03) 0.08(0.02, 0.15) 
Girls 0.08(0.00, 0.15) 0.08(-0.02, 0.17) 0.12(0.05, 0.19) -0.05(-0.12, 0.02) 0.06(-0.01. 0.13) 
Model 4 (All) 0.08(0.03, 0.14) 0.05(-0.02, 0.11) 0.11(0.06, 0.16) -0.00(-0.06, 0.05) 0.03(-0.02, 0.09) 
Model 1: Adjusted for maternal age, ethic group, parity, and early pregnancy cigarette exposures. For gestational weight gain, 
model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
Model 2: Model 1 + pre-pregnancy BMI Z-Score + GWG Z-Score + Glucose Z-Score + HDL-C Z-Score + TG Z-Score + gestational 
age of maternal weight measurements during pregnancy. 
Model 3: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, gestational age, neonatal sex, delivery 
mode, and sample storage duration. For gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational 
age of maternal weight measurements during pregnancy. 
Model 4: Model 3 + pre-pregnancy BMI Z-Score + GWG Z-Score + Glucose Z-Score + HDL-C Z-Score + TG Z-Score + gestational 
age of maternal weight measurements during pregnancy. 







Association between maternal metabolic parameter Z-score and cord blood insulin Z-score 
Maternal glucose Z-Score (adjusted β = 0.13, 95%CI 0.08 to 0.18) appears to be the most 
important contributor to cord blood insulin Z-Score in both boys and girls. Both maternal pre-
pregnancy BMI (adjusted β = 0.10, 95%CI 0.05 to 0.15) and triglycerides (adjusted β = 0.06, 
95%CI 0.01 to 0.11) Z-Scores showed positive associations with cord blood insulin Z-Score. 
No statistically significant association was observed between maternal early GWG and HDL-
C Z-Scores with cord blood insulin Z-Score.  
 
ABN analysis results for interdependent maternal metabolic parameters  
Figure 7 shows the optimal summary DAGs inferred by ABN analysis (Technical details are 
provided in Supplementary file S13). The adjusted regression coefficients (β) in the graph 
represent how much the dependent variable changes per unit increase in the independent 
variable. Maternal pre-pregnancy BMI appeared to be the most influential upstream factor for 
both maternal metabolic parameters in pregnancy (glycaemia: β = 0.14, 95%CI 0.09 to 0.19; 
early GWG: β = -0.12, 95%CI -0.17 to -0.06; triglycerides: β = 0.23, 95%CI 0.18 to 0.28; HDL-
C: β = -0.12, 95%CI -0.17 to -0.07) and birthweight (β = 0.27, 95%CI 0.22 to 0.32). An indirect 
effect on neonatal insulin secretion was also observed. Our DAGs results showed that maternal 
glycaemia was associated with cord blood insulin (β = 0.12, 95%CI 0.07 to 0.17). Birthweight 
was also associated with cord blood insulin (β = 0.24, 95%CI 0.19 to 0.29). Neither triglycerides 
nor HDL-C were linked to birthweight or cord blood insulin.  
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To our knowledge, this is perhaps the first large prospective birth cohort study to map the 
metabolic network, and assess associations between maternal modifiable metabolic risk factors, 
birthweight, and insulin secretion in neonates. We showed that high maternal pre-pregnancy 
BMI appears the most influential upstream metabolic risk factor for both maternal and neonatal 
health. Maternal early GWG is directly associated with birthweight, but not neonatal insulin 
secretion. Maternal fasting glucose is significantly associated with increased neonatal insulin 
secretion. Although maternal low HDL-C and high triglycerides concentrations are 
significantly associated with elevated birthweight, our results demonstrated that these lipid 
pathways may not be meaningfully involved in the metabolic network pathway between 
mothers and neonates, and instead be a proxy measure for maternal metabolic health. These 
findings suggest: 1) the primary focus of weight management in clinical practice to prevent 
adverse pregnancy outcomes should start from preconception; 2) the observed association 
between maternal glucose and birthweight is likely to be partly mediated through elevated 
neonatal insulin secretion; 3) The pathogenic relationships of maternal glucose/triglycerides 
with birthweight/CBI need to be inferred with caution and evaluated in further studies.  
 
Comparison with previous studies and potential mechanisms 
The ‘foetal origins’ hypothesis proposed that intrauterine nutrient environment has a significant 
impact on developmental adaptations in foetal organs, and might even contribute to health 
outcomes throughout the life through permanent physiological, behavioural, and genetic 
changes (326). Recent evidence also demonstrated that maternal nutrition factors in 
preconception might disturb metabolic pathways and contribute to poor pregnancy outcomes 
and future cardiovascular disease via one-carbon metabolism (402). The 1-C metabolism drives 
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the synthesis of proteins, biogenic amines and lipids required for early growth, together with 
the synthesis and methylation of DNA and histones essential for the regulation of gene 
expression.  
Our results are generally consistent with previous relevant evidence, but importantly we also 
provide new insights that differ from the conclusions of previous studies. The Hyperglycaemia 
and Adverse Pregnancy Outcome Study research group (HAPO) published a series of network 
analyses reporting that maternal metabolites (acylcarnitines, fatty acids, carbohydrates, and 
amino acids) during pregnancy are associated with BMI, fasting glucose, and insulin resistance 
in mothers (403) and birth size, growth, adiposity, and cord blood C-peptide in neonates (398, 
404). Consistent with our findings, another study that looked at all metabolic parameters but 
not in the context of network analysis and restricted to women with GDM only (n = 357) 
reported that the number of altered maternal metabolic characteristics (pre-pregnancy BMI, 
fasting glycaemia, HbA1c, triglycerides, and HDL-C) are associated with incidence of LGA 
(405). However, none of those studies explored the inter-dependent relationships between 
maternal metabolic risk factors and compared the strength of their associations with neonatal 
conditions.   
A robust systematic review published in 2013 concluded that maternal pre-pregnancy 
overweight/obesity is associated with an increased risk of LGA, and decreased risk of SGA 
(286). Our analyses demonstrated that maternal pre-pregnancy BMI is the most important 
contributor to increased birthweight, which is independent of maternal early GWG, glucose, 
and triglycerides levels during pregnancy. It is also worth noting that high maternal pre-
pregnancy BMI is closely related to gestational metabolic disorders, namely, increased fasting 
glucose and triglycerides levels, therefore, further contributing to elevated birthweight and 
insulin secretion in offspring. Similar to our results, a small study containing 66 mother-
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offspring pairs found that obese mothers might induce increased insulin secretion in offspring. 
Their results also showed a clear sexual dimorphism (boys have higher insulin secretion than 
girls) (406). In this study, the association between maternal pre-pregnancy BMI with cord blood 
insulin in boys seemed stronger than in girls (β [95%CI], boys 0.13 [0.07, 0.20] vs. girls 0.08 
[0.00, 0.15]), but the difference was not statistically significance. On the other hand, we found 
that maternal early GWG is only statistically associated with birthweight, but not cord blood 
insulin, which suggests that the weight accumulation in the early pregnancy may indirectly 
affect neonatal metabolism through increased birthweight.  
The HAPO trial, the biggest study anywhere on this, indicated that maternal glucose is strongly 
associated with increased birthweight and cord blood C-peptide levels (388). The 
recommendation from WHO (2013) also summarized that GDM is positively associated with 
the increased risk of LGA, and treatment of GDM could decrease the risk of LGA based on 
four RCTs (393). We observed a positive association between maternal fasting glucose and 
increased birthweight using classic multivariate linear regression analyses. However, the ABN 
results suggests that maternal fasting glucose is perhaps not directly linked with birthweight. 
When we entered cord blood insulin Z-Score in the regression model, the association between 
maternal glucose Z-Score and birthweight Z-Score decreased dramatically but remained 
statistically significant (β = 0.05, 95%CI 0.01 to 0.09). This suggests that maternal fasting 
glucose likely influences birthweight via increasing insulin secretion in foetus, in line with prior 
hypotheses.   
Maternal circulating glucose transports freely across the placenta, and provides energy to satisfy 
the growth needs of the foetus (407). Two studies found a significant association between 
maternal fasting glucose at the end of second trimester and insulin/C-peptide in the cord blood 
(407, 408). Lawlor et al. reported that the de novo anabolic effects of cord blood insulin is key 
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for foetal fat deposition (407). At the same time, Tam et al. argued that the association of 
maternal hyperglycaemia with neonatal high blood C-peptide may not be mediated through 
macrosomia at birth and childhood obesity (408). Our results demonstrated that cord blood 
insulin may partly be explained by a response to the concentration of glucose transported from 
the maternal end. The increased cord blood insulin might stimulate adipose accumulation in 
neonates. Meanwhile, in addition to maternal fasting glucose level, elevated birthweight might 
also be a strong contributor for cord blood insulin (196, 409).  
We recently published a systematic review which found that increased maternal triglycerides 
and decreased HDL-C are positively associated with high birthweight (392). Similar results 
were observed using multivariate regression analysis in this study. The association between 
maternal triglycerides and birthweight remain statistically significant even when adjusted for 
the other four metabolic risk factors. Additionally, Geraghty et al. reported that high maternal 
triglycerides throughout pregnancy is positively associated with sum of skinfold in neonates in 
331 mother-child pair from the ROLO study (117). However, our ABN analysis now take us a 
step further by suggesting that both maternal HDL-C and triglycerides are likely to be measures 
of gestational metabolic disorder, and not themselves involved in the metabolic pathway that 
increases birthweight and cord blood insulin. Importantly, a Mendelian randomization study 
analysing data from 30,487 women in 18 studies concluded that genetically higher maternal 
fasting HDL-C/triglycerides was not potentially causally associated with higher birthweight 
(410). Thus, both detailed pathways analyses in this paper and genetic finding go against lipid 
pathways being directly relevant to birthweight.  
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Strengths and limitations 
The major strengths of this study are the prospective design based on a relatively large sample 
size, standardization of strength of association for the comparison among maternal metabolic 
risk factors, and the use of powerful analytical tools for interpretation of multi-dimensional data. 
Given the practical constraints, maternal fasting glucose and triglycerides levels were measured 
only once during pregnancy. Therefore, we could not investigate the dynamic long-term 
influences of maternal metabolic risk factors in detail. The average pre-pregnancy BMI of 
included women and incidence of LGA/SGA babies in this study were significantly lower than 
for people living in the northern part of China. The relative healthiness of our cohort suggests 
that our results might underestimate the true impact of maternal metabolic disorders on neonatal 
health outcomes if extrapolated to this wider population. The pre-pregnancy weight was self-
reported, which might potentially underestimate the true value. However, evidence suggest that 
utilization of self-reported or measured pre-pregnancy weight for pre-pregnancy BMI 
classification results in identical categorization for most women (411). In addition, due to 
lacking of dynamic data, the ABN analysis might have limited ability on exploring feedback 
loop. Therefore, the results of ABN, as with any observational analyses, need to be interpreted 
with a degree of caution. 
 
Implication  
Most current clinical guidelines on preconception and antenatal care only focus on weight 
management during pregnancy. Our results provide further important evidence on the clinical 
importance of maternal pre-pregnancy high BMI for both maternal and neonatal health 
outcomes. Interventions to reduce weight in overweight/obese women before conception to 
reduce adverse effects of high maternal pre-pregnancy BMI may need further investigation in 
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randomized trials. Recommendations on pre-pregnancy weight management is limited and 
ambiguous (28, 78, 412). None of the guideline on weight management in adults provides 
advice to women in child-bearing age to prevent adverse pregnancy outcomes. Only one public 
health guideline in UK mentions potential course of actions that could be taken by health 
professional to improve outcomes in women with a BMI equal or in excess of 30 kg/m2 prior 
to pregnancy (412). Our results, if applied to wider communities, provide further evidence for 
public health measures at improving weight levels in women in general and particularly those 
of child-bearing age.  
 
Conclusion 
In conclusion, in this cohort study, high maternal pre-pregnancy BMI appeared to be the most 
influential upstream risk factor for gestational hyperglycaemia/hypertriglyceridemia in mothers 
and increased birthweight/insulin secretion in neonates. Our findings based on robust novel 
statistical methods highlights the impact of maternal pre-pregnancy BMI on maternal and 
neonatal metabolic outcomes. We also found that maternal hyperglycaemia was positively 
associated with elevated neonatal insulin secretion, suggesting this may be a key reason for 
foetal fat deposition. By contrast, maternal lipid levels do not appear to have meaningful 





Chapter 5 Glucose, insulin and lipids in cord 
blood of neonates and their association with 







Babies born small-for-gestational-age (SGA) and large-for-gestational-age (LGA) are at similar 
risks of developing obesity, diabetes, and cardiovascular disease. Little is known whether SGA 
and LGA babies have similar metabolic profile at birth that lead to adverse health outcomes 
subsequently. We investigated the association of birthweight with cord blood metabolic 
parameters (glucose, lipids, and insulin).  
 
Methods 
Data of 1,522 newborns were obtained from the Born in Guangzhou Cohort study (BIGCS). 
Generalized additive model and multivariable linear regression model were used to explore the 
non-linear and linear relationships between birthweight and cord blood metabolic parameters, 
and to evaluate the differences of metabolic parameters Z-Scores among SGA, appropriate-for-
gestational-age (AGA), and LGA babies.  
 
Results 
Birthweight Z-Score was linearly associated with increased cord blood insulin Z-Score 
(adjusted β = 0.32, 95%CI 0.26 to 0.37). Compared to AGA babies, neonates born SGA had 
significantly higher cord blood triglycerides Z-Score (adjusted mean difference [MDadj] = 0.70, 
95% CI 0.51 to 0.88) and lower cord blood insulin (MDadj = -0.54, 95%CI -0.74 to -0.35), high-
density-lipoprotein cholesterol (MDadj = -0.36, 95%CI -0.55 to -0.16), and total cholesterol 
(MDadj = -0.20, 95%CI -0.40 to -0.01) Z-Scores, while neonates born LGA had higher cord 
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blood insulin Z-Score (MDadj = 0.48, 95%CI 0.27 to 0.68) and lower triglycerides Z-Scores 
(MDadj = -0.24, 95%CI -0.43 to -0.04). 
 
Conclusions 
Our findings support the hypothesis that SGA and LGA babies are exposed to different intra-
uterine environments, which may contribute to altered fat accumulation patterns with 
implications for the risk of metabolic dysfunction later in life. There is a need to consider the 
development of tailored intervention strategies to prevent metabolic dysfunction in adult life 
for these babies. 
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Manuscript (Under review) 
Introduction 
Babies who are small-for-gestational-age (SGA) and large-for-gestational-age (LGA) are at a 
higher risk of similar adverse health outcomes, such as infant mortality, subsequent life-long 
risk of obesity, type 2 diabetes, and cardiovascular disease (65-67). These adverse metabolic 
conditions have become major public health concerns globally. The World Health Organisation 
estimated that over 381 million children and adolescents, and more than 1.9 billion adults were 
overweight or obese in 2016 globally (1). In parallel with the increasing prevalence of obesity, 
there has been an accompanying rise in the prevalence of associated metabolic and 
cardiovascular diseases (46, 391). Obesity and its related conditions have become major global 
health concerns resulting in significant social and economic burden. While birthweight has been 
used as a marker for risk of adverse health outcomes in adults, it is still unclear why relatively 
low and high birthweights have similar adverse effects.  
Fat accumulation is acknowledged as the common factor that mediates the effects of SGA and 
LGA on adult metabolic health (175). Meanwhile, metabolic dysfunction including 
hyperglycaemia, dyslipidaemia (altered cholesterol and triglycerides levels), hyperinsulinemia, 
and high body mass index (BMI) have been identified as major risk factors for diabetes and 
cardiovascular diseases (413, 414). The metabolic markers in cord blood could reflect the 
intrauterine environment or the initial metabolic status in the foetus, and may potentially be 
linked to subsequent metabolic dysfunction. 
Evidence on the association of birthweight with foetal metabolism is limited and controversial.  
Lindsay et al. found that cord blood insulin was independently associated with increased 
birthweight in neonates of mothers with type 1 diabetes but not in mothers without type 1 
diabetes (415). In contrast, Hou et al. observed a positive association in term neonates whose 
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mother did not have diabetes (416). Rodie V et al. reported that there was no evidence of the 
association between birthweight and foetal lipids (417), while Kelishadi R et al. observed 
elevated risk of high cord blood triglycerides levels in SGA and LGA babies (313). Most of 
these studies only focused on a specific population with small sample size (313, 415, 417), or 
ignored the potential non-linear relationship between birthweight and cord blood metabolic 
markers (313, 416). 
Understanding the metabolic profile in low and high birthweight babies may provide new 
insights on the underlying metabolic mechanism in newborns, and help uncover strategies for 
timely and effective intervention to prevent subsequent metabolic diseases. Therefore, the aim 
of this study is to determine the associations of birthweight with insulin, glucose, and lipids 




This study was conducted in a subgroup of the Born in Guangzhou Cohort Study (BIGCS), an 
ongoing large-scale prospective birth cohort study, in whom relevant maternal and cord-blood 
metabolic parameters were assessed. The cohort details of BIGCS have been described 
previously (400). Briefly, pregnant women (< 20 gestation week) with Chinese nationality 
living in Guangzhou and who intended to deliver at one of the two Guangzhou Women and 
Children’s Medical Centre (GWCMC) campuses were eligible for BIGCS. At recruitment, 
participants were asked to complete a semi-structured questionnaire (Q1) for demographic data 
collection. All women in BIGCS were offered a standard 2h 75g oral glucose tolerance test 
(OGTT) appointment at 22-28 weeks gestation.  
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To be eligible for this subgroup study, BIGCS women had to deliver at GWCMC with umbilical 
cord blood retained between January 2015 and June 2016. We excluded participants who: 1) 
were without available fasting blood samples at 14-27 weeks’ gestation; 2) did not complete an 
OGTT test; 3) had type 1 or type 2 diabetes, thyroid dysfunction, hypertension, virus hepatitis 
and kidney diseases prior to pregnancy; 4) were without maternal demographic information. 
Among the eligible participants, a total number of 1,522 randomly selected mother-child pairs 
were finally included in this study (Figure 6). The sample size was designed based on a 
previous study (Supplementary material S9). A sample of 1,552 will give 80% power to detect 
a correlation coefficient of 0.07 at the 5% significance level (two-sided). Ethical approval for 
this study was granted by the GWCMC Ethics Committee. 
 
Data and Biological Samples Collection 
Maternal demographic data, including age, height, pre-pregnancy weight, parity, ethnicity, 
family and personal medical history, and cigarette exposures were self-reported. Cigarette 
exposures, including both active and passive smoking, was categorised as a binary variable 
(yes/no). Pre-pregnancy BMI was calculated by dividing weight in kilograms by height in 
meters squared. Women were classified to lean group (< 24 kg/m2) and overweight group (≥ 
24 kg/m2) by pre-pregnancy BMI according to the recommendations of the China Obesity Task 
Force of the Chinese Ministry of Health (6).  
Participants were asked to complete an OGTT test in the morning after overnight fasting. 
Plasma samples were taken at three time points: 0 minutes, 60 minutes and 120 minutes, and 
were sent to the clinical laboratory centre in GWCMC for immediate assays. Women were 
diagnosed as having gestational diabetes mellitus (GDM) if their OGTT results met or exceeded 
at least one threshold of the International Association of Diabetes and Pregnancy Study Groups 
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criteria (fasting plasma glucose ≥ 5.1 mmol/L, 1h glucose ≥ 10.0 mmol/L, and 2h glucose ≥ 8.5 
mmol/L) (401).  
Birthweight was measured to the nearest 50g using electronic scales by the attending midwives 
immediately after delivery. Newborns’ information including sex, gestational age and delivery 
mode were obtained from routine medical records. Birthweight was standardized as birthweight 
Z-Score and birthweight percentile by gestational age and neonatal sex using 
INTERGROWTH-21st Newborn Size Standard and Tools (62). Babies with birthweight < 10th 
percentile and > 90th percentile for their gestational age and sex, were classified as SGA and 
LGA, respectively. Babies born before 37 weeks of pregnancy were defined as born pre-term. 
Venous umbilical cord blood samples were collected by midwives at birth and were stored and 
delivered to Guangzhou Biobank on ice within 3 hours. In the pre-treatment centre, all samples 
were separated to serum and plasma immediately by centrifugation and were stored in 
Ethylenediaminetetraacetic acid (EDTA) tubes at -80℃ in the Guangzhou Biobank until assays 
were carried out. 
 
Metabolic Parameter Assays 
The cord blood plasma samples were sent to a third-party medical laboratory for metabolic 
parameter assays. Samples were masked with the sample ID number, therefore, staff in pre-
treatment centre, Guangzhou Biobank and medical laboratory were blinded to participants’ 
information. 
Cord blood insulin was measured on Roche Immunology Analyser (cobas 8000 e602) using 
electrochemiluminescence immunoassay. The assays of glucose, total cholesterol (TC, 
cholesterol oxidase method), high-density lipoprotein cholesterol (HDL-C, ELISA), low-
density lipoprotein cholesterol (LDL-C, ELISA) and triglycerides (TG, enzymatic 
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measurements) were conducted on Roche Chemistry Analyser (cobas 8000 c702). Intra- and 
inter-day coefficients of variation (CVs) were consistently < 2% for all assays.  
 
Statistical Analysis 
Data were presented as mean ± standard deviation or median and interquartile range for 
describing symmetrical and skewed continuous variables respectively.  
Lipids profile has been demonstrated to be stable in EDTA tubes at -80 °C for a period of at 
least 24 months. Pearson correlation was used to detect the influence of the long-term -80 °C 
storage in EDTA tubes on insulin and glucose concentrations. Concentration was then adjusted 
for storage duration using the regression model if a statistically significant association was 
detected (Supplementary material S16).  All cord blood metabolic parameters (insulin, glucose, 
TC, HDL-C, LDL-C, and TG) were standardised as Z-Scores due to the different measurement 
units and scales. Cord blood insulin and TG concentrations were log-transformed prior to 
standardisation. The resultant adjusted regression coefficients represent differences in the mean 
of cord blood metabolic parameter Z-Scores on these scales per one unit increase in birthweight 
Z-Score. Multivariable linear regression analyses with birthweight Z-Score as the independent 
variable and Z-Score of cord blood parameters as dependent variables were adjusted for 
maternal age, parity, delivery mode, gestational age, baby’s sex, smoking exposure and ethnic 
group. It is well known that maternal GDM/obesity and pre-term delivery can significantly 
influence birthweight and neonatal metabolic status, we therefore conducted subgroup analyses 
to understand how these conditions might influence the association between birthweight and 
cord blood metabolic parameters (286, 388). Subgroup analyses were performed among non-
GDM/GDM, pre-term/term birth, and maternal lean/overweight groups. All statistical tests 
were two-tailed and a P-value less than 0.05 was considered statistically significant.  
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We also investigated the difference of cord blood metabolic parameter Z-Scores between SGA, 
appropriate-for-gestational-age (AGA), and LGA birthweight categories. The above analyses 
were carried out in Stata 14.0 (College Station, Texas, USA). 
To further investigate the potential non-linear relationship between birthweight and cord blood 
metabolic parameter at both ends of the birthweight spectrum, the generalised additive model 
(GAM) was conducted as a post-hoc analysis. GAM was adjusted for maternal age, parity, 
delivery mode, gestational age, neonatal gender, cigarette exposures, and ethnic group. The 
results of GAM can help explain how cord blood metabolic parameter Z-Scores vary along with 
different birthweight percentiles. GAM analysis was performed in R 3.5.0 (The R Foundation 




Table 11 shows baseline characteristics for all participants and separately for SGA, AGA, and 
LGA groups. The mean age of all included women at recruitment was 29.5 years. The vast 
majority of them were ethnic Han Chinese (97.7%). Around 12% of women were diagnosed 
with GDM. Women with LGA babies were on average older, less likely to deliver 
spontaneously, be primipara, and have higher pre-pregnancy BMI and GDM incidence than 









SGA(n=105) AGA(n=1,320) LGA(n=96) 
Maternal information 
  Maternal age (years) 29.50 ± 3.30 28.93 ± 3.31 29.44 ± 3.25 30.97 ± 3.58 
  Ethic Han 1,486 (97.70) 103 (98.10) 1292(97.88) 91(94.79) 
  Primiparous 1,223 (80.35) 93 (88.57) 1,064 (80.55) 66 (68.75) 
  Spontaneous delivery 1,239 (81.41) 85 (80.95) 1,101 (83.35) 53 (55.21) 
  Pre-pregnancy BMI (kg/m2) 20.47 ± 2.69 19.52 ± 2.09 20.41 ± 2.63 22.36 ± 3.15 
  GDM 181 (11.89) 9 (8.57) 154 (11.66) 18 (18.75) 
Neonatal information 
  Gestational age (days)* 275 (270-281) 276 (271-282) 275 (270-281) 276 (271-281) 
  Birthweight (g) 3,203 ± 411 2,603 ± 251 3,194 ± 334 3,982 ± 269 
  Male 820 (53.88) 46 (43.81) 730 (55.26) 44 (45.83) 
  Sample storage time (days)* 488(394-707) 519(389-695) 487 (395-707) 488 (394-707) 
Cord blood metabolic parameters 
  Insulin (μU/mL) * 7.43 (4.34-12.61) 5.64 (3.24-8.60) 7.39 (4.34-12.56) 11.53 (6.87-18.39) 
  Glucose (mmol/L) 4.81 ± 2.32 4.69 ± 2.32 4.90 ± 2.32 3.72 ± 2.10 
  TC (mmol/L) 1.72 ± 0.42 1.66 ± 0.39 1.73 ± 0.42 1.72 ± 0.51 
  HDL-C (mmol/L) 0.91 ± 0.28 0.83 ± 0.27 0.92 ± 0.28 0.92 ± 0.30 
  LDL-C (mmol/L) 0.61 ± 0.24 0.58 ± 0.24 0.61 ± 0.24 0.61 ± 0.31 
  TG (mmol/L) * 0.33 (0.27-0.41) 0.43 (0.34-0.52) 0.33 (0.27-0.41) 0.28 (0.23-0.36) 
Data are presented as mean ± SD or n (%), *Median (Inter Quartile Range). 
Abbreviation: SGA, small-for-gestational-age; AGA, appropriate-for-gestational-age; LGA, large-for-gestational-age; 
BMI, body mass index; GDM, gestational diabetes mellitus; TC, total cholesterol; HDL-C, high-density lipoprotein 




Multivariable linear regression model 
Table 12 shows the relationship between birthweight Z-Score and cord blood metabolic 
parameter Z-Scores. After standardization and adjustment, birthweight Z-Score had a positive 
association with cord blood insulin Z-Score (adjusted β = 0.32, 95% CI 0.26 to 0.37), HDL-C 
Z-Score (adjusted β = 0.10, 95% CI 0.04 to 0.16), and TC Z-Score (adjusted β = 0.06, 95% CI 
0.00 to 0.12); and an inverse association with cord blood TG Z-Score (adjusted β = -0.27, 95% 
CI -0.32 to -0.21). No statistically significant association was observed between birthweight Z-
Score and cord blood glucose and LDL-C levels.  
Compared to AGA babies, SGA babies were found to have much higher cord blood TG Z-
Score (adjusted Mean Difference [MD] = 0.70, 95%CI 0.51 to 0.88) and lower cord blood 
insulin (adjusted MD = -0.54, 95%CI -0.74 to -0.35), TC (adjusted MD = -0.20, 95%CI -0.40 
to -0.01), and HDL-C Z-Scores (adjusted MD = -0.36, 95%CI -0.55 to -0.16). Meanwhile, LGA 
babies had higher cord blood insulin Z-Score (adjusted MD = 0.48, 95%CI 0.27 to 0.68) and 




Table 12 Multivariable linear regression results of the association between birthweight 
and cord blood metabolic parameter Z-Scores 
Cord blood metabolic 
parameter Z-Scores 
Adjusted β*  
(95% CI) 
Adjusted Mean Difference (95% CI) ⁋ 
SGA AGA LGA 
    Insulin 0.32 (0.26, 0.37) -0.54 (-0.74, -0.35) Ref 0.48 (0.27, 0.68) 
    Glucose 0.01 (-0.04, 0.06) -0.10 (-0.26, 0.07) Ref -0.08 (-0.25, 0.09) 
    TC 0.06 (0.00, 0.12) -0.20 (-0.40, -0.01) Ref 0.02 (-0.18, 0.23) 
    HDL-C 0.10 (0.04, 0.16) -0.36 (-0.55, -0.16) Ref 0.00 (-0.20, 0.21) 
    LDL-C 0.04 (-0.02, 0.10) -0.14 (-0.34, 0.05) Ref 0.03 (-0.17, 0.24) 
    TG -0.27 (-0.32, -0.21) 0.70 (0.51, 0.88) Ref -0.24 (-0.43, -0.04) 
*multivariable linear regression model account for the linear relationship between birthweight Z-Score and cord blood 
metabolic parameter Z-Scores. Adjusted for maternal age, parity, delivery mode, gestational age, neonatal gender, cigarette 
exposures, and ethnic group. 
⁋multivariable linear regression model account for the adjusted mean difference of cord blood metabolic parameter Z-
Scores between SGA/LGA groups and reference group (AGA). Adjusted for maternal age, parity, delivery mode, gestational 
age, neonatal gender, cigarette exposures, and ethnic group. 
Abbreviation:  SGA, small-for-gestational age; AGA, appropriate-for-gestational age; LGA, large-for-gestational age; TC, 
total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, 






Figure 8 shows the scatter plots and the results of GAM estimation of the association between 
birthweight percentile and standardised residuals of cord blood metabolic parameter Z-Scores. 
The association between birthweight percentile and cord blood insulin Z-Score (p < 0.001) was 
approximately linear in the graph. Birthweight percentile was also negatively associated with 
cord blood TG Z-Score (p < 0.001), and positively associated with cord blood HDL-C Z-Score 
(p < 0.001). The slope of observed associations diminished along with increasing birthweight 
percentile for TG and HDL. When examining the association between birthweight and TC Z-
Score, there was a slight rise in the lowest 20th percentile but this was not statistically 
significant (p = 0.09). No association was evident between birthweight percentile with cord 




Figure 8 Results of Generalized Additive Model for the association between birthweight 
percentile and cord blood metabolic parameter Z-Scores 
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Subgroup analysis 
Figure 9 shows the findings of our subgroup analyses for the associations between birthweight 
Z-Score and cord blood metabolic parameter Z-Scores. The relationships of birthweight Z-
Scores and cord blood insulin/glucose Z-Scores were not influenced by GDM, maternal 
overweight status, or pre-term birth. The estimated effect sizes for HDL and TG Z-Scores in 
women with GDM were in the opposite direction to that observed in the non-GDM population. 
The estimated confidence intervals of effect sizes for HDL/TG Z-Scores in GDM group and 
non-GDM group did not overlap.  In preterm birth neonates, we observed strong negative 
estimate of associations of birthweight Z-Scores with cord blood TC (β = -0.43, 95%CI -0.83 










This study of 1,522 mother-child pairs found that neonates born with low and high birthweight 
had different metabolic profiles. Increased birthweight was strongly associated with increased 
insulin and decreased triglycerides concentrations in cord blood. Compared to AGA, neonates 
born SGA had significantly lower cord blood insulin, TC, and HDL-C levels, and had higher 
cord blood triglycerides concentrations, while neonates born LGA had significantly higher cord 
blood insulin and lower triglycerides concentrations. Birthweight did not show an evident 
association with cord blood glucose and LDL-C concentrations.   
 
Comparison with previous studies 
Several studies have described the association between birthweight and cord blood insulin, but 
results are conflicting. Most of them observed elevated cord blood insulin in LGA neonates 
(416, 418-421), while some studies reported decreased or unchanged cord blood insulin levels 
in LGA neonates (422, 423). However, most these studies were small in number (415, 418-421, 
423, 424) or failed to adjust for important confounding factors, such as gestational age and 
neonatal gender (415, 417, 418, 420, 421, 423, 424). Our study was the largest one that took 
into account clinically important confounders and demonstrated that birthweight was positively 
and linearly associated with cord blood insulin and that the estimates were consistent in GDM 
and non-GDM, lean and overweight, as well as preterm and full-term subgroups. 
Evidence regarding the association between birthweight and cord blood lipids profile is 
inconsistent. Similar to our findings, Katragadda et al. and Hou et al. observed elevated TG 
levels in SGA or low birthweight neonates (416, 425), while Aletayeb et al. reported elevated 
TC, LDL-C, and TG levels in neonates born low or high birthweight (426). On the other hand, 
Kelishadi et al. found decreased HLD-C/LDL-C in LGA (313), and Rodie et al. and Kenchappa 
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et al. found there is no association between birthweight and cord blood lipids profile (417, 427). 
However, these studies were again limited by small sample size and failed to take account of 
relevant confounding factors.  With appropriate design, our analysis showed that there was 
significant elevated cord blood TG and decreased TC and HDL-C levels in SGA, as well as 
decreased TG level in LGA. In the subgroup analysis, we found that birthweight was 
independently associated with increased cord blood HDL-C and decreased TG levels in 
neonates with non-GDM mothers, but not in neonates with GDM mothers. In addition, our 
results indicated that preterm birth neonates with lower birthweight might have higher cord 
blood cholesterol profile. 
It is believed that newborns with low and high birthweight are at increased risk of neonatal 
hypoglycaemia (428, 429) based on previous studies, but the studies did not account for 
potential confounders such as caesarean section, parity, and ethnicity (422, 430-432). In our 
study, after adjusting for important confounding factors, we did not find an evident association 
between birthweight and cord blood glucose concentration (Supplementary material S17).  
 
Potential mechanism 
The vast majority of cord blood glucose is transported freely from the maternal end, and largely 
determines the foetal glycaemia and insulin level at birth (407). Insulin secretion is known to 
play a central role in foetal growth. Elevated insulin concentration increases glucose uptake in 
muscle and adipose tissue, blocks glycogenolysis and gluconeogenesis in the liver, and 
stimulate glycogen synthesis (433). Meanwhile, it also promotes the circulating free fatty acids 
(FFAs) and triacylglycerol uptake in adipose and muscle tissues, therefore lowering the plasma 
TG level (434). Through stimulating lipogenesis, glycogen, and protein synthesis, and 
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inhibiting lipolysis, glycogenolysis, and protein breakdown, insulin could also stimulate the 
storage of substrates (lipids, protein, and glycogen) in adipose, liver, and muscle tissues (433).  
Adipose tissue plays a central role in metabolism, buffering the daily influx of dietary fatty 
acids and providing storage for excess energy in the form of TG. When TG accumulation 
exceeds the buffer capacity of adipose tissue, ectopic fatty acid deposition in non-adipose tissue 
organs, such as the liver and muscle, occurs (435). Ectopic fatty acid deposition contributes to 
the development of insulin resistance and cardiovascular morbidity. One key factor that 
determines the buffer capacity of adipose tissue is adipocyte cell size and the capability of 
adipose tissue expansion, either through adipocyte hyperplasia or hypertrophy (435). Little is 
known about the exact determinants of expansion capacity, although genetic and developmental 
factors appear plausible (436). In this light, the intrauterine environment may also play an 
important role in the development of adipose tissue and its ability to expand in early life. 
Compared to AGA, neonates born SGA, tend to experience intrauterine growth restriction 
(IUGR), and have deficits in skeletal muscle and absolute fat mass (175). Evidence indicated 
that IUGR could suppress β-cell replication, leading to diminished insulin production in the 
foetus (437). Rapid catch up growth experienced by most SGA babies in early postnatal life 
has been associated with increased risk of diabetes, obesity, and cardiovascular dysfunction in 
adulthood (438). We showed increased TG and low insulin concentrations within circulating 
blood, which could be linked to low intravascular lipolysis and decreased lipid deposition into 
adipose tissue. It could be speculated that this, in turn, results in smaller adipocytes postnatally, 
with decreased capacity for expansion during the catch-up growth period, thereby leading to 
ectopic fat deposition and future risk of cardio-metabolic diseases. 
Interestingly, LGA babies have also been shown to have an increased risk of obesity, diabetes, 
and cardiovascular diseases in later life (175). The elevated insulin secretion we observed in 
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LGA babies, which could be attributed to the increased nutrients supply from the maternal side, 
is key for circulating lipid uptake and fat deposition in the foetus, mirrored by our finding of 
low TG concentrations (407). It is therefore possible that LGA babies are born with an already 
expanded adipose tissue with reduced buffer capacity, potentially contributing to elevated 
insulin secretion in neonates (439) and, compared to AGA, a higher risk of ectopic fatty acid 
deposition and the associated cardiometabolic complications in later life (66, 67). Our findings 
suggest that there is an optimal intrauterine environment driven by physiological insulin 
concentrations which result in AGA babies who have a lower cardiometabolic risk compared 
to both SGA and LGA babies. While the exact mechanisms require further investigation, 
parents of SGA and LGA babies should be provided with tailored professional advice on 
optimal feeding and weight development of their babies as early as possible to prevent rapid 
postnatal growth and the risk of obesity in later life (438).  
 
Strengths and limitations 
The major strength of this study is comprehensive analyses based on a large prospective cohort 
study, which allowed us to have well-recorded clinical data and sufficient statistical power to 
test our hypothesis. Given the practical constraints, we could not measure the fat mass 
distribution in neonates. Instead of the exact neonatal fat mass, we used birthweight percentile, 
a widely utilised measurement in clinics, as an approximate measurement to improve the 
generalizability of our results. In addition, we could only measure metabolic factors in cord 
blood instead of in neonates due to ethical reasons, which needs to be considered when 




We found that LGA neonates have significantly higher cord blood insulin and lower TG levels, 
while SGA neonates have higher cord blood triglycerides and lower HDL-C/TC/insulin levels. 
No evident association was observed between birthweight and cord blood glucose level. Our 
findings suggest that the differential metabolic profile in SGA and LGA babies might be crucial 
for developing subsequent obesity, diabetes, and cardiovascular diseases. Differential 
intervention strategies may need to be developed to prevent life-long chronic metabolic 






Chapter 6 Association of birthweight and cord 
blood triglyceride and cord blood 






To explore the association of birthweight and cord blood triglycerides levels with 
proinflammatory cytokines (IL-6, CRP, TNF-α) in cord blood. 
 
Methods 
We prospectively collected 222 umbilical cord blood samples from healthy newborns whose 
mothers have participated in the Born in Guangzhou Cohort Study (BIGCS). Triglycerides, 
TNF-α, IL-6, and CRP concentrations were measured in cord blood. Information of birthweight, 
neonatal sex, gestational age, parity, and delivery mode was obtained from clinical records. 
Generalized additive model and multivariable linear regression model were used to explore and 
quantify the non-linear and linear relationships between birthweight/cord blood triglyceride and 
cord blood pro-inflammatory cytokines. Adjusted covariates included gestational age, neonatal 
sex, delivery mode, parity, and sample storage duration. 
 
Results 
Birthweight Z-Score is negatively associated with Z-scores of cord blood CRP (β = -0.18, 
95%CI -0.34 to -0.02), TNF-α (β = -0.15, 95%CI -0.32 to 0.02), and IL-6 (β = -0.17, 95%CI -
0.33 to -0.00). Cord blood triglycerides Z-Score is positively associated with Z-Scores of cord 
blood CRP (β = 0.22, 95%CI 0.07 to 0.37) and IL-6 (β = 0.20, 95%CI 0.08 to 0.23), but not 
with cord blood TNF-α Z-Score. After further adjusting for cord blood triglycerides Z-Score, 
the estimated association strength between birthweight Z-Score and pro-inflammatory 
cytokines reduced and its 95% CI did not reach statistically significant levels. After further 
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adjusting for birthweight Z-Score, the associations between cord blood triglycerides and 
CRP/IL-6 remained statistically significant.  
 
Conclusions 
Our findings suggest that elevated cord blood triglycerides observed in babies with a lower 
birthweight percentile are associated with systemic low-grade inflammation, which might 
contribute to short- and long-term metabolic and cardiovascular dysfunctions. We did not 






Pro-inflammatory cytokines are a certain type of signalling protein produced predominantly by 
immune cells and are typically elevated in acute inflammatory responses and chronic low-grade 
inflammation (440). Elevated pro-inflammatory cytokines in chronic low-grade inflammation 
have been associated with insulin resistance, endothelial dysfunction, and hypertension (441).  
Compared to AGA babies, we found that SGA babies have significantly higher triglycerides 
and lower insulin levels in cord blood, while LGA babies have significantly higher insulin and 
lower triglycerides levels in cord blood (Chapter 5). Both lipotoxicity and expanded adipocytes 
could induce systemic low-grade inflammation, therefore contributing to the development of 
metabolic dysfunctions (193, 194, 204). Two studies found that cord blood IL-6 and CRP levels 
in SGA babies were higher than in AGA babies (442, 443), while the other two studies did not 
observe the difference (444, 445).  
Therefore, we decided to conduct a small exploratory study to investigate whether altered 
birthweight/triglycerides levels would trigger low-grade inflammatory responses in neonates. 
The aim of this study is to assess the association of birthweight and triglycerides levels with 




This exploratory study was based on the Born in Guangzhou Cohort Study (BIGCS). The study 
design of BIGCS has been described in detail before. Chinese pregnant women living in 
Guangzhou who attended their first antenatal visit and intended to deliver at one of the two 
Guangzhou Women and Children’s Medical Centre (GWCMC) were eligible for BIGCS. In 
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the main campus of GWCMC, we obtained (February - March 2017) 222 cord blood samples 
of healthy newborns, whose mothers have participated in BIGCS, for measuring triglycerides 
and pro-inflammatory cytokines (TNF-α, IL-6, and CRP) levels. Previous studies only 
compared the difference of proinflammatory cytokines between SGA and LGA babies, but did 
not explore the association of birthweight and cord blood triglycerides levels with cord blood 
pro-inflammatory cytokines. Therefore, we assumed a correlation estimate of 0.20. After using 
‘Fisher’s z tests comparing one correlation to a reference value’ tool, a sample of 194 will give 
80% power to detect a correlation of 0.20 at 5% significance level (two-sided). We then 
assumed a 10% attrition rate due to missing data, thus giving a sample size of 216. Ethical 
approval for this study was granted by the GWCMC Ethics Committee.  
 
Data and Biological Samples Collection 
Information of birthweight, neonatal sex, gestational age, parity, and delivery mode was 
obtained from clinical records. Venous umbilical cord blood samples were collected by 
midwives at birth and were stored and delivered to Guangzhou Biobank on ice within 3 hours. 
In the pre-treatment centre, all samples were separated to serum and plasma immediately by 
centrifugation and were stored in Ethylenediaminetetraacetic acid (EDTA) tubes at -80℃ in the 
Guangzhou Biobank until assays were carried out.  
 
Metabolic Parameter Assays 
Cord blood plasma samples were sent to a third-party medical laboratory for measuring 
triglycerides and proinflammatory cytokines (IL-6, CRP, and TNF-). Samples were masked 
with the sample ID number, therefore, staff in pre-treatment centre, Guangzhou Biobank and 
medical laboratory were blinded to participants’ information.  
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Cord blood TNF-α and IL-6 concentrations were measured on Bio-Plex 200 suspension array 
system. The assays of triglycerides (enzymatic measurements) and CRP (immunoturbidimetry) 
were conducted on Roche Chemistry Analyser (cobas 8000 c702).  Intra-day CVs were 
consistently < 2% for all assays. 
 
Statistical Analysis 
Baseline characteristics were presented as mean ± standard deviation or median and 
interquartile range for describing symmetrical and skewed continuous variables respectively. 
Birthweight was standardised as birthweight Z-Score and birthweight percentile by gestational 
age and neonatal sex using INTERGROWTH-21st Newborn Size Standard and Tools (62). Cord 
blood triglycerides and proinflammatory cytokines (TNF-, IL-6, and CRP) were standardised 
as Z-Scores due to the different measurement units and scales. Cord blood triglycerides, IL-6, 
and CRP concentrations were log-transformed prior to standardisation.  
We first applied GAM to explore the potential non-linear relationship of birthweight and cord 
blood triglycerides with pro-inflammatory cytokines. Multivariable linear regression models 
were then used to quantify the associations of birthweight and cord blood triglycerides with 
pro-inflammatory cytokines.  Covariates that were considered in GAM and multivariable linear 
regression model included gestational age, neonatal sex, delivery mode, parity, and sample 
storage duration. Descriptive analysis and multivariable linear regression analysis were 
conducted in Stata 14.0 (College Station, Texas, USA). GAM analysis was performed in R 




Table 13 shows the baseline characteristics of all neonates. Among 222 neonates, there are 17 
babies born to SGA and 13 babies born to LGA.  Thirteen of 222 neonates were born before 
the 37th week of gestation. About 80% of babies were spontaneous vaginal delivered. One 
hundred and fifteen of 222 neonates (51.80%) were the first child of their mothers. The average 




Table 13 Baseline characteristics table 
Characteristics Mean ± SD 
  Gestational age (days) 273.26 ± 8.08 
  Spontaneous delivery 178 (80.18) 
  Male 123 (55.41) 
  Birthweight (g) 3183.29 ± 375.22 
  Sample storage time (days) 51.22 ± 12.28 
  Triglycerides (mmol/L) * 0.32 (0.26, 0.38) 
  IL-6 (pg/mL) * 3.14 (2.64, 3.65) 
  TNF- (pg/mL) 36.88 ± 0.62 
  CRP (mg/L) * 0.17 (0.15, 0.19) 
Data are mean ± SD,  n (%), * Median (Inter Quartile Range). 






Figure 10 shows the scatter plots and the results of GAM estimation of the association of 
birthweight percentile and triglycerides Z-Score with cord blood pro-inflammatory cytokine Z-
Scores. After adjusting for gestational age, neonatal sex, delivery mode, parity, and sample 
storage duration, the associations of birthweight and cord blood triglyceride Z-Score with cord 





Figure 10 GAM scatter plots of the association of birthweight percentile and cord blood 




Multivariable linear regression model 
Table 14 shows the estimated regression coefficients of the association of birthweight Z-Score 
and triglycerides Z-Score with cord blood pro-inflammatory factor Z-Scores. After adjusting 
for gestational age, neonatal sex, delivery mode, parity, and sample storage duration, the 
increased birthweight Z-Score is significantly associated with decreased CRP (β = -0.18, 
95%CI -0.34 to -0.02) and IL-6 (β = -0.17, 95%CI -0.33 to -0.00) Z-Scores. When further 
adjusting for cord blood triglyceride Z-Score, the association between birthweight Z-Score and 
cord blood pro-inflammatory cytokines was attenuated. Cord blood triglycerides Z-Score is 
positively associated with cord blood CRP (β = 0.22, 95%CI 0.07 to 0.37) and IL-6 (β = 0.20, 
95%CI 0.05 to 0.35) Z-Scores, and the results remained statistically significant when further 
adjusted for birthweight Z-Score (CRP: β = 0.20, 95%CI 0.04 to 0.35; IL-6: β = 0.18, 95%CI 




Table 14 Multivariable analysis of the association of birthweight and cord blood 
triglycerides Z-Scores with cord blood proinflammatory cytokine Z-Scores 
Proinflammatory cytokine 





Model 1   
CRP -0.18 (-0.34, -0.02) 0.22 (0.07, 0.37) 
TNF- -0.15 (-0.32, 0.02) 0.07 (-0.08, 0.23) 
IL-6 -0.17 (-0.33, -0.00) 0.20 (0.05, 0.35) 
Model 2   
CRP -0.13 (-0.30, 0.03) 0.20 (0.04, 0.35) 
TNF- -0.14 (-0.31, 0.03) 0.05 (-0.11, 0.21) 
IL-6 -0.14 (-0.30, 0.03) 0.18 (0.03, 0.33) 
Model 1: Adjusted for gestational age, neonatal sex, delivery mode, parity, and sample storage 
duration. 
Model 2: For birthweight Z-Score, further adjusted for cord blood triglycerides Z-Score based on 
model 1; For cord blood triglycerides Z-Score, further adjusted for birthweight Z-Score based on 
model 1 
Abbreviations: CI, confidence interval; CRP, C-reactive protein; TNF-α, Tumour necrosis factor 






In this study, we found that the decreased birthweight was associated with increased CRP, TNF-
α, and IL-6 levels but this effect was attenuated when further adjusted for triglycerides. 
Increased cord blood triglycerides were significantly associated with increased CRP and IL-6 
levels in cord blood independent of birthweight.  
 
Comparison with previous studies 
Results from previous studies on the association between birthweight and cord blood pro-
inflammatory cytokine are inconsistent.  Two small studies showed that SGA babies have 
significantly higher levels of cord blood IL-6 and CRP than LGA babies (442, 443). Compared 
to AGA babies, Amarily et al. (n = 40) found a slightly higher IL-6 level in SGA babies (IL-6: 
p = 0.001; TNF-α: p = 0.087; CRP: p = 0.005) (442). Similar results were found in the study 
led by Lausten-Thoms et al. (n = 90, IL-6: p = 0.002; TNF-α: p = 0.70; CRP: p = 0.042) (443). 
In contract with their results, Matoba et al. (n = 493) and Linder et al. (n = 93 preterm infants) 
found there is no difference in cord blood IL-6 and TNF-α between SGA and AGA babies (444, 
445).  
Evidence from different age groups are also conflicting. In prepubertal children (n = 168), 
Galcheva et al. found that increased BMI is significantly associated with increased CRP level 
(r = 0.39, p < 0.0001) but not with IL-6 and TNF-α levels, while triglyceride was not associated 
with all three pro-inflammatory factors (446). In adolescents, Gobel et al. observed statistically 
positive associations between BMI and CRP (r = 0.53, p < 0.01), and between triglycerides and 
IL-6 (r = 0.87, p < 0.001), but findings were limited to obese children (n = 51)  (447). Piche et 
al found that both BMI and triglycerides were significantly associated with increased CRP 
(BMI: r = 0.60, p <0.0001; triglycerides: r = 0.33, p < 0.01) and IL-6 (BMI: r = 0.49, p < 0.0001; 
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triglycerides: r = 0.32, p < 0.01) levels, but not with TNF-α, in healthy postmenopausal women 
(n = 112) (448).  
In contrast with the results in adolescents and adults, our results showed that decreased 
birthweight is associated with increased cord blood IL-6, CRP, and TNF-α levels, while 
increased cord blood triglycerides was significantly associated with increased CRP and IL-6 
levels in cord blood. In this study, we took into account clinically important confounders, 
applied rigorous methodology, and examined if the association of birthweight and cord blood 
triglycerides with proinflammatory cytokines were independent to each other. 
 
Potential mechanism 
IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine, which is 
produced by various cells with pleiotropic activity (449). Specifically, it induces the synthesis 
of CRP and has an inhibitory effect on TNF-α. The hepatic synthesis of CRP, stimulated by the 
increased level of IL-6, activates the complement system and promotes phagocytosis by 
macrophages, inducing the clearance of necrotic and apoptotic cells (450). TNF-α is a signalling 
cytokine that is predominantly produced by the macrophage. It plays an important role in the 
regulation of the immune cell (451). Increased TNF-α indicates infiltration of macrophage in 
tissues (e.g. fat mass).  
In light with previous findings, there are two possible mechanisms to explain our results. Firstly, 
the fat mass and beta-cell deficiency in SGA babies induced by IUGR results in increased 
circulating triglycerides levels, leading to systemic low-grade inflammatory responses. 
Intrauterine growth restriction (IUGR) has been recognised as a major reason for SGA babies. 
SGA babies who experienced IUGR tend to have deficits in absolute fat mass, skeletal muscle, 
and beta-cells (175, 437), leading to insulin deficiency and increased circulating triglycerides 
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(Chapter 5).  Our results showed that the elevated triglycerides in babies with relatively lower 
birthweight percentile are significantly associated with increased CRP and IL-6 levels, but not 
with TNF-α. It indicates that the lipotoxicity induced by the increased triglycerides might 
trigger systemic low-grade inflammation that is independent to local inflammation response 
(e.g. adipocytes). Unlike adolescents and adults, we did not observe elevated pro-inflammatory 
cytokines in babies with relatively higher birthweight percentile. Therefore, our results suggest 
that the expanded adipocytes in babies with a higher birthweight percentile does not induce 
low-grade inflammation at birth. 
Secondly, in IUGR pregnancy, the pro-inflammatory cytokines produced by placenta may 
induce systematic low-grade inflammation in the foetus, which can influence foetal 
development systematically and results in decreased birthweight as well as increased 
triglycerides. It has been well known that maternal innate immune response during pregnancy 
has a critical role in spontaneous abortion, preterm delivery, and IUGR (452). However, it is 
still unknown whether babies experienced IUGR have higher circulating levels of 
proinflammatory cytokines at birth. Compared to AGA babies, Mullins observed an elevated 
cord blood IL-6 level, not CRP or TNF-α, in babies experienced foetal growth restriction (453). 
Systemic inflammation can expose the foetus to unfavourable conditions, therefore may 
potentially influence foetal morphogenesis. For example, Kristina et al. demonstrated that IL-
1β can disrupt postnatal lung morphogenesis in the mouse (454). Evidence suggested that acute 
infection and inflammation is associated with changes in triglycerides and lipoproteins (455), 
but it remains unclear if chronic low-grade inflammation is independently associated with 
increased triglycerides or not.  
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Strengths and Limitations 
The major strengths of this study includes rigorous statistical methods and consideration of 
adjusting for clinically important confounding factors. Although there is relatively small 




We found that the increased cord blood triglycerides observed in babies with a lower 
birthweight percentile are independently associated with increased cord blood CRP and IL-6 
levels, but not with TNF-α. We did not observe increased proinflammatory cytokines in babies 
with higher birthweight percentile. Our findings suggest that babies with lower birthweight 
percentile are at risk of systemic low-grade inflammation, which might contribute to short- and 






Chapter 7 Discussion 
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In this chapter, I will summarize and interpret the key findings of my research. After that, I will 
discuss the strengths and limitations of this project and potential future investigations.  The 
research within this thesis aimed to address: 1) the association between maternal lipid levels 
during pregnancy and adverse birthweight outcomes; 2) the interdependency between maternal 
metabolic risk factors and their association with birthweight and cord blood insulin 
concentration; 3) the association between birthweight and cord blood metabolic parameters; 4) 
the association of birthweight and cord blood triglycerides with cord blood pro-inflammatory 
cytokine levels. 
 
7.1 Summary of findings 
Other than for gestational dyslipidaemia, there is substantial evidence for an association 
between other maternal metabolic risk factors and adverse neonatal health outcomes (100, 102-
104, 106, 111, 112, 130). Therefore, the purpose of Chapter 3 was to synthesize previous 
epidemiological studies on the association of maternal lipid levels during pregnancy with 
birthweight and neonatal metabolic parameters through robust review methodology and 
analyses. This systematic review found that maternal circulating low HDL-C and high TG 
levels throughout pregnancy are associated with increased birthweight. No evidence of 
association was observed between maternal TC/LDL-C and birthweight. Among mothers with 
pre-pregnancy obesity, maternal HDL-C and TG levels during pregnancy were found to have a 
more profound impact on birthweight. The review hardly found any studies that investigated 
the association between gestational dyslipidaemia and other neonatal metabolic parameters at 
birth or in early childhood. 
Since metabolic risk factors are often tightly linked to one another, exploring the 
interdependency between them is critical for causal inference. All studies we identified in the 
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systematic review utilized classical statistical methods, which has limited capacity to analyse 
complex interdependent variables. Meanwhile, a robust individual patient data meta-analysis 
concluded that diet and lifestyle interventions in pregnancy only achieved modest success in 
reducing GWG and had no effect on composite maternal and foetal outcomes. Understanding 
how maternal metabolic risk factors influence neonatal health outcomes, and then identifying 
key metabolic pathways that lead to adverse health outcomes in neonates is crucial for 
developing future tailored interventions during preconception and pregnancy period to improve 
maternal and neonatal outcomes. Chapter 4 aimed to quantify the interdependency between 
maternal metabolic risk factors and their association with birthweight and cord blood insulin 
concentration using Additive Bayesian Network analysis, a data-driven causal inference model. 
In this study, maternal pre-pregnancy BMI was demonstrated to be the most influential 
upstream risk factor for both maternal and neonatal metabolic conditions, compared to GWG, 
gestational hyperglycaemia, and gestational dyslipidaemia. The results also highlight the key 
role of maternal hyperglycaemia towards increasing neonatal hyperinsulinemia that could result 
in foetal fat deposition. In contrast with the results of systematic review, maternal lipid levels 
appear to be secondary to maternal pre-pregnancy obesity with no clear links to metabolic 
adverse outcomes in neonates.  
Babies born either SGA or LGA have an increased risk of developing obesity, diabetes, and 
cardiovascular diseases. The ectopic fat deposition was believed to be the key common feature 
for developing metabolic dysfunctions in both SGA and LGA babies (175). Little is known 
about whether SGA and LGA babies have similar metabolic characteristics that result in ectopic 
fat deposition and subsequent metabolic condition s in later life. Insulin is known to play a 
central role in glucose, lipids, and adipocyte regulation generally (187). Our previous results 
also suggested that increased neonatal insulin secretion might be driven by both maternal 
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glycaemic level and increased birthweight. To address the metabolic profiles in SGA and LGA 
babies, Chapter 5 aimed to address the association of birthweight with cord blood glucose, 
lipids, and insulin levels. In this study, SGA babies were found to have significantly higher 
cord blood TG and lower HDL-C, TC, and insulin levels. Meanwhile, LGA babies were found 
to have significantly higher cord blood insulin and lower TG levels. 
Thereafter, we conducted an exploratory study (Chapter 6) to examine whether the altered 
birthweight or triglycerides would trigger low-grade inflammatory responses in neonates, 
which could lead to the development of systemic metabolic dysfunctions. This study found that 
increased cord blood TG levels and decreased birthweight are linearly associated with increased 




7.2 Interpretation and implications of findings 
Research in context 
It is well established that maternal high pre-pregnancy BMI, excessive GWG, and gestational 
hyperglycaemia are associated with an increased risk of a series of metabolic dysfunctions in 
offspring (100, 102-104, 106, 111, 112, 130). In the general population, people with obesity or 
diabetes were often found to have dyslipidaemia, which has been found to accelerate the 
progression of metabolic dysfunctions (263, 456). In 1985, Knopp et al. first proposed that fatty 
acids in maternal triglycerides might cross the placenta and contribute to foetal fat deposition 
(360). Results of subsequent several studies indicated that the altered maternal lipid levels 
during pregnancy might be a neglected strong determinant of foetal growth and that it may be 
as important as maternal glycaemic status (118, 166, 367). Existing systematic reviews 
concluded that maternal lipid levels during pregnancy are associated with an increased 
incidence of gestational diabetes, pre-eclampsia, and preterm delivery (108, 110, 331, 457). 
However, evidence regarding the association of maternal lipid levels during pregnancy with 
birthweight and metabolic dysfunctions in neonates was controversial. We first estimated the 
association of maternal lipid levels during pregnancy with neonatal birthweight and metabolic 
dysfunctions systematically. Data from 42 longitudinal studies firstly show that maternal HDL-
C and TG levels throughout pregnancy are inversely and positively associated with neonatal 
birthweight respectively. However, due to the nature of the included studies, we were unable to 
demonstrate if gestational dyslipidaemia is an independent risk factor for increased birthweight.  
The vast majority of previous studies focused only on one specific maternal metabolic trait or 
on the number of metabolic disorders, but neglected the underlying interacted effect of the 
natural metabolic network. To address the interdependency of maternal metabolic risk factors 
and their association with birthweight and cord blood insulin level appropriately, a traditional 
 183 
multivariable regression model followed by the Additive Bayesian Network (ABN) methods 
were used in Chapter 4. The results of the multivariable regression model are in line with our 
previous findings in Chapter 3. In contrast to the conclusion of our systematic review, the results 
of ABN demonstrated that the altered maternal lipid profiles during pregnancy are likely to be 
measures of gestational metabolic dysfunctions, and not themselves involved in the pathway 
relevant to adverse birthweight and cord blood insulin levels. Although this result challenges 
the conclusions of most previous observational studies, it is consistent with the result of a large 
Mendelian randomizations study (another causal inference design) (410). Meanwhile, ABN 
indicated that maternal high pre-pregnancy BMI is the most influential upstream risk factor for 
both maternal and neonatal health outcomes, while gestational weight gain seems only 
moderately associated with increased birthweight but not with cord blood insulin. Similar 
results were also found in the latest individual-patient-data meta-analysis published in The 
Journal of the American Medical Association (JAMA) (458). This meta-analysis began with 
the association between GWG and adverse pregnancy outcomes, but ultimately emphasized the 
importance of pre-pregnancy BMI (458). To the best of our knowledge, our study is the first 
one to date that weighs all maternal key metabolic risk factors systematically. The conflicting 
results of these two models also indicate the importance of using appropriate methods in future 
research to address the causal relationship in complex causal pathways. 
In adults, people with a higher BMI often have higher lipid levels and impaired glucose 
tolerance and are at a higher risk of metabolic dysfunctions (e.g. insulin resistance and high 
blood pressure) (459, 460). The metabolic profiles in neonates are largely unknown in previous 
literature. We hypothesised that babies with a higher birthweight may have metabolic profiles 
similar to those of adults. Neonates born to either SGA or LGA are at a higher risk of developing 
metabolic dysfunction subsequently, but the underlying mechanisms remain unclear. Ectopic 
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fat deposition is thought to be a common pathway to further metabolic dysfunctions for both 
SGA and LGA babies (175). Similar to obese adults, it is believed that the lipid accumulation 
in LGA babies might exceed the buffering capacity of adipocyte, therefore contributing to the 
development of metabolic dysfunctions (461). In Chapter 5, we observed an elevated cord blood 
insulin level, but not triglycerides levels, in LGA babies. The results show that the expanded 
fat mass in LGA babies, in the presence of insulin, buffers lipid accumulation in adipocytes. It 
indicates that moderately expanded adipose tissue might play an important role in preventing 
adverse metabolic health outcomes by absorbing oversupplied nutrients. The ectopic fat 
deposition in SGA babies is attributed to catch-up-growth previously (462, 463). However, it 
is hard to explain why SGA babies with moderate catch-up-growth still show impaired insulin 
sensitivity in their childhood (176, 464). Previous in vivo evidence proposed that IUGR 
universally experienced by SGA babies may be linked to reduced pancreatic β-cell mass, 
leading to insulin deficiency and glucose insensitivity (465). The results in Chapter 5 supports 
this hypothesis. Apart from the reduced pancreatic β-cell replication, SGA babies are often 
deficit in skeletal muscle and absolute fat mass, which could partly be explained by low 
nutrition utilization rate induced by insulin deficiency. In SGA babies with or without catch-up 
growth, impaired glucose sensitivity in their subsequent life has been frequently observed (176). 
In light of this, the amount of fat mass impaired by IUGR may partially determine its expansion 
capacity in early life. Therefore, it is possible that lipotoxicity together with the impaired 
capacity of adipocyte expansion results in ectopic fat deposition, leading to further metabolic 
dysfunctions in SGA babies.  
Chapter 6 further explored whether increased birthweight or triglycerides would induce low-
grade inflammation. The results indicate that elevated triglycerides observed in SGA babies are 
strongly associated with increased cord blood CRP and IL-6 levels, which might contribute to 
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the development of metabolic dysfunctions. In LGA babies, the expanded adipose tissue does 
not induce low-grade inflammatory responses. The findings in Chapter 6 further emphasises 
that the differential metabolic risk of LGA and SGA babies would contribute to their short- or 
long-term metabolic health in different ways. 
In summary, maternal pre-pregnancy BMI and gestational hyperglycaemia are the most critical 
metabolic risk factors for neonatal insulin secretion and fat deposition, whereas the differential 
insulin, lipids, and proinflammatory cytokines observed in SGA and LGA babies may 
contribute to future metabolic dysfunctions through different mechanisms. The potential 
mechanism pathway is summarised in Figure 11. 
 
Implication to practice 
Although it is already known that maternal pre-pregnancy BMI is associated with both maternal 
and neonatal health conditions, most current clinical recommendations on maternal weight 
management focus only on antenatal period (28, 78, 83). People used to believe that weight 
management during pregnancy may help to improve adverse pregnancy outcomes. However, 
our results and other recent robust studies demonstrate that pre-pregnancy BMI is the most 
influential metabolic risk factors for adverse pregnancy outcomes, while gestational weight 
gain may not have a profound impact as previously expected (303, 458). We are missing an 
optimal opportunity to prevent subsequent adverse health outcomes in both mothers and babies. 
This situation is partially because of the gaps in services for women in child-bearing age and 
lack of contact with health professionals in the preconception period. This gap could be filled 
by prenatal consultation in general practices or health education and promotion delivered by 
public health professionals in communities. Our results, if applied to wider communities, 
provide further evidence for public health measures at improving weight management in 
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women in general and particularly those of child-bearing age. Moreover, unlike previous 
evidence, our results indicate that maternal lipid levels during pregnancy are not involved in 
the pathway towards birthweight and neonatal insulin secretion. Although maternal lipid levels 
in pregnancy are secondary to pre-pregnancy BMI, it can potentially be a clinical marker of 
maternal metabolic status for predicting birthweight. 
Although babies born either SGA or LGA are linked to adverse health outcomes, there is no 
specific guidelines or recommendations on how to feed them. The metabolic profiles in SGA 
and LGA babies are largely unknown in current literature. Therefore, it could not reliably 
inform clinical practice and recommendations to avoid subsequent metabolic dysfunctions in 
babies. We are the first study to date that addressed the metabolic profiles of SGA and LGA 
babies in a detailed and rigorous way. The robust evidence that we provided would help to 
uncover tailored intervention strategies to prevent subsequent metabolic dysfunctions in SGA 




7.3 Strengths and limitations 
In the systematic review, a comprehensive search was conducted to capture the majority of 
studies on the association between maternal lipid levels during pregnancy and adverse 
birthweight outcomes. We also took special care on handling missing data by contacting the 
authors to minimize reporting bias. Since the results of included studies were reported in various 
formats, a novel and thorough approach was used to utilize every piece of existing evidence. 
The inclusion of longitudinal data allowed us to address the temporal association between 
maternal lipid levels in three trimesters and neonatal outcomes. The major limitation of the 
systematic review was the substantial heterogeneity of included studies on settings, populations, 
and covariates adjustments, which was addressed by the subgroup analysis. Due to the nature 
of the individual study, it is not feasible to explore whether the effects of gestational 
dyslipidaemia are independent of other important maternal metabolic factors, such as maternal 
pre-pregnancy BMI, gestational hyperglycaemia, as well as GWG. Therefore, we conducted a 
primary study to address this issue.  
The study in Chapter 4 is based on a large birth cohort study, the prospective design of which 
allows us to investigate the temporal relationship between maternal metabolic risk factors and 
neonatal outcomes. The two-way analytic approaches, multivariable regression model 
(hypothesis-driven) and additive Bayesian Network analysis (data-driven), were used to 
address the independent association between maternal metabolic risk factors and neonatal 
outcomes appropriately. Given the practical constraints, the maternal fasting glucose and 
triglycerides levels were measured only once in the second trimester. The one-point 
measurement does not allow us to investigate the dynamic long-term influences of maternal 
metabolic risk factors and limit our ability in exploring feedback loop between nodes in 
Bayesian Network analysis. The information on maternal pre-pregnancy BMI was self-reported, 
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which might potentially underestimate the true value. However, evidence suggest that 
utilization of self-reported or measured pre-pregnancy weight for pre-pregnancy BMI 
classification results in identical categorization for most women (466). 
The major strength of the Chapter 5 is the comprehensive analyses based on longitudinal data. 
In this study, the utilization of generalized additive model allows us to investigate the non-
linear relationships between birthweight and cord blood metabolic parameters. Given the 
practical constraints, we could not measure the distribution of fat mass in neonates. Instead of 
fat mass, birthweight percentile was used as an approximate measurement to improve the 
generalizability of our results. The relatively small sample size is the major limitation of the 
exploratory study. However, we were still able to observe the direction of the associations 





7.4 Future investigations 
Missed opportunity for prevention of adverse pregnancy outcomes in preconception 
period 
In my study, pre-pregnancy BMI was found to be the most influential upstream risk factor for 
both maternal and neonatal metabolic health conditions. Therefore, interventions should focus 
more on tackling weight management in the preconception period. However, very few previous 
trials have attempted to target the preconception period for improving maternal weight 
management. Future intervention studies on weight management of women in child-bearing 
age are needed to prevent subsequent adverse pregnancy outcomes. Before implementing pre-
pregnancy weight management interventions, it is critical to understand the potential barriers 
and facilitators among women and health professionals in the communities to develop 
appropriate strategies.  It is likely to be a multifaceted intervention involving women with 
overweight/obesity, public health professionals, general practices, clinicians, community staffs, 
and policymakers at different stages. The culture differences and ethical issues in the barriers 
to implementing weight management need to be taken into consideration. In addition to 
assessing the effects of pre-pregnancy weight management on preventing adverse pregnancy 
outcomes, the cost-effectiveness of the intervention strategy should also be considered. 
 
Future research on maternal lipid levels during pregnancy 
Although we found that maternal lipid levels during pregnancy may not have a causal 
relationship with neonatal metabolic conditions at birth, we still do not know whether maternal 
lipid levels will have a profound long-term influence on neonates in childhood/adulthood 
through epigenetic programming. A two-steps Mendelian Randomization study might be 
needed in the future to examine the potential epigenetic programming effects of maternal lipid 
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levels during pregnancy on neonatal metabolic status. Meanwhile, maternal lipid levels can be 
a potential clinical marker for maternal metabolic condition or for predicting neonatal size, due 
to its strong correlation with increased risk of gestational diabetes, preeclampsia, and increased 
birthweight. Therefore, it is still worthwhile to add maternal lipid levels during pregnancy to 
the clinical prediction models for adverse pregnancy outcomes in future studies. 
 
Tailored intervention strategies for prevention of further metabolic dysfunctions in babies 
born SGA and LGA 
Based on the differential metabolic profiles that we found in babies born SGA and LGA, 
tailored interventions strategies for preventing further metabolic dysfunctions in babies with 
low or high birthweight is needed. Although breastfeeding if preferable for all babies, special 
care might be needed for improving metabolic profile of SGA or LGA babies to prevent 
subsequent metabolic dysfunctions, especially for those babies who can not get or take human 
milk. Omega-3 fatty acids supplements, such Eicosapentaenoic acid (EPA) and 
Docosahexaenoic acid (DHA), may help to improve lipid profiles, therefore might be a potential 
intervention for babies born SGA (467). A recent study published in the Journal of Clinical 
Investigation identified a bioactive component named alkylglycerols in human breast milk that 
could maintain beige adipose tissue (BeAT) and prevent the transdifferentiation from BeAT to 
white adipose tissue (468). Therefore, it might be worthwhile to explore the association between 
the duration of breastfeeding and childhood obesity in babies born LGA for future research.  
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Figure 11 Diagrammatic portrayal of metabolic components in mothers and babies.  
The enlarged adipose tissue in women with obesity could induce systemic low-grade inflammation, insulin 
resistance, and increased circulating lipid levels, especially triglycerides (TG). All these may jointly influence the 
development and production of the oocyte in the pre-conception period through epigenetic programming. Pregnant 
women with obesity are often found to have increased TG and glucose levels. The quality and quantity of nutrients 
transported through the placenta are also regulated by maternal obesity. The de novo synthesized insulin in foetus 
induce lipogenesis in the liver using nutrients transported from the maternal side and promote lipids uptake in the 
adipocyte. The expanded adipocyte become less insulin sensitivity thereafter inducing a state of hyperinsulinemia 
in large-for-gestational-age (LGA) babies. The adipose buffering capacity of LGA babies is close to saturation 
point, so if they experience rapid growth, they have a higher risk of obesity in adulthood. In intrauterine growth 
restriction (IUGR) pregnancy, the deficiency of fat mass and β-cell could jointly induce low insulin secretion and 
high circulating TG levels. The increased circulating TG, low-grade inflammatory response, and catch-up growth 
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S1 Systematic review: Sample search in MEDLINE 
1. exp Lipids/ or lipid$.mp. 
2. lipoprotein$.mp. or exp Lipoproteins/ 
3. exp Fatty Acids/ or fat* acids.mp. 
4. triglycerides.mp. or exp Triglycerides/ 
5. exp Lipoproteins, VLDL/ or exp Cholesterol, VLDL/ or VLDL.mp. 
6. LDL.mp. or exp Cholesterol, LDL/ or exp Lipoproteins, LDL/ 
7. IDL.mp. or exp Lipoproteins, IDL/ 
8. exp Lipoproteins, HDL/ or exp Cholesterol, HDL/ or HDL.mp. 
9. exp Cholesterol/ or cholesterol.mp. or exp Cholesterol Esters/ 
10. hyperlipid?emia$.mp. or exp Hyperlipidemias/ 
11. dyslipid?emia$.mp. or exp Dyslipidemias/ 
12. hypertriglycerid?emia$.mp. or exp Hypertriglyceridemia/ 
13. hypercholesterol?emia.mp. or exp Hypercholesterolemia/ 
14. metabolic.mp. 
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. exp Maternal Health/ or maternal.mp. 
17. exp Pregnanes/ or pregnan*.mp. 
18. exp Pregnancy/ or gestation*.mp. 
19. gravidity.mp. or exp Gravidity/ 
20. mother$.mp. or exp Mothers/ 
21. 16 or 17 or 18 or 19 or 20 
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22. (birth weight or birthweight).mp. or exp Birth Weight/ or exp Infant, Low Birth Weight/ 
23. overweight.mp. or exp Obesity/ or exp Overweight/ or exp Body Weight/ 
24. (SGA or Small for gestational age).mp. or exp Infant, Small for Gestational Age/ 
25. (LGA or Large for gestational age).mp. 
26. exp Fetal Macrosomia/ or macrosomia.mp. 
27. exp "Growth and Development"/ or exp Growth/ or (growth or development).mp. or exp 
Fetal Growth Retardation/ or exp Fetal Development/ or exp Child Development/ 
28. weight gain.mp. or exp Weight Gain/ 
29. (hyperglyc?emia or hypoglyc?emia).mp. or exp Hyperglycemia/ or exp Hypoglycemia/ 
30. (insulin* or hyperinsulinism or IR).mp. or exp Insulin/ or exp Insulin Resistance/ or exp 
Hyperinsulinism/ 
31. exp Glucose Intolerance/ or glucose.mp. or exp Glucose/ or exp Glucose Metabolism 
Disorders/ 
32. skinfold thickness.mp. or exp Skinfold Thickness/ 
33. (monocyte chemoattractant protein-1 or MCP-1).mp. 
34. (interleukin 6 or IL-6).mp. 
35. exp Tumor Necrosis Factor-alpha/ or tumour necrosis factor-alpha.mp. 
36. exp 11-beta-Hydroxysteroid Dehydrogenase Type 1/ or HSD1.mp. 
37. exp Leptin/ or leptin.mp. 
38. exp Inflammation/ or inflammat*.mp. 
39. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 22 or 23 or 24 or 25 
or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
40. (neonatal or fetal or foetal or fetus or foetus or infant or offspring or new born).mp. or exp 
Infant/ 
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41. 15 and 21 and (39 and 40) 
42. (animal or mouse or mice or rodent or sheep or mutton or pig or hoggory or hog or swine 
or rabbit$).mp. 
43. 41 not 42 
44. cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or 
retrospective studies/ or cohort.ti,ab. or longitudinal.ti,ab. or prospective.ti,ab. or 
retrospective.ti,ab. 
45. "randomized controlled trial".pt. 
46. (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
47. (retraction of publication or retracted publication).pt. 
48. or/44-47 
49. (animals not humans).sh. 
50. ((comment or editorial or meta-analysis or practice-guideline or review or letter or journal 
correspondence) not "randomized controlled trial").pt. 
51. (random sampl$ or random digit$ or random effect$ or random survey or random 
regression).ti,ab. not "randomized controlled trial".pt. 
52. or/49-51 
53. 48 not 52 
54. 43 and 53 
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S2 Systematic review: Data extraction form 
A. Reference information 




5. Publication Year 
6. Language 
7. Sponsor 
B. Study design 
1. Study design 
2. Setting 
3. Locations 
4. Data collection 
C. Participants 
1. Eligibility criteria (source and methods of selection of participants) 
2. Matching criteria (if applicable) 
a. Matching criteria 
b. Attempts were made within the design or analysis to balance the comparison 
groups for potential confounders (YES/NO). 
c. The groups are comparable at baseline, including all major confounding and 
prognostic factors (YES/NO).  
3. Sample Size 
a. Number of both exposed and unexposed groups 
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b. Report numbers of individuals at each stage of study 
c. Give reasons for non-participation at each stage (YES/NO) 
d. Does the size of samples have enough power to detect the difference of 
primary outcomes? (YES/NO) 
4. Demographic, clinical and social characteristics 
a. Age 
b. Ethnicity 
c. Pre-pregnant BMI/weight 
d. Marital status 
e. Education 
f. Other potential confounders information 
D. Follow-up 
1. Enrolment time 
2. Length of follow-up 
a. Length of follow-up (average and total amount) 
b. All groups were followed up for an equal length of time (or analysis was 
adjusted to allow for differences in length of follow-up) 
3. Methods of follow-up 
4. Lost to follow-up 
a. Attrition rate in each group 
b. How many participants in each group were no outcome data available? 
(number & proportion) 
c. Does it comparable? (YES/NO) 
E. Exposure 
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1. Definition of exposures 
2. When did they take samples 
3. Exposure measurement 
F. Outcomes 
1. Primary outcomes (definition and measurement) 
2. Secondary outcomes (definition and measurement) 
G. Statistical methods 
1. Statistical methods, including those used to control for confounding 
2. Describe any methods used to examine subgroups and interactions 
3. How missing data were addressed 
4. Explain how lost to follow-up was addressed 
5. Describe any sensitivity analysis 
H. Results 
1. Number of outcomes events or summary measures over time 
2. Give unadjusted estimates and, if applicable, confound der-adjusted estimates and 
their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
3. Report category boundaries when continuous variables were categorized 
4. Alpha value and beta value 
I. Limitations 
1. Interpretation 
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other relevant evidence.  
2. Generalizability (external validity) 
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J. Other notes 
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S3 Systematic review: Newcastle-Ottawa Scale 
Selection 
1. Representativeness of exposed cohort population 
1) Truly representative of the average, community-dwelling target pregnant women ★ 
2) Somewhat representative of the average, community-dwelling target pregnant 
women★ 
3) Selected group of pregnant women, e.g. only certain socio-economic groups/areas 
4) No description of the derivation of the cohort 
 
2. Selection of the unexposed cohort 
1) Drawn from the same source as the exposed cohort★ 
2) Drawn from a different source 
3) No description of the derivation of the unexposed cohort 
 
3. Ascertainment of exposures 
1) Laboratory diagnosed ★ 
2) Secure record (e.g. health care/clinical record) ★ 
3) Written self-report 
4) Other/ no description 
 






1. Comparability of cohort based on the design or analysis 
1) Study controls for  
①  Outcomes measured at delivery: gestational age ★ 
②  Outcomes measured over 1 month after delivery: neonatal age ★ 
2) Study controls for any two of additional factors (e.g. neonatal gender, maternal age, 
parity, socio-economic level, cigarette exposures, delivery mode and so on) ★ 
 
Outcome 
1. Assessment of outcomes 
1) Independent blind assessment★ 
2) Record linkage★ 
3) Self-report 
4) Other/ no description 
 
2. Was follow up long enough for outcomes to occur 
1) Yes, if the study follow their subjects until outcomes occur★ 
2) No, if the study follow their subjects until outcomes occur 
 
3. Adequacy of follow up of cohorts 
1) Complete follow up : all subjects accounted for★ 
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2) Subjects lost to follow up unlikely to introduce bias: number lost <= 20%, or 
description of those lost suggesting no different from those followed★ 
3) Follow up rate <80% and no description of those lost 
4) No statement
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A1 A2 A3 A4 B1 B2 C1 C2 C3 
Harmon et al.2011 0 1 1 1 0 0 0 1 1 5 
Son et al.2010 0 1 1 1 0 0 0 1 1 5 
Di et al.2005 0 1 1 1 0 0 0 1 1 5 
Schaefer-Graf et 
al.2008 
0 1 1 1 0 0 0 1 1 5 
Slagjana et al.2014 0 1 1 1 0 0 0 1 1 5 
Zhou et al.2012 0 1 1 1 0 0 0 1 1 5 
Zawiejska et al.2008 0 1 1 1 0 0 0 1 1 5 
Emet et al.2013 0 1 1 1 0 0 0 1 1 5 
Schaefer-Graf et 
al.2011 
0 1 1 1 0 0 0 1 1 5 
Mossayebi et al.2014 0 1 1 1 0 0 0 1 1 5 
Swierzewska et 
al.2015 
0 1 1 1 0 0 0 1 1 5 
Ortega et al.1996 0 1 1 1 0 0 0 1 1 5 
Alberti-Fidanza et 
al.1995 
0 1 1 1 0 0 1 1 0 5 
Charles et al. 2016 0 1 1 1 0 0 0 1 1 5 
Wang et al.2015 0 1 1 1 1 0 0 1 1 6 
Ahmad et al.2006 0 1 1 1 1 0 0 1 1 6 
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Whyte et al. 2013 0 1 1 1 0 0 1 1 1 6 
Vinod et al. 2011 0 1 1 1 1 0 0 1 1 6 
Olmos et al.2014 0 1 1 1 1 0 0 1 1 6 
Knopp et al.1992 0 1 1 1 1 0 0 1 1 6 
Nolan et al.1995 0 1 1 1 1 0 0 1 1 6 
Friis et al.2012 0 1 1 1 1 0 0 1 1 6 
Lei et al.2016 0 1 1 1 1 0 0 1 1 6 
Kitajima et al.2001 0 1 1 1 1 0 0 1 1 6 
Couch et al.1998 0 1 1 1 0 0 1 1 1 6 
Brockerhoff 1986 0 1 1 1 0 0 1 1 1 6 
Retnakaran et al.2012 0 1 1 1 1 1 0 1 1 7 
Hou et al.2014 0 1 1 1 1 1 0 1 1 7 
Laleh et al.2013 0 1 1 1 1 1 0 1 1 7 
Liu et al.2016 0 1 1 1 1 0 1 1 1 7 
Brunner et al.2013 0 1 1 1 1 0 1 1 1 7 
Knopp et al.1985 0 1 1 1 1 0 1 1 1 7 
Geraghty et al.2016 0 1 1 1 1 1 0 1 1 7 
Jin et al.2016 0 1 1 1 1 1 0 1 1 7 
Robin et al. 2007 0 1 1 1 1 1 0 1 1 7 
Ye et al.2015 0 1 1 1 1 1 1 1 1 8 
Crume et al.2015 0 1 1 1 1 1 1 1 1 8 
Hwang et al.2015 0 1 1 1 1 1 1 1 1 8 
Kulkarni et al.2013 1 1 1 1 0 1 1 1 1 8 
Vrijkotte et al.2012 0 1 1 1 1 1 1 1 1 8 
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Kramer et al.2014 0 1 1 1 1 1 1 1 1 8 
Vrijkotte et al. 2011 0 1 1 1 1 1 1 1 1 8 
Clausen et al.2005 1 1 1 1 0 1 1 1 1 8 
Mathews et al.2003 0 1 1 1 1 1 1 1 1 8 




S5 Systematic review: Data analysis for birthweight 
Data summary 














The first trimester 1 1 2(1) 4 
The second trimester 1 4 7(2) 12 
The third trimester 3(1) 12 8(3) 23 
HDL-C 
The first trimester 2(1) 0 0 2 
The second trimester 6(2) 4 1 11 
The third trimester 11(6) 6 1 18 
LDL-C 
The first trimester 1 0 1 2 
The second trimester 1 5 2 8 
The third trimester 2 5 7(3) 15 
TG 
The first trimester 0 1 4(3) 5 
The second trimester 0 2 10(8) 12 
The third trimester 3(1) 4 20(14) 27 
VLDL 
The first trimester 0 0 0 0 
The second trimester 0 0 0 0 
The third trimester 0 1 1 2 
FFAs The first trimester 0 1 0 1 
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The second trimester 0 0 1 1 
The third trimester 0 3 4(2) 7 
1. This table summarised the results distribution of studies that reported the association of maternal lipid levels 
with birthweight throughout pregnancy; 
2. Number in this table represent the number of studies; 
3. 'No direction' means that the number of studies reported statistically insignificant results without its 
direction, as well as the number of studies did not report their results; 
4. Number in the bracket means the number of studies reported statistically significant results; 
5. Abbreviation: Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 





Total cholesterol (TC) 
S7.2 Table Results summary of the association of maternal TC level with birthweight 
















The control of confounding factors 
a b c d e f g h 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β -19.33  -120.03  81.36  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β 58.00  -67.86  183.87  ND SLR 6 × × × × × × × × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Crude β 11.82  -10.00  33.65  ND 
Univariate 
analyses 
8 √ √ × × × × √ × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Adjusted β 22.67  4.00  41.33  ND MLR 8 √ √ √ √ √ × √ × 
Nolan et al.1995 General Australia 388 1 ND ND   ND ND 6 ND ND ND ND ND ND × ND 
Liu et al.2016 General China 1,546 2 r 0.02    0.518 
Partial 
correlation 
7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -50.27  -112.24  11.69  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β 3.87  -91.02  98.75  ND SLR 6 × × × × × × × × 
Mathews et al.2003 General UK 733 2 Adjusted β 30.10  1.21  58.90  ND MLR 8 √ √ × × × × √ × 
Crume et al.2015 General USA 804 2 Adjusted β 17.79  -11.82  47.39  0.200 MLR 8 √ √ √ × × × √ × 
Kulkarni et al.2013 non-GDM India 631 2 Adjusted β 39.07  10.57  67.58  ND MLR 8 × √ √ √ × × √ × 
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The control of confounding factors 
a b c d e f g h 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β 27.87  -17.89  73.63  ND MLR 7 √ √ × √ √ × × × 
Whyte et al. 2013 General Ireland 189 2 ND ND   ND ND 6 ND ND ND ND ND ND × ND 
Wang et al.2015 General China 636 2 ND ND   ND 
Partial 
correlation 
6 √ √ × × × × × × 
Di et al.2005 OGTT+ Italy 83 2 ND ND   ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 2 ND ND   ND ND 6 ND ND ND ND ND ND × ND 
Mossayebi et 
al.2014 
General Iran 154 3 r 0.50    <0.001 
Pearson 
correlation 
5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r -0.103   <0.0001 
Pearson 
correlation 
4 × × × × × × × × 
Ahmad et al. 2006 non-GDM Malaysia 246 3 r 0.16    0.021 
Univariate 
analyses 
6 √ × × × × × √ × 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.01    0.990 SLR 6 × × × × × × √ × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β -46.40  -118.05  25.24  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β 15.47  -89.10  120.03  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β -4.20  -39.40  31.00  ND SLR 9 × × × × × × √ × 
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The control of confounding factors 
a b c d e f g h 
Sommer et al.2015 General Norway 699 3 Adjusted β -6.10  -37.50  25.20  ND MLR 9 √ √ √ × × × √ × 
Mathews et al.2003 General UK 537 3 Adjusted β 11.10  -18.00  40.30  ND MLR 8 √ √ × × × × √ × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 9.10  -6.40  24.60  ND MLR 8 √ √ √ √ √ √ √ × 
Kulkarni et al.2013 non-GDM India 631 3 Adjusted β 54.34  24.85  83.88  ND MLR 8 × √ √ √ × × √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 24.85  -9.39  59.09  ND MLR 7 √ √ × √ √ × × × 
Couch et al.1998 General USA 40 3 p ND   >0.05 
Pearson 
correlation 
6 × × × × × × × × 
Ortega et al.1996 General Spain 292 3 p ND   >0.05 Student t test 5 × × × × × × √ × 
Swierzewska et 
al.2015 
General Poland 136 3 p ND   >0.05 MLR 5 ND ND ND ND ND ND × ND 
Emet et al.2013 General Turkey 801 3 p ND   0.616 
Pearson 
correlation 
5 × × × × × × × × 
Friis et al.2012 General German 207 3 p ND   >0.05 MLR 6 √ × × × × × × × 
Retnakaran et 
al.2012 





7 × × × × × × × × 
Schaefer-Graf et 
al.2011 
non-GDM German 190 3 p ND   >0.05 
Pearson 
correlation 
5 × × × × × × √ × 
Son et al.2010 GDM Korea 104 3 p ND   >0.05 ND 5 ND ND ND ND ND ND √ ND 
Crume et al.2015 General USA 804 3 ND ND   ND MLR 8 √ √ √ × × × √ × 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 ND ND   ND ND 5 ND ND ND ND ND ND × ND 
Olmos et al.2014 GDM Chile 279 3 ND ND   ND ND 6 ND ND ND ND ND ND × ND 
Schaefer-Graf et 
al.2008 
GDM German 150 3 ND ND   ND 
Spearman 
correlation 
5 × × × × × × × × 
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The control of confounding factors 
a b c d e f g h 
Robin et al. 2007 General American 957 2  Adjusted MD(g) p MLR 7 √ √ √ × × × √ × 
   High-TC group (n=100) Ref group Ref group           
   Mid-TC group(n=757) 29 0.47           
   Low-TC group(n=100) -150 0.001           
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients.  
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. 
Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), 




S7.1 Figure Overall meta-analysis of crude regression coefficients for the association between 




S7.2 Figure Overall meta-analysis of adjusted regression coefficients for the association 






S7.3 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 2nd trimester_ 










S7.5 Figure Adjusted regression coefficients_ exclude studies control for pre-pregnancy BMI 
or gestational weight gain  
 
S7.6 Figure Adjusted regression coefficients_ exclude studies control for maternal glucose level 
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S7.7 Figure Crude regression coefficients_ exclude studies control for pre-term birth 
 





High-Density lipoprotein Cholesterol (HDL-C) 





















The control of confounding 
factors 
a b C d e f g h 
Vinod et al.2011(1) normal weight USA 65 1 Crude β -81.21  -300.02  137.61  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β -309.36  -603.69  -15.03  ND SLR 6 × × × × × × × × 
Wang et al.2015 General China 636 2 r -0.12    0.010 Partial correlation 6 √ √ × × × × × × 
Liu et al.2016 General China 1,546 2 r -0.01    0.701 Partial correlation 7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -158.55  -340.57  23.48  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β -286.16  -545.63  -26.68  ND SLR 6 × × × × × × × × 
Crume et al.2015 General USA 804 2 Adjusted β -20.88  -109.69  67.93  0.600 MLR 8 √ √ √ × × × √ × 
Kulkarni  et al.2013 non-GDM India 631 2 Adjusted β 17.57  -11.64  46.77  ND MLR 8 × √ √ √ × × √ × 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β -1236.25  -3322.95  850.45  ND MLR 7 √ √ × √ √ × × × 




ND × ND 




ND × ND 




ND × ND 




ND × ND 
Knopp et al.1985 General USA 248 3 r -0.06    >0.05 Spearman 
correlation 
7 √ √ × × × × √ × 
Mossayebi et al.2014 General Iran 154 3 r -0.47    <0.00
1 
Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r -0.139   <0.00
01 
Pearson correlation 4 × × × × × × × × 
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Vinod et al.2011(1) Normal weight USA 69 3 Crude β -139.21  -332.85  54.43  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β -386.70  -681.03  -92.37  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β -98.90  -188.10  -9.60  ND SLR 9 × × × × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Crude β -120.54  -244.42  3.35  ND SLR 7 × × × × × × √ × 
Sommer et al.2015 General Norway 699 3 Adjusted β -105.40  -183.80  -27.00  ND MLR 9 √ √ √ × × × √ × 
Friis et al.2012 General German 207 3 Adjusted β -170.00  -329.00  -9.00  0.040 MLR 6 √ × × × × × × × 
Crume et al.2015 General USA 804 3 Adjusted β -43.31  -128.33  41.71  0.300 MLR 8 √ √ √ × × × √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Adjusted β -57.16  -189.42  75.09  ND MLR 7 √ √ √ √ √ √ √ √ 
Kulkarni  et al.2013 non-GDM India 631 3 Adjusted β -8.89  -38.72  20.95  ND MLR 8 × √ √ √ × × √ × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β -69.50  -110.00  -28.20  ND MLR 8 √ √ √ √ √ √ √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 30.00  -114.85  174.84  ND MLR 7 √ √ × √ √ × × × 
Emet et al.2013 General Turkey 801 3 p ND   0.754 Pearson correlation 5 × × × × × × × × 
Couch et al.1998 General USA 40 3 p ND   >0.05 Pearson correlation  6 × × × × × × × × 




ND × ND 




ND √ ND 
Slagjana et al.2014 non-GDM Yugoslavi
a 




ND × ND 




ND × ND 
The bold font represents statistically significant results. r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear 
regression(SLR), Multiple linear regression(MLR), United Kingdom(UK). 
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Meta-analysis 
S7.9 Figure Overall meta-analysis of crude regression coefficients for the association between 
maternal HDL-C levels and birthweight throughout pregnancy 
 
 
S7.10 Figure Overall meta-analysis of adjusted regression coefficients for the association 




Subgroup analysis  
S7.11 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 3rd trimester_ 




S7.12 Figure Adjusted regression coefficients_ exclude studies control for pre-pregnancy BMI 















Low-Density lipoprotein Cholesterol (LDL-C) 

























The control of confounding 
factors 
A b c d e f g h 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β -34.80  -152.92  83.32  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obe
se 
USA 71 1 Crude β 108.28  -42.76  259.31  ND SLR 6 × × × × × × × × 
Liu et al.2016 Gen ral China 1,546 2 r -0.01    0.843 Partial correlation 7 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β -58.00  -133.52  17.51  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obe
se 
USA 71 2 Crude β 34.80  -83.32  152.92  ND SLR 6 × × × × × × × × 
Geraghty et al.2016 non-GDM UK 331 2 Adjusted β 18.39  -38.44  75.21  ND MLR 7 √ √ × √ √ × × × 
Wang et al.2015 General China 636 2 ND ND   ND Partial correlation 6 √ √ × × × × × × 
Whyte et al. 2013 General Ireland 189 2 ND ND   ND ND 6 ND ND N
D 
ND ND ND × ND 
Di et al.2005 OGTT+ Italy 83 2 ND ND   ND ND 5 ND ND N
D 
ND ND ND √ ND 
Olmos et al.2014 GDM Chile 279 2 ND ND   ND ND 6 ND ND N
D 
ND ND ND × ND 
Knopp et al.1985 General USA 248 3 r 0.01    >0.05 Spearman 
correlation 
7 √ √ × × × × √ × 
Mossayebi et al.2014 General Iran 154 3 r 0.40    <0.001 Pearson correlation 5 × × × × × × √ × 
Charles et al. 2016 General Multiple 1062 3 r 0.001   <0.0001 Pearson correlation 4 × × × × × × × × 
Retnakaran et al.2012 non-GDM Canada 472 3 Crude β -15.22  -55.49  25.05  ND SLR 7 × × × × × × √ × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β -50.27  -131.60  31.06  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obe
se 
USA 70 3 Crude β 38.67  -79.45  156.79  ND SLR 6 × × × × × × × × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 35.40  10.10  60.80  ND MLR 8 √ √ √ √ √ √ √ × 
Retnakaran et al.2012 non-GDM Canada 472 3 Adjusted β -6.79  -46.98  33.39  ND MLR 7 √ √ √ √ √ √ √ √ 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 19.97  -24.34  64.27  ND MLR 7 √ √ × √ √ × × × 
Emet et al.2013 General Turkey 801 3 p ND   0.440 Pearson correlation 5 × × × × × × × × 
Couch et al.1998 General USA 40 3 p ND   >0.05 Pearson correlation 6 × × × × × × × × 
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Swierzewska et al.2015 General Poland 136 3 p ND   >0.05 MLR 5 ND ND N
D 
ND ND ND × ND 
Sommer et al.2015 General Norway 699 3 ND ND   ND ND 9 ND ND N
D 
ND ND ND × ND 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 ND ND   ND ND 5 ND ND N
D 
ND ND ND × ND 
Son et al.2010 GDM Korea 104 3 ND ND   ND ND 5 ND ND N
D 
ND ND ND √ ND 
Olmos et al.2014 GDM Chile 279 3 ND ND   ND ND 6 ND ND N
D 
ND ND ND × ND 
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear 
regression(SLR), Multiple linear regression(MLR), United Kingdom(UK). 
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Meta-analysis 
S7.15 Figure Overall meta-analysis of crude regression coefficients for the association between 
maternal LDL-C levels and birthweight throughout pregnancy 
 
S7.16 Figure Overall meta-analysis of adjusted regression coefficients for the association between 









S7.18 Figure Adjusted regression coefficients_ exclude studies that did not control for other 


























The control of 
confounding factors 
a b c d e f g h 
Nolan et al.1995 General Australia 388 1 r 0.12    0.020 Univariate analyses 6 √ √ × × × × × × 
Vinod et al.2011(1) Normal weight USA 65 1 Crude β 132.86  13.11  252.62  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 1 Crude β 124.00  -40.10  288.11  ND SLR 6 × × × × × × × × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Crude β 47.14  12.42  81.87  ND Univariate analyses 8 √ √ × × × × √ × 
Vrijkotte et al.2011 General Netherlands 2,052 1 Adjusted β 86.72  56.13  117.30  ND MLR 8 √ √ √ √ √ × √ × 
Harmon et al.2011 non-GDM USA 38 1 p ND   >0.05 Pearson correlation 5 × × × × × × × × 
Liu et al.2016 General China 1,546 2 r 0.10    
<0.00
1 
Partial correlation 7 × × × × × × × × 
Wang et al.2015 General China 636 2 r 0.19    <0.01 Partial correlation 6 √ √ × × × × × × 





















The control of 
confounding factors 
a b c d e f g h 
Zawiejska et al. 
2008 
GDM Poland 357 2 r 0.14    <0.01 SLR 5 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 71 2 Crude β 97.43  4.29  190.57  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 71 2 Crude β 132.86  4.24  261.49  ND SLR 6 × × × × × × × × 
Crume et al.2015 General USA 804 2 Adjusted β 7.97  -44.19  60.13  0.700 MLR 8 √ √ √ × × × √ × 
Kulkarni et al.2013 non-GDM India 631 2 Adjusted β 14.76  -13.34  42.86  ND MLR 8 × √ √ √ × × √ × 








0.002 MLR 8 √ √ √ × √ × × × 
Whyte et al. 2013 General Ireland 189 2 p +   <0.05 SLR 6 × × × × × × × × 
Geraghty et al.2016 non-GDM UK 331 2 p ND   >0.1 MLR 7 √ √ × √ √ × × × 





















The control of 
confounding factors 
a b c d e f g h 
Mossayebi et 
al.2014 
General Iran 154 3 r 0.68    
<0.00
1 
Pearson correlation 5 × × × × × × √ × 





4 × × × × × × × × 
Son et al.2010 GDM Korea 104 3 r 0.17    0.070 ND 5 × × × × × × √ × 
Ahmad et al. 2006 non-GDM Malaysia 246 3 r 0.12    0.057 Univariate analyses 6 √ × × × × × √ × 
Couch et al.1998(1) non-GDM USA 20 3 r 0.46    <0.05 Pearson correlation  6 × × × × × × × × 
Slagjana et al.2014 non-GDM Yugoslavia 200 3 r 0.16    0.077 Correlation analysis 5 × × × × × × × × 
Olmos et al.2014(1) GDM-normal weight Chile 128 3 r 0.12    0.158 SLR 6 × × × × × × × × 
Olmos et al.2014(2) GDM-overweight Chile 105 3 r 0.42    
<0.00
1 





















The control of 
confounding factors 
a b c d e f g h 
Olmos et al.2014(3) GDM-obese Chile 46 3 r 0.47    
<0.00
1 
SLR 6 × × × × × × × × 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.22    0.009 SLR 6 × × × × × × √ × 
Knopp et al.1992(1) OGTT- USA 521 3 r 0.09    ≤0.05 Spearman correlation 6 × × × × × × × × 
Knopp et al.1992(2) OGTT+ plus GDM USA 264 3 r 0.16    ≤0.01 Spearman correlation 6 × × × × × × × × 
Vinod et al.2011(1) Normal weight USA 69 3 Crude β 79.72  -8.99  168.42  ND SLR 6 × × × × × × × × 
Vinod et al.2011(2) Overweight/obese USA 70 3 Crude β 168.29  52.97  283.61  ND SLR 6 × × × × × × × × 
Sommer et al.2015 General Norway 699 3 Crude β 48.80  -14.80  112.40  ND SLR 9 × × × × × × √ × 
Retnakaran et 
al.2012 
non-GDM Canada 472 3 Crude β 61.11  -1.18  123.40  ND SLR 7 × × × × × × √ × 





















The control of 
confounding factors 
a b c d e f g h 
Retnakaran et 
al.2012 
non-GDM Canada 472 3 Adjusted β -1.59  -70.67  67.49  ND MLR 7 √ √ √ √ √ √ √ √ 
Brunner et al.2013 General German 208 3 Adjusted β -47.83  -138.75  43.09  >0.05 MLR 7 √ √ × √ √ √ × × 
Friis et al.2012 General German 207 3 Adjusted β 94.00  2.00  187.00  0.046 MLR 6 √ × × × × × × × 
Mossayebi et 
al.2014 
General Iran 154 3 Adjusted β 464.13  370.24  558.02  ND MLR 5 × √ × × × × √ × 
Crume et al.2015 General USA 804 3 Adjusted β 17.71  -24.01  59.44  0.400 MLR 8 √ √ √ × × × √ × 
Geraghty et al.2016 non-GDM UK 331 3 Adjusted β 111.18  8.48  213.87  ND MLR 7 √ √ × √ √ × × × 
Ye et al.2015 non-GDM China 1,243 3 Adjusted β 25.20  7.90  42.60  ND MLR 8 √ √ √ √ √ √ √ × 
Kulkarni et al.2013 non-GDM India 631 3 Adjusted β 36.27  4.32  68.23  ND MLR 8 × √ √ √ × × √ × 
Hwang et al.2015 non-GDM Korea 1,011 3 
Adjusted 
β^ 
11609.12  6177.20  17041.05  
<0.00
01 





















The control of 
confounding factors 
a b c d e f g h 
Swierzewska et 
al.2015 
General Poland 136 3 p ND   >0.05 MLR 5 ND ND ND ND ND ND × ND 
Emet et al.2013 General Turkey 801 3 p¶ +   0.033 Pearson correlation 5 × × × × × × × × 
Schaefer-Graf et al.2011 non-GDM German 190 3 p ND   >0.05 Pearson correlation 5 × × × × × × √ × 
Couch et al.1998(2) GDM USA 20 3 p ND   >0.05 Pearson correlation  6 × × × × × × × × 
Schaefer-Graf et al.2008 GDM German 150 3 p ND   >0.05 Spearman correlation 5 × × × × × × × × 
The bold font represents statistically significant results. 
^ Maternal TG level was log-transformed 
¶ Exposure of this study is change in maternal TG level from the first trimester to the third trimester 
r: Correlation coefficients; β: regression coefficients. 
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear regression(SLR), 




S7.19 Figure Overall meta-analysis of crude regression coefficients for the association between 
maternal TG levels and birthweight throughout pregnancy 
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S7.20 Figure Overall meta-analysis of adjusted regression coefficients for the association between 





S7.21 Figure Adjusted regression coefficient_ General vs. non-GDM_ the 3rd trimester_ Random 




S7.22 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for pre-
pregnancy BMI or gestational weight gain 
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S7.23 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for 
maternal glucose level 
 
S7.24 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for other 
maternal lipid levels 
 
S7.25 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies control for pre-
term birth  
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S7.26 Figure Adjusted regression coefficients_ the 3rd trimester_ exclude studies that did not 
control for gestational age  
  
 292 
Free Fatty Acids (FFAs) 
S7.6 Table Results summary of the association of maternal FFAs levels with birthweight 
















The control of confounding factors FFAs’ 
unit a b c d e f g h 
Harmon et al.2011 non-GDM USA 38 1 p ND   >0.05 Pearson correlation 5 × × × × × × × × μEq/L 
Crume et al.2015 General USA 804 2 Adjusted β 0.06  -0.12  0.24  0.500 MLR 8 √ √ √ × × × √ × mg/dL 
Crume et al.2015 General USA 804 3 Adjusted β 0.21  0.01  0.41  0.030 MLR 8 √ √ √ × × × √ × mg/dL 
Knopp et al.1985 General USA 248 3 r 0.002    >0.05 
Spearman 
correlation 
7 √ √ × × × × √ × μmol/L 
Kitajima et al.2001 OGTT + Japan 146 3 r 0.03    0.730 SLR 6 × × × × × × √ × mEq/dL 
Schaefer-Graf et al.2008 GDM German 150 3 r 0.27    0.002 
Spearman 
correlation 
5 × × × × × × × × μmol/L 
Couch et al.1998 General USA 40 3 p ND   >0.05 Pearson correlation 6 × × × × × × × × mg/dL 
Friis et al.2012 General German 207 3 p ND   >0.05 MLR 6 √ × × × × × × × ND 
Schaefer-Graf et al.2011 non-GDM German 190 3 p ND   >0.05 Pearson correlation 5 × × × × × × √ × μmol/L 
The bold font represents statistically significant results. 
r: Correlation coefficients; β: regression coefficients.  
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Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 
Abbreviation: Trimesters(Tri.), Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Simple linear regression(SLR), 




Very Low-density lipoprotein cholesterol (VLDL) 
S7.7 Table Results summary of the association of maternal VLDL-C levels with birthweight 












The control of confounding factors 
a b c d e f g h 
Couch et 
al.1998 
General USA 40 3 p ND >0.05 
Pearson 
correlation 
6 × × × × × × × × 
Knopp et 
al.1985 
General USA 248 3 r 0.03  >0.05 
Spearman 
correlation 
7 √ √ × × × × √ × 
r: Correlation coefficients  
Confounding factors: a. Gestational age; b. Neonatal gender; c. Maternal age; d. Pre-pregnancy BMI; e. Gestational weight gain; f. Maternal glucose level; g. pre-term birth; h. Maternal lipid levels. 




S6 Systematic review: Data analysis for Large for gestational age (LGA) 
Total cholesterol (TC) 
S8.1 Table Results summary of the association of maternal TC levels with LGA 
















The control of 
confounding factors 
a b c d e f 
Jin et al.2016 non-GDM China 934 1 ND ND   ND ND 7 ND ND ND ND × ND 
Vrijkotte et al.2012 non-GDM Netherlands 4,008 1 Crude OR 1.10 0.97 1.25 ND Logistic regression 8 × × × × × × 
Vrijkotte et al.2012 non-GDM Netherlands 4,008 1 Adjusted OR 1.08 0.95 1.22 ND MLOR 8 √ √ × × × × 
Jin et al.2016 non-GDM China 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Di et al.2005 OGTT+ Italy 83 2 ND ND   ND ND 5 ND ND ND ND × ND 
Mossayebi et al.2014 General Iran 82 3 Crude OR* 13.30 2.80 62.50 ND Chi-squared test 5 × × × × √ × 
Mossayebi et al.2014 General Iran 82 3 Adjusted OR* 1.10 0.20 8.10 ND MLOR 5 √ √ × √ √ √ 
Ye et al.2015 non-GDM China 1,204 3 Adjusted OR 1.04 0.94 1.15 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 non-GDM China 934 3 Adjusted OR 0.98 0.81 1.11 0.715 MLOR 7 √ √ √ × √ × 
Hou et al.2014 non-GDM China 2,790 3 Adjusted OR¶ 1.08 0.75 1.56 ND MLOR 7 √ √ × × √ × 
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Schaefer-Graf et al.2008 GDM German 150 3 p ND   >0.05 MLOR 5 √ √ √ √ × × 
Laleh et al.2013 GDM Iran 112 3 p ND   >0.05 ANCOVA 7 √ √ × × × × 
Kitajima et al.2001 OGTT + Japan 146 3 ND ND   ND ND 6 ND ND ND ND √ ND 
Retnakaran et al.2012 non-GDM Canada 472 3 ND ND   ND ND 7 ND ND ND ND √ ND 
Ahmad et al. 2006 non-GDM Malaysia 246 3 ND ND   ND ND 6 ND ND ND ND √ ND 
     mmol/L Reference LGA p         
Slagjana et al.2014 non-GDM Yugoslavia 200 3 x±SD 
6.5±1.4 
(AGA) 
6.0±1.0 >0.05 Student t test 5 × × × × × × 
Son et al.2010 GDM Korea 104 3 x±SD 
5.8±1.1 
(non-LGA) 
5.5±0.9 0.352 Student t test 5 × × × × √ × 










7 × × × × √ × 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TC level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal TC level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), 





S8.1 Figure Meta-analysis of adjusted odds ratio for the association between maternal TC levels 
and LGA 
 
S8.2 Figure Meta-analysis for mean difference of maternal TC levels between LGA and reference 




High-density lipoprotein cholesterol (HDL-C) 
S8.2 Table Results summary of the association of maternal HDL-C levels with LGA 
















The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND × ND 
Lei et al.2016 China General 5,535 2 Crude OR^ 0.75 0.63 0.89 ND Logistic regression 6 × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Di et al.2005 Italy OGTT+ 83 2 ND ND   ND ND 5 ND ND ND ND × ND 
Mossayebi et al.2014 Iran General 82 3 Crude OR* 0.06 0.01 0.29 ND Chi-squared test 5 × × × × √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 0.89 0.69 1.15 ND Logistic regression 7 × × × × √ × 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 0.62 0.47 0.82 ND MLOR 8 √ √ √ √ √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.99 0.70 1.39 ND MLOR 7 √ √ √ √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.79 0.52 1.21 0.281 MLOR 7 √ √ √ × √ × 
Mossayebi et al.2014 Iran General 82 3 Adjusted OR* 1.67 0.19 14.29 ND MLOR 5 √ √ × √ √ √ 
Hou et al.2014* China non-GDM 2,790 3 Adjusted OR¶ 0.81 0.64 1.04 ND MLOR 7 √ √ × × √ × 
Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 ANCOVA 7 √ √ × × × × 
     mmol/L Reference  LGA          
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7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 1.6±0.4(non-LGA) 1.3±0.4 0.001 Student t test 5 × × × × × × 
Son et al.2010 Korea GDM 104 3 x±SD 1.7±0.5(non-LGA) 1.6±0.3 0.232 Student t test 5 × × × × √ × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 1.3 mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal HDL-C level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal HDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 




S8.3 Figure Meta-analysis of adjusted odds ratio for the association between maternal HDL-C 
levels and LGA in the third trimester 
 
 
 S8.4 Figure Meta-analysis for mean difference of maternal HDL-C levels between LGA and 








Low-density lipoprotein cholesterol (LDL-C) 
S8.3 Table Results summary of the association of maternal LDL-C levels with LGA  



















The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND × ND 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Di et al.2005 Italy OGTT+ 83 2 ND ND   ND ND 5 ND ND ND ND × ND 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 0.80 0.61 1.05 ND Logistic regression 7 × × × × √ × 
Mossayebi et al.2014 Iran General 82 3 Crude OR* 5.80 1.50 22.60 ND Chi-squared test 5 × × × × √ × 
Mossayebi et al.2014 Iran General 77 3 Adjusted OR* 0.80 0.10 4.40 ND MLOR 5 √ √ × √ √ √ 
Hou et al.2014 China non-GDM 2,790 3 Adjusted OR¶ 0.83 0.59 1.17 ND MLOR 7 √ √ × × √ × 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 1.25 1.06 1.47 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.93 0.78 1.11 0.418 MLOR 7 √ √ √ × √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.98 0.72 1.34 ND MLOR 7 √ √ √ √ √ √ 
Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 ANCOVA 7 √ √ × × × × 
Son et al.2010 Korea GDM 104 3 ND ND   ND ND 5 ND ND ND ND √ ND 
     mmol/L Reference LGA          
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7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 3.5±1.2 3.8±1.0 >0.05 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal LDL-C level 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal LDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 





S8.4 Figure Meta-analysis of adjusted odds ratio for the association between maternal LDL-C 




S8.5 Figure Sensitivity analysis _ Adjusted odds ratio _ The third trimester_ exclude studies adjust 





S8.4 Table Results summary of the association of maternal TG levels with LGA 

















The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND × ND 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 1.48 1.23 1.78 ND MLOR 8 √ √ × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 1.44 1.20 1.71 ND Logistic regression 8 × × × × × × 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.60 1.42 2.01 ND Logistic regression 6 × × × × × × 
Di et al.2005 Italy OGTT+ 83 2 Crude OR^ 5.60 0.93 33.77 ND Chi-squared test 5 × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Retnakaran et al.2012 Canada non-GDM 472 3 Crude OR 1.26 0.98 1.62 ND Logistic regression 7 × × × × √ × 
Ahmad et al. 2006 Malaysia non-GDM 246 3 Crude OR^ 3.07 1.33 7.08 ND Chi-squared test 6 × × × × √ × 
Kitajima et al.2001 Japan OGTT + 146 3 Crude OR^ 14.80 1.59 137.28 0.012 Chi-squared test 6 × × × × √ × 
Mossayebi et al.2014 Iran General 154 3 Adjusted OR 1.04 1.02 1.05 ND MLOR 5 √ √ × √ √ √ 
Ye et al.2015 China non-GDM 1,204 3 Adjusted OR 1.15 1.03 1.27 ND MLOR 8 √ √ √ √ √ × 
Retnakaran et al.2012 Canada non-GDM 472 3 Adjusted OR 0.98 0.70 1.38 ND MLOR 7 √ √ √ √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.13 1.02 1.26 0.025 MLOR 7 √ √ √ × √ × 
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Hou et al.2014 China non-GDM 2,790 3 Adjusted OR¶ 3.30 1.18 9.27 ND MLOR 7 √ √ × × √ × 
Ahmad et al. 2006 Malaysia non-GDM 246 3 Adjusted OR^ 1.48 1.15 1.93 ND MLOR 6 × √ × √ √ × 
Kitajima et al.2001 Japan OGTT + 146 3 Adjusted OR^ 11.60 1.10 122.00 0.040 MLOR 6 × × × × √ × 
Son et al.2010 Korea GDM 104 3 Adjusted OR^ 4.43 1.33 14.82 ND MLOR 5 √ √ √ × √ × 
Schaefer-Graf et al.2008 German GDM 150 3 p ND   0.040 MLOR 5 √ √ √ √ × × 
Laleh et al.2013 Iran GDM 112 3 p +   0.040 ANCOVA 7 √ √ × × × × 
     mmol/L Reference LGA         











7 × × × × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 x±SD 3.1±1.1 3.8±1.8 0.012 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: Lei et al.2016, 3.49 mmol/L; Di et al.2005, 2.30mmol/L; Ahmad et al. 2006, 2.78mmol/L; Kitajima et al. 2001, 2.92 mmol/L; Son et al. 2010, 3.33mmol/L. 
¶ Result was calculated by comparing the highest tertile with the lowest tertile maternal TG level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 





S8.6 Figure Meta-analysis of adjusted odds ratio for the association between maternal TG levels 
and LGA throughout pregnancy 
 
 
S8.7 Figure Forest plots of crude odds ratio for the association between maternal TG levels and 
LGA throughout pregnancy 
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S8.8 Figure  Forest plots of adjusted odds ratio for the association between maternal TG levels 
and LGA throughout pregnancy 
 
Sensitivity analysis 






Free fatty acids (FFAs) 
S8.5 Table Results summary of the association of maternal FFAs levels with LGA 
 














The control of 
confounding factors Unit 
a b c d e f 
Schaefer-Graf et 
al.2008 
German GDM 150 3 p ND 0.008 MLOR 5 √ √ √ √ × × μmol/L 




S7 Systematic review: Data analysis for Small for gestational age (SGA) 
Total cholesterol (TC) 
S9.1 Table Results summary of the association of maternal TC levels with SGA 




















The control of confounding 
factors 
a b c d e f 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 0.97 0.85 1.10 ND 
Logistic 
regression 
8 × × × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 0.98 0.86 1.12 ND MLOR 8 √ √ × × × × 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.94 0.74 1.20 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.12 0.80 1.56 0.520 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p    >0.05 Student t test 5 × × × × × × 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR). 
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High-density lipoprotein cholesterol (HDL-C) 
S9.2 Table Results summary of the association of maternal HDL-C levels with SGA 


















The control of confounding 
factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 Adjusted OR 1.41 0.32 5.38 ND MLOR 7 √ √ √ × √ × 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.13 0.80 1.61 ND 
Logistic 
regression 
6 × × × × × × 
Jin et al.2016 China non-GDM 934 2 Adjusted OR 1.88 0.47 7.59 ND MLOR 7 √ √ √ × √ × 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 1.57 0.87 2.83 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 3.15 1.15 8.65 0.026 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p    >0.05 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 1.3 mmol/L 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 








Low-density lipoprotein cholesterol (LDL-C) 
S9.3 Table Results summary of the association of maternal LDL-C levels with SGA 



















The control of confounding 
factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.75 0.50 1.14 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.16 0.71 1.89 0.565 MLOR 7 √ √ √ × √ × 
Slagjana et 
al.2014 
Yugoslavia non-GDM 200 3 p    >0.05 
Student t 
test 
5 × × × × × × 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 










S9.4 Table Results summary of the association of maternal TG levels with SGA 




















The control of confounding factors 
a b c d e f 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND √ ND 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Crude OR 1.06 0.87 1.29 ND Logistic regression 8 × × × × × × 
Vrijkotte et al.2012 Netherlands non-GDM 4,008 1 Adjusted OR 0.97 0.79 1.19 ND MLOR 8 √ √ × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND √ ND 
Lei et al.2016 China General 5,535 2 Crude OR^ 1.51 1.08 2.12 ND Logistic regression 6 × × × × × × 
Ye et al.2015 China non-GDM 912 3 Adjusted OR 0.69 0.47 1.03 ND MLOR 8 √ √ √ √ √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.63 0.40 0.99 0.046 MLOR 7 √ √ √ × √ × 
Slagjana et al.2014 Yugoslavia non-GDM 200 3 p    0.012 Student t test 5 × × × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 3.49 mmol/L 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 









S8 Systematic review: Data analysis for Macrosomia 
Total cholesterol (TC) 
S10.1 Table Results summary of the association of maternal TC levels with macrosomia 
















p Statistical methods 
Qualit
y 
The control of confounding 
factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 1,037 2 Crude OR* 1.10 0.60 2.00 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,037 2 
Adjusted 
OR* 
1.10 0.60 2.00 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 P    >0.05 
Non-parametric Mann-Whitney 
Test  
5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.99 0.81 1.21 0.903 MLOR 7 × √ √ √ √ × √ × 
318 
 
Laleh et al.2013 Iran GDM 112 3 P ND   >0.05 
Bonferroni multiple comparison 
test 
7 × × √ √ × × × × 
Mossayebi et al.2014 Iran General 154 3 ND ND   ND ND 5 ND ND ND ND ND ND √ ND 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TC level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), No documented(ND), Multiple logistic regression(MLOR), Analysis of 





High-density lipoprotein cholesterol (HDL-C) 
S10.2 Table Results summary of the association of maternal HDL-C levels with macrosomia 
















p Statistical methods 
Qualit
y 
The control of confounding 
factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 Adjusted OR 0.51 0.19 1.36 0.178 MLOR 7 × √ √ √ √ × √ × 
Zawiejska et al. 2008 Poland GDM 357 2 Crude RR 0.59 0.32 1.02 ND Chi-squared test 5 × × × × × × × × 
Clausen et al.2005 Norway General 1,025 2 Crude OR* 0.30 0.20 0.60 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,025 2 
Adjusted 
OR* 
0.30 0.20 0.60 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 
Adjusted 
OR^ 
0.61 0.38 0.98 ND MLOR 5 × × √ √ √ × × × 
Jin et al.2016 China non-GDM 934 2 Adjusted OR 0.25 0.09 0.73 0.011 MLOR 7 × √ √ √ √ × √ × 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.46 0.22 0.94 0.034 MLOR 7 × √ √ √ √ × √ × 
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Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 
Bonferroni multiple comparison 
test 
7 × × √ √ × × × × 
Mossayebi et al.2014 Iran General 154 3 ND ND   ND ND 5 ND ND ND ND ND ND √ ND 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 2.205mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal HDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 










Low-density lipoprotein cholesterol (LDL-C) 
S10.3 Table Results summary of the association of maternal LDL-C levels with macrosomia 












p Statistical methods Quality 
The control of confounding 
factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 1,018 2 Crude OR* 2.20 1.20 4.00 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 1,018 2 
Adjusted 
OR* 
2.10 1.20 3.90 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 p    >0.05 
Non-parametric Mann-Whitney 
Test  
5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND ND ND √ ND 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 0.93 0.69 1.25 0.621 MLOR 7 × √ √ √ √ × √ × 
Laleh et al.2013 Iran GDM 112 3 p ND   >0.05 
Bonferroni multiple comparison 
test 
7 × × √ √ × × × × 
Mossayebi et 
al.2014 
Iran General 154 3 ND ND   ND ND 5 ND ND ND ND ND ND √ ND 
The bold font represents statistically significant results. 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal LDL-C level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), Not documented(ND), Multiple logistic regression(MLOR), Analysis of 






S10.4 Table Results summary of the association of maternal TG levels with macrosomia 














p Statistical methods Quality 
The control of confounding 
factors 
a b c d e f g h 
Jin et al.2016 China non-GDM 934 1 ND ND   ND ND 7 ND ND ND ND ND ND × ND 
Clausen et al.2005 Norway General 988 2 Crude OR* 2.90 1.40 5.90 ND Logistic regression 8 × × × × × × √ × 
Clausen et al.2005 Norway General 988 2 
Adjusted 
OR* 
2.90 1.40 5.90 ND MLOR 8 × × √ × × × √ × 
Zhou et al.2012 China General 1,000 2 p    >0.05 
Non-parametric Mann-Whitney 
Test  
5 × × × × × × × × 
Jin et al.2016 China non-GDM 934 2 ND ND   ND ND 7 ND ND ND ND ND ND √ ND 
Mossayebi et al.2014 Iran General 154 3 Adjusted OR 1.04 1.02 1.07 ND MLOR 5 × × √ √ × √ √ √ 
Jin et al.2016 China non-GDM 934 3 Adjusted OR 1.19 1.02 1.39 0.024 MLOR 7 × √ √ √ √ × √ × 
Lin et al.2013 China General ND ND OR^ 2.20 1.54 3.14 ND ND NA ND ND ND ND ND ND ND ND 
Laleh et al.2013 Iran GDM 112 3 p +   0.001 
Bonferroni multiple 
comparison test 
7 × × √ √ × × × × 
The bold font represents statistically significant results. 
^ Results was calculated with self-defined cut-off point: 2.27 mmol/L 
* Result was calculated by comparing the highest quartile with the lowest quartile maternal TG level 
Confounding factors: a. Maternal age; b. Pre-pregnancy BMI; c. Gestational weight gain; d. Maternal glucose level; e. pre-term birth; f. Maternal lipid levels. 
Abbreviation: Gestational diabetes mellitus(GDM), Positive screenes of Oral Glucose Tolerance test(OGTT+), Confidence interval(CI), No documented(ND), Not applicable(NA), Multiple logistic 




S10.2 Figure Meta-analysis of adjusted odds ratio for the association between maternal TG 





S10.3 Figure Forest plots of adjusted odds ratio for the association between maternal TG 





S9 Bayesian study: Sample size calculation 
We powered the study for the potentially least associated maternal metabolic risk factor 
(triglycerides) for birthweight. Knopp et al. reported a correlation between maternal 
triglycerides and birthweight of r = 0.09 (p < 0.05) in non-GDM women (361)(1). We, 
conservatively assumed an effect size of 0.08. STATA 14.0 is used to calculate the sample 
size. After using ‘Fisher’s z tests comparing one correlation to a reference value’ tool, a 
sample of 1225 will give 80% power to detect a correlation of 0.08 at the 5% significance 
level (two-sided). We conservatively assumed a 20% attrition rate due to missing data and 






S10 Bayesian study: Testing for degradation for cord blood insulin 
No prior literature reported the impact of long-term -80 °C storage on plasma insulin. We 
therefore fit a regression model to detect the potential degradation for cord blood insulin. 
The median storage duration of cord blood sample is 488 (IQR 394 to 707) days. Cord blood 
insulin was found to be slightly degraded over time (r = -0.07, p = 0.01). In the multivariate 
regression model, we included sample storage time as a covariate. In the additive Bayesian 
Network analysis, adjustments were made to account for any degradation by correcting the 
initial value using linear regression methods (adjusted cord blood insulin = initial value of 





S11 Bayesian study: Adjusting gestational age at sampling for maternal 
lipid profile 
The average sampling time for maternal overnight fasting blood sample at the second 
trimester is 20.46 gestation weeks. The table below represented the estimate of associations 
between maternal plasma lipid levels and blood sampling gestational age. 
 
lipids Regression coefficient (β) 




Linear regression model 
 




S12 Bayesian study: Baseline characteristics of participants with and 








Maternal age at enrolment (years)* 29.53 (3.30) 28.99 (3.11) 0.18 
Primiparous$ 289 (19.94) 10 (13.70) 0.19 
Early pregnancy cigarette exposure$ 415 (28.68) 22 (28.77) 0.99 
GDM$ 168(11.59) 13 (17.81) 0.11 
Pre-pregnancy BMI (kg/m2)* 20.47 (2.69) 20.37 (2.58) 0.76 
*Mean (Standard deviation), T test used 





S13 Bayesian study: Sensitivity analysis results 













Model 1 (All) 0.20(0.15, 0.24) 0.18(0.13, 0.23) 0.08(0.04, 0.12) -0.05(-0.09, -0.00) 0.12(0.08, 0.16) 
non-GDM 0.20(0.15, 0.25) 0.18(0.12, 0.24) 0.06(0.01, 0.11) -0.04(-0.09, 0.00) 0.13(0.08, 0.17) 
GDM 0.19(0.09, 0.29) 0.11(-0.03, 0.25) 0.16(0.07, 0.24) -0.08(-0.19, 0.03) 0.04(-0.09, 0.17) 
p 0.84 0.62 0.06 0.55 0.22 
Cord blood insulin Z-Score 
Model 2 (All) 0.10(0.05, 0.15) 0.06(-0.01, 0.12) 0.13(0.08, 0.18) -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
non-GDM 0.03(0.01, 0.05) 0.05(-0.01, 0.12) 0.10(0.04, 0.16) -0.03(-0.08, 0.03) 0.06(0.01, 0.12) 
GDM 0.14(0.03, 0.25) 0.09(-0.07,0,26) 0.19(0.09, 0.29) -0.12(-0.27, 0.03) 0.01(-0.12, 0.15) 
p 0.38 0.65 0.13 0.23 0.50 
Model 1: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, and delivery mode. For 
gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight 
measurements during pregnancy. 
Model 2: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, gestational age, neonatal 
gender, delivery mode, and sample storage duration. For gestational weight gain, model was further adjusted for pre-
pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, 



















Model 1 (All) 0.20(0.15, 0.24) 0.18(0.13, 0.23) 0.08(0.04, 0.12) -0.05(-0.09, -0.00) 0.12(0.08, 0.16) 
lean 0.23(0.16, 0.29) 0.15(0.09, 0.21) 0.08(0.03, 0.12) -0.02(-0.07, 0.02) 0.11(0.06, 0.15) 
overweight 0.20(0.03, 0.36) 0.13(0.01, 0.25) 0.05(-0.07, 0.17) -0.09(-0.22, 0.05) 0.13(-0.01, 0.27) 
p 0.73 0.79 0.67 0.37 0.75 
Cord blood insulin Z-Score 
Model 2 (All) 0.10(0.05, 0.15) 0.06(-0.01, 0.12) 0.13(0.08, 0.18) -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
lean 0.15(0.07, 0.23) 0.05(-0.01, 0.12) 0.13(0.08, 0.19) -0.03(-0.08, 0.02) 0.07(0.02, 0.12) 
overweight 0.07(-0.09, 0.24) 0.10(-0.04, 0.25) 0.11(0.00, 0.22) -0.11(-0.26, 0.03) -0.00(-0.13, 0.13) 
p 0.41 0.54 0.72 0.25 0.34 
Model 1: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, and delivery mode. 
For gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal 
weight measurements during pregnancy. 
Model 2: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, gestational age, 
neonatal gender, delivery mode, and sample storage duration. For gestational weight gain, model was further 
adjusted for pre-pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, 





















Model 1 (All) - - - -0.05(-0.09, -0.00) 0.12(0.08, 0.16) 
fasting - - - -0.05(-0.10, -0.01) 0.12(0.08, 0.16) 
non-fasting - - - 0.01(-0.12, 0.14) 0.07(-0.07, 0.21) 
p - - - 0.39 0.50 
Cord blood insulin Z-Score 
Model 2 (All) - - - -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
fasting - - - -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
non-fasting - - - -0.01(-0.17, 0.14) 0.11(-0.04, 0.25) 
p - - - 0.73 0.56 
Model 1: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, and delivery mode. For 
gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight 
measurements during pregnancy. 
Model 2: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, gestational age, neonatal 
gender, delivery mode, and sample storage duration. For gestational weight gain, model was further adjusted for pre-
pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, 
triglycerides; GDM, gestational diabetes mellitus. 
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Model 1 (All) 0.20(0.15, 0.24) 0.18(0.13, 0.23) 0.08(0.04, 0.12) -0.05(-0.09, 0.00) 0.12(0.08, 0.16) 
primiparous 0.18(0.13, 0.22) 0.15(0.09, 0.21) 0.08(0.03, 0.12) -0.05(-0.09, 0.00) 0.11(0.07, 0.16) 
non-primiparous 0.28(0.18, 0.37) 0.12(-0.01, 0.25) 0.11(0.01, 0.21) -0.04(-0.13, 0.05) 0.14(0.06, 0.23) 
p 0.06 0.74 0.52 0.87 0.51 
Cord blood insulin Z-Score 
Model 2 (All) 0.10(0.05, 0.15) 0.06(-0.01, 0.13) 0.13(0.08, 0.18) -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
primiparous 0.10(0.04, 0.15) 0.06(-0.01, 0.13) 0.14(0.09, 0.19) -0.03(-0.08, 0.04) 0.07(0.01, 0.12) 
non-primiparous 0.10(0.00, 0.20) -0.00(-0.12, 0.13) 0.09(-0.01,0.19) -0.10(-0.19, -0.00) 0.05(-0.04, 0.14) 
p 0.89 0.39 0.42 0.24 0.75 
Model 1: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, and delivery mode. For 
gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight 
measurements during pregnancy. 
Model 2: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette exposures, gestational age, neonatal 
gender, delivery mode, and sample storage duration. For gestational weight gain, model was further adjusted for pre-
pregnancy BMI and gestational age of maternal weight measurements during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; 
GDM, gestational diabetes mellitus. 
334 
 













before 0.20(0.15, 0.24) 0.18(0.12, 0.23) 0.08(0.04, 0.12) -0.04(-0.09, -0.00) 0.12(0.08, 0.16) 
after 0.20(0.15, 0.24) 0.18(0.13, 0.23) 0.08(0.04, 0.12) -0.05(-0.09, -0.00) 0.12(0.08, 0.16) 
Cord blood insulin Z-Score 
before 0.11(0.06, 0.16) 0.07(0.00, 0.13) 0.14(0.09, 0.19) -0.04(-0.09, 0.01) 0.07(0.02, 0.12) 
after 0.10(0.05, 0.15) 0.06(-0.01, 0.12) 0.13(0.08, 0.18) -0.04(-0.09, 0.01) 0.06(0.01, 0.11) 
Model for birthweight Z-Score: Adjusted for maternal age, ethic group, parity, and early pregnancy cigarette 
exposures. For gestational weight gain, model was further adjusted for pre-pregnancy BMI and gestational age of 
maternal weight measurements during pregnancy. 
Model for cord blood insulin Z-Score: Adjusted for maternal age, ethic group, parity, early pregnancy cigarette 
exposures, gestational age, neonatal gender, delivery mode, and sample storage duration. For gestational weight 
gain, model was further adjusted for pre-pregnancy BMI and gestational age of maternal weight measurements 
during pregnancy. 
BMI, body mass index; GWG, gestational weight gain; HDL-C, high-density lipoprotein cholesterol; TG, 





S14 Bayesian study: Additive Bayesian Network methodologies 
Introduction to Additive Bayesian Network analysis 
A Bayesian network is a probabilistic graphical model that represents a set of variables and 
their conditional dependencies via a directed acyclic graphs (DAGs).(320) It is a well-
established unsupervised machine learning methodology that is typically referred to as 
structure discovery model for dealing with multidimensional data.(321) Unlike other widely 
used multivariate approaches, such as principal component analysis, propensity score 
matching analysis and multivariable regression model, graphical modelling does not involve 
any dimension reduction. Most graphical models, including path analysis and structural 
equation modelling, rely on a pre-specified structure, whereas Bayesian network is entirely 
data-driven. 
Unlike the contingency table parameterization in standard Bayesian network models, 
Additive Bayesian networks (ABN) allow us to obtain interpretable DAGs where each node 
in graph comprises a generalized linear model (GLM) or a generalized linear mixed model 
(GLMM, if binary variable involved).(323, 399) There are two mutually dependent parts in 
ABN model: a network structure (i.e. the DAG) and a set of parameters. Each node 
(corresponding to the variables in the dataset) in the DAG is the equivalent of a potential 
dependent variable in a Bayesian GLM or GLMM regression model. While other DAG 
nodes where relevant as identified by the unsupervised learning act as covariates, having a 
role of corresponding parameters. Therefore, an ABN model is ideally suited to analyzing 
highly complex epidemiological data comprising many inter-dependent variables.  
 
The technical process of ABN 
After an initial data preparation phase we used a three-step procedure to determine an 
optimal DAGs for our data.  
Step 0 Data pre-processing 
Ten variables were chosen for ABN based on our knowledge gained from prior literature 
and findings of the classical statistical analyses. These included maternal age, maternal pre-
pregnancy BMI, maternal fasting glucose concentration in OGTT, early gestational weight 
gain (GWG, adjusted for gestational age at weight measurement), maternal fasting plasma 
high-density lipoprotein cholesterol (HDL-C, adjusted for gestational age at blood sampling) 
in 2nd trimester, maternal fasting plasma triglycerides in 2nd trimester (adjusted for 
gestational age at blood sampling), birthweight Z-Score (adjusted for gestational age at 
delivery and neonatal gender), cord blood insulin (CBI, adjusted for sample storage 
duration) concentration, gestational age at delivery, and neonatal gender. All continuous 
variables were standardized to Z-Scores to eliminate the influence of different measurement 
units (maternal triglycerides and cord blood insulin were log-transformed before 
standardization). Participants with data missing for at least one of these ten variables (6% of 
participants) were excluded from the analysis. The number of mother-child pairs that was 
finally included in ABN analysis is 1,429. 
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Step 1 Identification of the optimal model 
The identification of the single optimal model is referred to as structure discovery. The 
purpose of this step is to combine all individual GLMs into a single, probabilistically 
cohesive model describing all the inter-dependent relationships via a DAG. We blocked all 
directions of arcs between variables that are biologically impossible to occur. This was done 
using the adjacency matrix in figure S1. 
 
Variable labels explanation: 01 mage, maternal age; 02 prebmi, maternal pre-pregnancy BMI; 03 gwg, 
gestational weight gain; 04 glu, maternal fasting glucose level; 05 hdl, maternal plasma high-density 
lipoprotein cholesterol level; 06 tg, maternal plasma triglyceride level; 07 bwz, birthweight Z-Score; 08 ins, 
cord blood insulin; 09 sex, neonatal gender;  10 gaw, gestational age at delivery. Same labels also apply to the 
numbers across the top of the matrix.  
DAG definition. Rows are children nodes, columns are parent nodes. 1 represents block from parent node 
(column) towards child node (row), 0 represents unblock. 
 
Figure S1 ABN block matrix definition 
 
To find the DAG with the best goodness of fit (network score - log marginal likelihood), 
exact searches were conducted across the parent limits (the limit number of arcs from parent 
nodes to child node), starting from a minimum of 1 and reaching a maximum of 9. As shown 
in Figure S2, we found that the goodness of fit (maximum marginal likelihood=-19153.30) 




Figure S2 Comparison of goodness of fits for different parent limits 
 
Variables explanation: mage, maternal age; prebmi, maternal pre-pregnancy BMI; gwg, gestational weight 
gain; glu, maternal fasting glucose level; hdl, maternal plasma high-density lipoprotein cholesterol level; tg, 
maternal plasma triglyceride level; bwz, birthweight Z-Score; ins, cord blood insulin; sex, neonatal gender;  
gaw, gestational age at delivery.  



























Step 2 Adjustment for overfitting: parametric bootstrapping  
We have identified the optimal DAG, but there is a risk of overfitting because of the 
combinatoric nature of Bayesian hypotheses. To address this, 12,800 independent 
parametric bootstrapping analyses were performed. This involves simulating data sets of the 
same size as the original dataset, and see how often the different structural features are 
recovered. Arcs present in less than 50% frequencies of the globally optimal DAGs 
estimated from the bootstrap data were considered not to be robust and need to be trimmed 
(removed) from the DAG generated in the first step.  
The resulting optimal summary network was inferred from data with a total of 14 high-
confidence arcs across 10 variables (Figure S3). The DAGs presented using pruning at 50% 
was constructed from 12,800 searches with a parent limit of four parents per node. Collating 
results across these 12,800 searches, all 14 arcs were recovered for at least 12,742 times, as 
resulting from the frequencies matrix at Figure S4. 
 
Variables explanation: mage, maternal age; prebmi, maternal pre-pregnancy BMI; gwg, gestational weight 
gain; glu, maternal fasting glucose level; hdl, maternal plasma high-density lipoprotein cholesterol level; tg, 
maternal plasma triglyceride level; bwz, birthweight Z-Score; ins, cord blood insulin; sex, neonatal gender;  
gaw, gestational age at delivery. 
Figure S4 Optimal final DAG (Containing 14 arcs after removal of arcs supported at 






Variables explanation: mage, maternal age; prebmi, maternal pre-pregnancy BMI; gwg, gestational weight 
gain; glu, maternal fasting glucose level; hdl, maternal plasma high-density lipoprotein cholesterol level; tg, 
maternal plasma triglyceride level; bwz, birthweight Z-Score; ins, cord blood insulin; sex, neonatal gender;  
gaw, gestational age at delivery.  
Rows are children nodes, columns are parent nodes. The number in each cell represents the frequencies at 
which each arc (from parent node towards child node) was recovered during 12,800 times of bootstrapping. 





Step 3 Estimating marginal from the final DAG 
Once the optimal DAG has been identified, we need to examine the strength of the various 
arcs in our analysis. This process is very similar to when estimating the marginal for the 
bootstrapping. All of the effect parameters of this analysis has been provided in Table S1 
with 95% confidence intervals.    
Arcs 
Effect estimate  
(β, 95%CI) 
95% CI 
Mage  prebmi 0.19 (0.14, 0.24) 
Prebmi  gwg -0.12 (-0.17, -0.06) 
mage  glu 0.11 (0.06, 0.16) 
Prebmi  glu 0.14 (0.09, 0.19) 
Prebmi  hdl -0.12 (-0.17, -0.07) 
Gwg  hdl 0.09 (0.05, 0.14) 
Tg  hdl -0.33 (-0.38, -0.28) 
Prebmi  tg 0.23 (0.18, 0.28) 
Prebmi  bwz 0.27 (0.22, 0.32) 
Gwg  bwz 0.17 (0.12, 0.22) 
Glu  ins 0.12 (0.07, 0.17) 
Bwz  ins 0.24 (0.19, 0.29) 
Sex  ins 0.19 (0.09, 0.29) 
Sex  gaw 0.20 (0.10, 0.31) 
Variables explanation: mage, maternal age; prebmi, maternal pre-pregnancy BMI; 
gwg, gestational weight gain; glu, maternal fasting glucose level; hdl, maternal 
plasma high-density lipoprotein cholesterol level; tg, maternal plasma triglyceride 
level; bwz, birthweight Z-Score; ins, cord blood insulin; sex, neonatal gender;  gaw, 





S15 Bayesian study: Results summary of the association between maternal 






Regression Coefficients (95%CI)   
    Birthweight(g)∆ -0.78(-20.32, 18.76) 0.66(-23.23, 21.91) 
    Cord blood insulin¶ (μU/mL) -0.14(-0.77, 0.49) -0.14(-0.87, 0.58) 
Odds Ratio (95%CI)   
    LGA§ 0.99(0.79, 1.24) 1.00(0.77, 1.30) 
    SGA§ 0.91(0.73, 1.15) 0.98(0.75, 1.27) 
∆ Adjusted for maternal age, ethnic group, parity, gestational age, neonatal gender, 
and early pregnancy cigarette exposures. For gestational weight gain, model was 
further adjusted for pre-pregnancy BMI and gestational age of maternal weight 
measurements during pregnancy. 
¶ Adjusted for maternal age, ethnic group, parity, gestational age, neonatal gender, 
early pregnancy cigarette exposures, and delivery mode. For gestational weight 
gain, model was further adjusted for pre-pregnancy BMI and gestational age of 
maternal weight measurements during pregnancy. 
§ Adjusted for maternal age, ethnic group, parity, and early pregnancy cigarette 
exposures. For gestational weight gain, model was further adjusted for pre-
pregnancy BMI and gestational age of maternal weight measurements during 
pregnancy. 
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; LGA, large-for-





S16 The association between cord blood metabolic parameter 
concentrations and storage duration. 
Cord blood glucose concentration in EDTA tube at -80℃ was not related to storage duration 
(r = 0.03, p = 0.27), while cord blood insulin was found to be slightly degraded over time (r 
= -0.07, p = 0.01). Therefore, cord blood insulin was adjusted for storage duration using 
regression model, the equation of which is as follows: log (adjusted insulin) = log (raw 
insulin) + slope (mean of storage duration -storage duration). This equation yield a 
downward adjusted of raw insulin values where storage duration < 536 days and an upward 





S17 Regression analysis for the association between birthweight Z-Score 
and cord blood glucose Z-Score 
 
 
